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1.1 Introduction
The increase in health expenditures has raised important questions about 
the appropriate height of health care spending as well as the justification of 
these expenditures. One tool in the search of ensuring the optimal allocation 
of scarce societal and health care resources is economic evaluation of health 
care interventions, such as new pharmaceuticals, diagnostics or preventive 
measures. In economic evaluations, the costs of an intervention are compared 
to its benefits, expressed in some meaningful manner. Consistently applying 
these evaluations, in theory, would ensure an optimal level of spending in the 
health care sector (that is, the size of the budget, or how much to spend on 
health) as well as an optimal use of the available resources within the budget 
(that is, on what the budget is spent). This optimal spending can be defined in 
light of the twin goals of health care policy; efficiency and equity. (1) As such, 
economic evaluations can be seen as applied welfare economics, aimed at in-
forming social choices to come to a maximization of broadly defined welfare. (2)
In recent years the role of economic evaluation in health care decisions has 
become more prominent. (3) For instance, pharmaceutical companies may be 
obliged to provide information on the costs and effects of new drugs when ap-
plying for coverage within a collectively funded health care system. While the 
influence of this information on subsequent decisions may still be limited (3-5), 
an increasing number of countries appear to wish to include this information 
in the process of reimbursement decisions (6). The increased use of economic 
evaluation in health care also increases the need to ensure a sound methodol-
ogy of these evaluations. Obviously, this need increases with the influence of 
outcomes on subsequent decision making. While important developments 
have been achieved in the methodology of economic evaluations over the past 
decades (7), it is important to note that numerous methodological debates re-
garding how to best perform economic evaluations are, nonetheless, ongoing. 
Often, these disputes strike at the heart of economic evaluations and concern 
(normative) methodological choices that can have a very large influence on 
subsequent outcomes (and, potentially, decision making). 
One of the areas of debate concerns (the inclusion of) productivity costs, 
which can be defined as “Costs associated with production loss and replacement 
costs due to illness, disability and death of productive persons, both paid and un-
paid.” (8). This thesis deals with the methodology of including productivity costs 
in economic evaluations of health care interventions. It will address several is-
sues related to the inclusion of productivity costs, as further highlighted below. 
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First, however, some background to the thesis will be provided by introducing 
the more general methodology of economic evaluations. Subsequently, the 
place of productivity costs in economic evaluations is highlighted, as well as 
important debates regarding whether and how to include them in the preferred 
type of economic evaluation (cost-utility analysis). 
1.2 Economic evaluations
Economic evaluations1 can be defined as ‘the comparative analysis of alterna-
tive courses of action in terms of both their costs and consequences’ (7). As such, 
they have a clear root in welfare economics, where changes in ‘states of the 
world’ (i.e. reimbursing some new drug or not) are compared in terms of their 
effects on welfare. Hence, an economic evaluation must always compare at 
least two alternative courses of action (or states of the world), by which it can 
be determined whether moving for instance from the current state (not yet 
funding the drug) to an alternative state (funding the drug) would improve 
welfare. As illustrated in figure 1.1, in performing economic evaluations, the 
costs and benefits (often confined to health effects) of an old intervention are 
commonly compared with the costs and health effects of a new intervention. 
In doing so, economic evaluations aim to provide information on whether the 
improvement in health status justifies the additional resources required for the 
new intervention as compared to the old intervention. 
 
  
 
Required resources old intervention 
Required resources new intervention 
Old 
intervention 
(Health) effects old intervention  
 
(Health) effects new intervention  
 
New 
intervention 
Figure 1.1 A graphical representation of an economic evaluation. 
1  Although strictly speaking these terms are not necessarily synonyms, in this thesis the terms 
‘economic evaluation’, ‘health technology assessment’, ‘cost-effectiveness study’ and cost-effec-
tiveness analysis’ are used interchangeably.
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Comparing health interventions can be done in several ways. Four types 
of economic evaluations are commonly distinguished. All four express costs 
in monetary terms, but differ in whether and how they express the benefits. 
The first type of economic evaluation is the traditional cost-benefit analysis 
in which both costs and effects are expressed in monetary terms. This type of 
evaluation is relatively uncommon in the field of health care, which appears 
to have to do with difficulties of finding an appropriate monetary valuation of 
health gains as well as the fact that ‘pricing life’ may be considered undesirable 
(or even ‘unethical’). This paved the way for a second type of economic evalu-
ation: cost-effectiveness analysis. In such an analysis costs are still expressed 
in monetary terms but the effects are expressed in natural (clinically relevant) 
units such as hip fractures avoided, number of successfully treated patients, or 
life years gained. While this type of economic evaluation relates well to clini-
cal practice, it makes societal decisions difficult due to the incomparability of 
outcome measures and results. Hence, the third type of economic evaluation, 
cost-utility analysis, became popular. This is a specific type of cost-effectiveness 
analysis in which effects are expressed in quality adjusted life years (QALYs). 
The QALY is a comprehensive generic preference-based health measure en-
compassing both length of life and quality of life, as further explained below. 
The fourth type is cost-minimization analysis (CMA). In such an analysis only 
costs are considered, not health effects. The use of CMA is only appropriate 
when there is no (significant) difference in terms of health benefits. (7)
Cost-utility analysis
Cost-utility analysis currently appears to be the preferred type of economic 
evaluation (7), since it allows comparing outcomes of economic evaluations 
across diverse interventions, without expressing them in monetary terms. 
Rather, the effects are expressed in terms of QALYs. To calculate QALYs life 
years are multiplied with the quality of life value during those years. These 
values are commonly referred to as QALY weights. QALY weights are anchored 
at full health (or best imaginable health state) and the state ‘dead’. The value 
for full health is normalized at ‘1’, while that for ‘dead’ is normalized at ‘0’. 
One year in perfect health thus equals 1 QALY, while one year in the state 
‘dead’ equals 0 QALYs. Likewise, (abstracting from discounting) ten years in 
perfect health represents ten QALYs. The values of all other health states are 
determined based on their relative position compared to full health and dead. 
States considered to be ‘worse than dead’ are assigned values below zero. (7) To 
illustrate, a simple QALY calculation looks as follows. If an individual will live 
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for an additional 30 years with a quality of life of 0.8, the remaining life time 
QALYs of that individual would equal 0.8 * 30 = 24. If that person is treated for 
some illness, improving his health to 0.9 for the full 30 year period, this means 
an improvement of 3 QALYs (since he now will live 30*0.9 = 27 QALYs). 
The outcomes of cost-utility analyses are commonly expressed as the 
costs per QALY gained, or, correspondingly, the incremental cost-utility ratio 
(ICUR)2 . The ICUR is calculated by dividing the difference in costs by the dif-
ference in effects of the old and new intervention. This is expressed in equation 
1.1, where B represents the new health intervention and A the old intervention.
Equation 1.1
ICUR =
(Costs B – Costs A)
(QALYs B – QALYs A)
The comparability of ICURs is a pivotal advantage over outcomes of cost-
effectiveness analyses, since decision makers typically need to make choices 
between different technologies and at different points in time. In relation to 
productivity costs two important issues need to be discussed regarding equa-
tion 1.1: (i) which costs are relevant to include and (ii) are productivity costs 
(best) placed in the numerator or denominator of the equation. These ques-
tions are addressed below. 
Defining relevant costs
Costs in economic evaluations of health care interventions can be divided in 
direct medical and non-medical costs and indirect medical and non-medical 
costs. Direct medical costs refer to health care costs directly associated with 
the illness and treatment of interest. Examples of direct medical costs are drug 
costs, costs of health care personnel and hospital costs. Direct non-medical 
costs refer to costs that accrue to patients and their families while receiving 
health care, such as costs of traveling to the hospital, but these also include 
time-costs, such as the time significant others spent on providing informal 
care. Indirect medical costs refer to medical costs indirectly associated with 
the illness and intervention of interest, for instance medical costs occurring in 
life years gained as a result of the intervention. Indirect non-medical costs are 
costs emerging outside the health care system and indirectly associated with 
2 In this thesis instead of ICUR, the more general term incremental cost-effectiveness ratio (ICER) is 
regularly.
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the illness and related intervention. These costs are commonly restricted to 
productivity costs.(2)
Importantly, not all economic evaluations include all cost-categories. The 
issue of which costs to include in economic evaluations is strongly related to 
the perspective adopted in the evaluation. Most commonly, economic evalu-
ations are performed from either the health care (payer) perspective or the 
societal perspective. Evaluations taking a health care perspective limit the 
costs included to costs falling on the health care budget (i.e. medical costs). 
By contrast, evaluations from a societal perspective aim to include all relevant 
societal costs (and effects), regardless of where these costs fall (7). There seems 
to be no consensus on which perspective to take in economic evaluations. 
The normative choice of the appropriate perspective relates to the assumed 
context of health care decision making. If the main aim of economic evalu-
ations is considered to be informing decision makers who wish to maximize 
(or optimize) population health from a given health care budget, only costs 
falling on the health care budget are relevant. Costs falling outside the health 
care sector, including productivity costs, then are irrelevant. However, if it is 
assumed that the decision maker has the broader objective of contributing to 
maximizing social welfare, costs falling outside the health care budget can be 
considered equally important as those falling on the health care budget. Then, 
obviously, productivity costs are fully relevant, and included in the analysis. At 
present, there is no theoretical or practical consensus on which perspective is 
most appropriate. This lack of consensus regarding the appropriate perspec-
tive in economic evaluations, and the relevance thereof for productivity costs, 
is further explained and discussed in chapter 2 of this thesis. 
Inclusion of productivity costs
Even when a societal perspective is taken, productivity costs are not systemati-
cally included in economic evaluations. This is disturbing since productivity 
costs may strongly affect cost-effectiveness outcomes and their absolute height 
can exceed medical costs (9-11). The reasons for omitting productivity costs are 
diverse. First, concerns have been raised regarding the ethical implications of 
including productivity costs (12,13). Inclusion of these costs could lead to favor-
ing interventions targeted at the working population, since health interven-
tions successfully increasing the (paid) productivity of patients could result in 
substantial societal savings. Consequently, these savings could result in more 
favorable ICURs than equally effective treatments targeted at older patients.
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Second, there is dissensus regarding the appropriate methodology for produc-
tivity cost inclusion. Many debates, which are far from being settled, have focused 
on the question how to derive valid productivity cost estimates for use in economic 
evaluations. The most important debates are related to the three main aspects of 
costing methodology in economic evaluations: identification, measurement and 
valuation of costs (7). These debates are recaptured in this thesis and some issues 
are empirically investigated and discussed more extensively. Examples of ongoing 
productivity cost debates are the relevance of productivity cost inclusion in (indi-
vidual) economic evaluations, the appropriate valuation approach, and the iden-
tification of commonly ignored relevant health related productivity changes, such 
as the effects of ill-health on unpaid labor and effects on coworkers’ productivity. 
Most commonly, productivity costs are estimated by placing a wage-based value 
on an ill worker’s absenteeism and (occasionally) presenteeism (i.e. productivity 
losses related to being ill at work). However, it has been suggested that common 
productivity cost estimates are, in fact, underestimations of actual costs (14-16), since 
these do not account for the negative effect of absenteeism and presenteeism on 
coworkers’ productivity in case of team-dependent production. At most, an entire 
team’s productive output can be at risk when one of its members experiences 
health problems. Oppositely, it has been suggested that common estimates may 
be an overestimation of true productivity costs (17,18), since productivity losses may 
partly be compensated during normal working hours. Although compensation of 
lost productivity in normal hours is not costless ‘true’ productivity costs may then 
be lower than common productivity cost estimates. 
Third, productivity cost inclusion in economic evaluations may be hampered 
by practical limitations. In some particular circumstances (e.g. when researchers 
are highly dependent on retrospective data) it may not be possible to collect data 
on the effects of ill-health and treatment on patients’ productivity. Currently, in 
such situations productivity costs are typically ignored regardless of whether the 
inclusion of these costs would be appropriate. Given the potential effect of pro-
ductivity costs on cost-effectiveness outcomes, excluding these costs may lead 
to a misrepresentation of actual costs and benefits and hence to misinforming 
decision makers. It has been suggested that in cases where collecting productiv-
ity data proves impossible, productivity may be predicted based on information 
on quality of life. Although the significant correlation between productivity 
and quality of life has been previously investigated (19,20), it is unclear whether 
adequately predicting productivity based on quality of life data is possible.
17
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Productivity costs in QALYs?
One of the unresolved productivity cost issues that stirred quite some de-
bate is whether productivity costs should be captured as costs or in terms 
of QALYs (2,8,21-23). Importantly, QALY weights for use in economic evaluations 
are obtained by means of valuation surveys among the general public. These 
weights are thus usually based on societal preferences regarding health states 
rather than patients’ preferences (2). In such valuation surveys, a representative 
sample from the general public is asked to value a variety of distinct health 
states. These health states are often described by using level and domain 
descriptions of generic quality of life questionnaires, for instance the EQ-5D 
(24) or the Health Utility Index (25). The health states are commonly valued with 
techniques such as the Visual Analogue Scale, the Standard Gamble method or 
the Time Trade-Off method (26-30). Based on the respondents’ answers, a value 
set can be constructed producing QALY weights for all possible health states 
described with the relevant generic quality of life instrument. Using such QALY 
weights, health gains due to interventions can be quantified as QALY gains and 
used in cost-utility analyses. 
What the health state values underlying QALY gains exactly represent is 
unclear. In a typical Time Trade-Off exercise to obtain health state valuations, 
respondents are required to make trade-offs between living in a better health 
state for a shorter period or in a worse health state for a longer period of time. 
It has been suggested that respondents in such exercises may not only consider 
health itself but also broader effects, such as effects of ill-health on income 
(2). Traditionally, productivity costs (if included) in economic evaluations were 
commonly included in monetary terms on the cost side of the cost-utility ratio. 
In 1996 the Washington Panel, however, stated that productivity was already 
included on the effect side of the ratio (that is, in health state values), and 
should therefore be excluded from the cost side to avoid double counting of the 
effect of ill-health on productivity and income. Although this recommenda-
tion was strongly criticized (22,31), it was never empirically investigated whether 
respondents to health state valuation exercises in fact included income effects. 
1.3  Productivity costs questions addressed in this thesis
The main questions addressed in this thesis relate to unresolved issues that 
have emerged from earlier debates regarding productivity cost inclusion in 
economic evaluations. These questions are:
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1. Do respondents to health state valuations include the effects of ill-health 
on income and if so, how does such inclusion affect valuations?
2. How common is productivity cost inclusion in economic evaluations?
3. How does productivity cost inclusion or exclusion affect cost-effectiveness 
outcomes?
4. How is reduced productivity related to ill-health compensated and how 
do compensation mechanisms and multiplier effects potentially affect 
productivity cost estimates?
5. Can productivity losses be predicted based on quality of life estimates?
By answering these questions, this thesis seeks to contribute to the ongo-
ing debates regarding theoretical and practical aspects of productivity cost 
inclusion in economic evaluations. In doing so, it aims to stimulate the process 
towards standardizing productivity cost inclusion and methodology.
1.4 Outline of this thesis
Chapter 2 provides an overview of the most important past and present de-
bates and developments regarding productivity cost inclusion, identification, 
measurement and valuation. Moreover, this chapter describes important un-
derexplored research questions for future research regarding productivity costs 
in economic evaluations. The future research topics are based on present-day 
issues discussed in recent literature.
Chapters 3, 4 and 5 describe empirical work on the question whether 
productivity costs are or even should be included on the effect side of the 
cost-effectiveness ratio. It is investigated whether respondents to health state 
valuations take the effects of ill-health on income into account when partici-
pating in health state valuation exercises. Furthermore, it is investigated how 
spontaneous inclusion or exclusion of income-effects influences final health 
state valuations. Moreover, the effects of explicitly instructing respondents 
to either include or exclude income-effects are explored. The effects of such 
instructions are important to identify, considering that if respondents to health 
state valuations do not consistently include or exclude income effects sponta-
neously, explicit instructions may be required to ensure consistency.
In chapters 6 and 7 insight is provided in the current role of productivity costs 
in economic evaluations. It is investigated to what extent productivity costs are 
included in economic evaluations. Moreover, in evaluations where these costs 
are included it is examined how these costs were identified, measured and 
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valued. Additionally, the amount of productivity costs within studies including 
these costs is discussed (both in absolute terms and as a fraction of total costs) 
as is the impact of including productivity costs on cost-effectiveness outcomes.
In chapter 8 it is discussed whether common productivity cost estimates ac-
curately reflect actual productivity costs. In this chapter it is investigated how 
ill workers’ absenteeism is compensated. Additionally, it is explored how com-
pensation mechanisms and effects of ill-health on team workers potentially 
affect common productivity cost estimates.
In chapter 9 of this thesis it is explored whether patients’ productivity levels 
can be estimated based on EQ-5D quality of life data. It does so by asking 
respondents in an online survey about whether they would be able to attend 
to work in different health states and if so, how they would expect to function 
in that health state. Subsequently, based on these responses two prediction 
models are presented to enable productivity predictions based on EQ-5D 
information. The validity of the models is tested and discussed by means of 
comparing predictive productivity levels with measured productivity levels in 
a group of patients suffering from low back pain.
Chapter 10 draws together the results of the previous chapters. It provides a 
discussion of the results and explores the implications and the limitations of 
this thesis. 
To note, the chapters of this thesis are based on research articles published, 
or planned to be published in scientific peer reviewed journals. As a result, 
the chapters of this thesis can be read independently and some overlap exists 
between some of the chapters.

2. 
Productivity costs in economic evaluations:
Past, present, future
Based on: Krol M, Brouwer WBF, Rutten FFH.
Productivity costs in economic evaluations: Past, present, future. 
Accepted for publication in Pharmacoeconomics.
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Summary
The inclusion of productivity costs and its respective methodologies have been 
fiercely debated in the literature. Productivity costs occur when the productiv-
ity of individuals is affected by illness, treatment, disability, or premature death. 
The main debates and divides in theory and practice of economic evaluations 
of health technologies have centered on the questions of whether and how to 
include productivity costs, especially productivity costs related to paid work. 
We focus on past and current developments related to productivity costs and 
address its role in economic evaluations. We highlight how debates in the area 
have evolved and where we currently stand in theory and practice of includ-
ing productivity costs in economic evaluations. The objectives of this chapter 
are (i) to discuss the main debates and developments regarding the inclusion, 
identification, measurement, and valuation of productivity costs; and (ii) to 
summarize the most topical unresolved issues regarding productivity costs in 
economic evaluations, and (iii) to encourage future research in the area.
23
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2.1 Introduction
Economic evaluations are increasingly used to aid decision makers in allocating 
scarce health care resources. Given the direct influence the results of economic 
evaluations may have on health care decisions, ensuring a sound methodology 
is critical. Many fierce debates regarding the methodology of economic evalua-
tions are ongoing. Importantly, these debates normally do not relate to method-
ological choices that marginally affect final outcomes of economic evaluations. 
In many cases, their influence can be profound. Examples of such debates 
relate to the normative foundations of economic evaluations, the perspective of 
economic evaluations (i.e., what costs and benefits to include), how to discount 
future costs and benefits, and the nature and height of the threshold value used 
in judging cost-effectiveness results (e.g. (32-38)). One area of debate and dissensus 
closely related to the appropriate perspective of economic evaluations is the 
inclusion of productivity costs and the methodologies used to measure and 
value them. Productivity costs can be defined as the costs associated with paid 
and unpaid production loss and replacement due to illness, disability, or death 
of productive persons.(8) The main debates and divides in theory and practice of 
economic evaluations of health technologies have centered on whether and how 
to include these costs, especially those related to paid work. 
Several important topics regarding the questions above have been recently 
reviewed and discussed by Zhang et al.,(39) who pointed out, ‘more attention 
should be paid to the methodologies of measuring and valuing productivity loss,’ 
since many concerns regarding productivity costs are yet to be resolved. Table 
2.1 presents a summary of important questions addressed in the literature and 
a selection of literature references pertaining to them, highlighting the atten-
tion the topic has captured. 
In this chapter, we focus on past and current developments related to the 
inclusion of productivity costs and address their inclusion in economic evalu-
ations. This highlights how the debates in this area have evolved and where 
we currently stand in the theory and practice of including productivity costs 
in economic evaluations. The objectives of this chapter are (i) to discuss the 
main debates and developments regarding the inclusion, identification, 
measurement, and valuation of productivity costs; and (ii) to summarize the 
most topical unresolved issues regarding productivity costs in economic evalu-
ations, and (iii) to encourage future research in this area.
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2.2 Inclusion
The question of whether to include productivity costs has been addressed in 
the literature mainly by focusing on the ethical consequences of inclusion 
(e.g.(12,13)) and taking the appropriate perspective in economic evaluation (e.g. 
(33-35,40,41)). Moreover, whether the costs are relevant (9,23,42-45) is a matter of debate.
Ethical concerns
Some authors (e.g. Williams and Olsen and Richardson (12,13)) have raised con-
cerns regarding the equity implications of including productivity costs in eco-
nomic evaluations. One issue is that health care programs aimed at productive 
people (especially in exchange for pay) can produce substantial societal gains 
due to improved productivity. Inclusion of these costs would therefore result in 
more favorable cost-effectiveness results of interventions aimed at employed 
Table 2.1 Important aspects related to the estimation of productivity costs within economic 
evaluations
Aspects Main questions Selection of 
literature discussing 
these issues
Inclusion of PC Should productivity costs be included in economic 
evaluations?
 Ethics Is it ethical to include productivity costs? (12,13)
 Perspective Which perspective should be taken in economic evaluations? (2,7,33-35,40,41)
 Relevance Are productivity costs relevant to include? (9,42-45)
Identification How can health related productivity changes be identified?
 Input and output How do health changes affect productive input and output? (46,47)
  Paid and unpaid labor How can and should productivity changes in paid and unpaid 
labor be identified?
(43,46,48-50)
  Ill workers and 
coworkers
How can the effects of productivity changes on coworkers be 
identified?
(14-16)
Measurement How can productivity changes best be measured?
 Data collection How and when should data on productivity be collected? (39)
 Content of instruments Which productivity related information should be collected? (17,39,51)
  Availability of 
instruments
Which instruments are available and how is their 
performance?
(52-54)
 Indirect measurement Is it possible to adequately measure productivity changes 
indirectly?
(19,20,55)
Valuation How can productivity changes best be valued?
 Approach: theory Which valuation approach should be applied? (8,11,21-23,47,56-59)
 Approach: empirical Are income effects already captured in the QALY? (60-67)
 Values Which values should be placed on productivity changes? (46,68)
Reporting outcomes How should productivity cost estimates be reported in 
economic evaluations?
(41,44)
PC = productivity costs
QALY = quality adjusted life year
25
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persons than those aimed at the unemployed or retirees. This could, in turn, 
lead to fewer resources allocated to interventions aimed at unemployed indi-
viduals, which could be considered inequitable. While inclusion of productivity 
costs can indeed have such distributional consequences, several issues temper 
the subsequent conclusion that their outright exclusion is warranted. 
First, economic evaluations are commonly used to inform decisions on 
reimbursement of interventions through the inclusion in some basic insur-
ance package (which covers all individuals, regardless of productivity). They 
are normally not used to decide which groups have access to the interventions 
within the total patient group. 
Second, inclusion of productivity costs does not necessarily lower cost-
effectiveness estimates or favors interventions for productive individuals.(9,43-45) 
When interventions require substantial time from productive individuals (e.g., 
intensive psychotherapy), inclusion of productivity costs may cause interven-
tions to become less cost-effective and the treatment of individuals without 
paid work would thus be more cost-effective than that of those with paid work.
(9,44) 
Third, complete exclusion of costs based on equity considerations seems 
difficult and dangerous, since many types of costs (including medical) may 
be perceived to ‘discriminate’ between different groups (e.g., young and old). 
Therefore, health policy makers have to balance the desirable effects of freeing 
additional resources due to productivity gains with the equity implications 
of including productivity costs. As recommended (e.g. by Brouwer et al. and 
Pritchard and Sculpher (41,43)), final cost-effectiveness ratios may best presented 
with both scenarios, i.e., with and without productivity costs. Moreover, as 
recently argued,(69) equity considerations should have a prominent place in de-
liberations on final policy decisions based on results of economic evaluations.
Perspective
The debate on in- or excluding productivity costs in an economic evaluation is 
closely related to the issue of the appropriate perspective to take in economic 
evaluations and (therefore) the relevant decision context and decision rule [2]. 
Two prominent perspectives are the health care perspective and the societal per-
spective. Evaluations performed from a health care perspective do not include 
productivity costs, since these costs (or savings) do not fall within the health 
care budget. Economic evaluations conducted from the societal perspective, 
however, include all costs – including productivity costs – whenever relevant.
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The important normative choice of perspective relates to the context of eco-
nomic evaluations (e.g., health care) and the objective(s) of the decision maker. 
(See Claxton et al. and Brouwer et al.) (33,41) for more elaborate discussion.) If we 
assume that economic evaluations are to inform a decision maker with the aim 
of maximizing health from a given health care budget, costs falling outside of 
that budget (and non-health benefits) can be left out of the evaluation. Influen-
tial textbooks (e.g. (2,7)), however, suggest that taking a broader, societal perspec-
tive in economic evaluations is appropriate. Such thinking furthermore seems 
to align with the welfare economic roots of economic evaluations.(70) Adopting 
a societal perspective all costs and effects directly or indirectly induced by the 
intervention are incorporated (when significantly present) in the evaluation, 
regardless of where the burden (or benefit) falls. (2) This relates to the decision 
maker’s broader underlying objective of maximizing social welfare.(34) When 
adopting such a perspective, productivity costs are clearly relevant and should 
be included in the evaluation.
While the discussions regarding appropriate perspectives are ongoing at 
the theoretical level, different viewpoints have been taken in practice. For 
instance, when investigating the various national guidelines for (pharmaco-)
economic evaluations, we notice that many countries (e.g., the UK, Belgium, 
New Zealand (71,72)) require analysts to take a narrower, health care perspective, 
encouraging analysts to ignore costs outside the health care sector, including 
productivity costs (or at least not to report them). Other countries (e.g., Sweden 
and the Netherlands (73,74)) do prescribe a societal perspective and thus require 
analysts to consider productivity costs whenever relevant. 
Although practical and theoretical consensus regarding this important issue 
of perspective remains out of reach, recent developments in the literature may 
represent steps toward it. Brouwer et al.(41) have attempted to reconcile both 
viewpoints to some extent. They argued that, while productivity costs repre-
sent real societal impacts on welfare and should not be systematically ignored 
in economic evaluations, they can carry a different weight in health care deci-
sions because their opportunity costs may be different from costs falling on the 
health care budget. Moreover, for costs outside their budget health care policy 
makers are not directly or formally responsible, and may weigh any adverse eq-
uity implications that productivity cost inclusion may have, indicating that the 
context in which health economic evaluations are performed is relevant. This 
does not imply, however, that a health care policy maker should be left ignorant 
of costs and savings external to the health care sector that occur due to actions 
in the health care sector. As several authors (e.g. (75,76)) have argued, a health care 
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program improving productivity of patients produces additional savings to 
society that free resources for welfare-improving purposes, which may include 
health care. Such a program therefore uses fewer societal resources to produce 
the same benefit than a comparable program without improved productivity 
or, when the savings are used to produce additional health benefits (e.g., added 
to the health care budget3), it leads to higher benefits for the same health care 
costs. While these broader costs and benefits may be viewed as externalities 
from the viewpoint of a health care decision maker, having decision makers 
ignorant of them may result in non-optimal decisions from a societal perspec-
tive.(34,40) In that sense, Brouwer et al.(41) refer to the concept of “local optimal-
ity.” (77) The puzzle of maximizing welfare is too complex for single decision 
making bodies; all solve a part (education, health care, defense, and so on) of 
the puzzle, each with its own budget and objectives. Such local optimality, how-
ever, does not necessarily translate into an overall optimal outcome, especially 
when externalities exist. A two-perspective approach was therefore proposed 
as a new standard in economic evaluations, whereby the cost-effectiveness 
ratios from both the health care and the full societal perspective are presented.
(41) Such an approach would highlight discrepancies (i.e., when an intervention 
is deemed cost-effective from a societal perspective but not from a health care 
perspective and vice versa) that inspire further attention. The approach also 
allows decision makers to attach more weight to some costs than to others. In 
some ways, the suggestion aligns with recent work on appropriate perspectives 
(33) in the sense that costs outside the health care sector could be accounted for 
but weighted differently.
The two-perspective approach is already recommended in several national 
health economic guidelines (e.g., Italy and Norway.(78,79)) Moreover, numerous 
country guidelines prescribing a health care perspective for the base-case 
analysis allow presenting results from additional perspectives. Whether and 
how this affects (or improves) decision making, however, remains unclear. In 
general, balancing outcomes from evaluations using different perspectives 
may be a demanding task for decision makers. Future research could be aimed 
at investigating (i) how to support decision makers in this context, (ii) the ex-
tent to which external costs and savings are important, and (iii) whether they 
can be directly or indirectly transferred into health care funds. 
3 Reallocation of savings outside the health care sector to the health care budget is likely to be difficult 
to accomplish in practice. (43) Such reallocation would, at the least, involve transaction costs (33)
28
 
Relevance 
While systematically ignoring productivity costs seems hard to defend, their 
inclusion is not necessarily influential. In general, the inclusion of productiv-
ity costs related to paid work is especially relevant when the intervention is 
targeted at patients of working age or younger patients whose future produc-
tivity is at stake.4 Moreover, productivity cost inclusion is only relevant if an 
intervention indeed affects patients’ work ability and, in turn, productivity. In-
terventions may not affect productivity in cases involving very mild conditions 
(patients continue to work) or very severe conditions (patients work neither 
before nor after treatment). Finally, for productivity costs to affect incremental 
cost-effectiveness, the intervention and comparator should affect productiv-
ity differently. If we can reasonably expect cost-effectiveness outcomes to be 
unaffected by productivity costs, they can be ignored even when adopting a 
societal perspective.(45)
Hence, in some cases productivity cost inclusion seems irrelevant. However, 
a decision to exclude productivity costs in an economic evaluation should be 
taken with caution. Several studies have shown that, if work ability of produc-
tive, working age individuals is indeed affected, the choice of including or 
excluding productivity costs in economic evaluations can strongly influence 
both incremental costs and incremental cost-effectiveness (e.g. (9,42,43,45)). Ny-
man has recently suggested that excluding productivity costs in the friction 
cost approach may not substantially bias incremental cost-effectiveness 
estimates since “under the frictional approach, the omitted costs are likely to be 
relatively small.”(23) We urge caution here, since it seems that in practice such 
biases can still be considerable. Krol and colleagues have shown that even with 
the more conservative friction cost estimates, productivity costs on average re-
flected 23% of total costs in studies considering expensive drugs administered 
in a hospital setting (45) and 56% among interventions targeted at depressive 
disorders.(44) The precise impact of productivity cost inclusion varied strongly 
in individual economic evaluations, both as a fraction of total costs and incre-
mental cost-effectiveness outcomes. Nevertheless, the strong potential impact 
of productivity costs on cost-effectiveness outcomes confirms that structurally 
ignoring them may lead to suboptimal decision making (in terms of welfare) 
and inefficient use of societal resources.
4 Whether it is relevant to include potential effects on future productivity depends on the valuation 
approach. If the friction cost approach is adopted, these costs normally need not be included, 
since they will commonly fall beyond the friction period. Their inclusion is important, however, 
when using the human capital approach.
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In sum, while there may be reasons for decision makers to assign different 
weights to productivity costs depending on where they fall, a case for their full 
and systematic exclusion is hard to defend. The question of how these costs 
need to be included is then the relevant one. 
2.3  Identification of factors influencing productivity costs
To be able to identify health-related productivity changes it is important to 
understand where and when they can emerge. In general, the several ways are: 
(i) lower production levels and hence welfare decrease; (ii) higher cost of pro-
duction levels (e.g., hiring additional labor); or (iii) some combination of both 
(e.g., when a replacement is not as productive as the worker replaced).(47) In this 
section we highlight the identification of relevant factors driving productivity 
costs. 
Paid labor
In the context of paid labor, several aspects need to be addressed. 
Absenteeism
Traditionally, patients having paid work and experiencing absenteeism due 
to illness, disability, or premature death would be a reason to consider pro-
ductivity costs in economic evaluations. Absenteeism from paid work clearly 
represents a major source of productivity costs as emphasized in the literature. 
Presenteeism
Reduced productivity at work, also called presenteeism, can be important. Pre-
senteeism may occur without absenteeism, but can also precede absenteeism 
(e.g., a progressive illness whose onset is mild) or follow absenteeism (e.g., a 
partial recovery that allows return to less productive work).(20) For some illness-
es (e.g., depression or migraine) presenteeism may be particularly important 
and may, in fact, be more important (cost-wise) than absenteeism. Moreover, 
we should note that in jurisdictions where sickness benefits for absenteeism 
are less generous, presenteeism (and its related costs) may be more prominent. 
Compensation mechanisms
Not all reduced productivity results in reduced production. Compensating for 
lost work is quite common.(17,18,80) For instance, an ill worker may compensate 
30
 
for lower productivity in normal or extra hours (potentially after returning 
to work); colleagues may take over some or all tasks (in normal or additional 
hours); new personnel may be hired to compensate for losses. Compensation 
mechanisms (even those involving compensation during normal work hours) 
are not costless, but little is known about their actual costs. 
Multiplier effects
Productivity losses in one individual may negatively affect coworkers’ produc-
tivity in case of team-dependent production. The productive output of a full 
team can be jeopardized by one member’s illness. This is especially relevant 
when substitutes are less equipped or unavailable. The effect of ill health on 
coworkers’ productivity (‘the multiplier effect’ (14-16)) can be non-negligible.
Unpaid labor
That productivity costs involve costs related to paid and unpaid labor is of-
ten ignored. Productivity costs related to unpaid work are rarely included in 
economic evaluations and, as a consequence, have little influence in decision-
making processes. From a societal viewpoint productivity losses related to 
unpaid labor are important. Swiebel (81) defines unpaid labor as “all productive 
activities outside the official labor market done by individuals for their own 
households or for others.” Inter alia, this includes household work, caring for 
significant others, and volunteer work. Productivity costs related to unpaid 
work may result from loss of unpaid production or replacement costs. Little 
is known about lost unpaid work involving absenteeism and presenteeism. 
Along with the growing number of interventions targeted at the elderly, unpaid 
productivity should have a more prominent role in economic evaluations.
In sum, productivity costs related to paid and unpaid work are complex. They 
involve costs related to lost production or replacement costs due to absentee-
ism and presenteeism. Diminished productivity of ill workers can negatively 
affect coworkers’ productivity, increasing productivity costs. Compensation 
mechanisms can reduce production losses, but their costs are underexplored. 
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2.4 Measurement 
Once it is clear what needs to be included in the analysis (identification), the 
next issue is to measure the relevant quantities. In this section we highlight 
measurement of different aspects related to productivity costs. 
Paid productivity
A sound estimation of productivity costs requires sound measurement of the 
relevant components. Unfortunately, there is an apparent lack of standardiza-
tion of measurement methods for productivity costs and no consensus on the 
best instruments to reliably capture changes in productivity. Ideally, informa-
tion is also gathered on the effects of productivity changes on coworkers and 
the relevance and costs of compensation mechanisms. When using the friction 
cost method (section 5), total absenteeism, its frequency and the duration of 
each separate period of absenteeism must be captured. Actual, objective mea-
surement of productivity changes (absenteeism and presenteeism) at the work 
sites of the relevant patients is normally impossible in the context of health 
economic evaluations. Commonly, patients are required to self-assess dimin-
ished productivity in terms of absenteeism and, occasionally, presenteeism. 
The reliability of such measures has not often been tested.(82)
Many instruments (mostly written questionnaires suitable for self-administra-
tion by ill workers) have been developed to measure health-related productiv-
ity changes. Selecting an appropriate instrument among the available instru-
ments is challenging.(52) Empirical research has shown that the use of different 
instruments can lead to large differences in outcomes.(83) Such differences are 
worrisome, since they seriously hamper comparability of productivity cost 
outcomes and can lead to justifiable doubt regarding the validity of productiv-
ity cost estimates. Differences in outcomes secondary to instrument choice 
are likely to be influenced by how questions are framed and the applied recall 
period. Zhang et al.(39) pointed out in a recent review that outcomes of scientific 
research on the appropriate recall period for absenteeism and presenteeism 
are inconclusive. Still, given the available evidence, they recommend apply-
ing a three-month recall period for questions regarding absenteeism and a 
one-week time period for questions related to presenteeism. The feasibility of 
different time-frames within one questionnaire for self-completion, however, 
deserves attention. 
It is not clear which of the currently available instruments provides the best 
estimates of absenteeism and presenteeism.(39) Most instruments focus on a 
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particular part of productivity losses, such absenteeism. Other, typically more 
recently developed instruments, capture both diminished productivity related 
to presenteeism and absenteeism. (For reviews of productivity instruments see 
(52-54).) Few instruments seem to include measurement of unpaid productivity 
losses by, for instance, questioning the ability to perform household tasks (e.g. 
the Health and Labor Questionnaire (84)). Furthermore, the validity of the answers 
to such questions has rarely been investigated. Zhang et al.(85) recently developed 
a new productivity cost questionnaire, which seems to be the first to combine 
absenteeism, presenteeism, paid and unpaid labor, job characteristics, compen-
sation mechanisms, and team dynamics. While being the most comprehensive 
instrument to date, to our knowledge, its validity needs to be further explored.
Some elements relevant to productivity costs, especially compensation 
mechanisms and multiplier effects, are inherently difficult to measure by 
patient-completed questionnaires. Patients may not have sufficient knowledge 
of how their health problems affect team output and how their diminished pro-
ductivity is compensated for. Employees and their supervisors appear to pro-
vide different answers on how health-related absenteeism is compensated.(18) 
Regarding the effects of illness on coworkers and team output some attempts 
have been made to construct ‘job-dependent multipliers’ that take account 
of the (average) effect of co-worker absenteeism and presenteeism in specific 
job types. The idea behind them – which is worthy of future research – is that 
if multipliers are robust and transferable it would be possible to include the 
effects on coworkers in economic evaluations solely based on information of 
the ill worker’s job-type. Investigating how compensation of health-related 
productivity losses interacts with the effects of the losses on coworkers’ pro-
ductivity is also important.
Another measurement difficulty is deciding on how often to repeat measurement. 
The appropriate frequency obviously depends on the type of intervention and when 
and how often changes in productivity are expected. A trade-off must be made 
between the costs of measurement, study compliance, and accuracy of outcomes. 
Accuracy is likely to increase with the number of measurements but at the expense 
of evaluation costs and patient burden, the latter of which is likely to negatively af-
fect compliance rates. In this light, it is important to note that it is unclear how to 
estimate productivity when measurement gaps exceed the recall period.
Unpaid productivity
Two approaches seem most commonly used in measuring health-related 
productivity changes in the context of unpaid labor.(2,7) The first measures the 
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changes in time spent on unpaid labor and the second measures the additional 
time others spend on unpaid labor tasks not performed by the patient due to 
illness. Both approaches have difficulties. In the first, distinguishing between 
time spent on unpaid labor and leisure time is challenging. Time spent with 
one’s children, for example, may be considered leisure time but it is also 
childcare; should the parent become ill someone else would have to look after 
them, a task that, at least in part, could be considered unpaid work. In 1934 
Reid (86) introduced the ‘third person criterion’, whereby all output replaceable 
by a third person can be considered unpaid labor. Elements people cannot take 
over (e.g., the enjoyment of playing tennis) are then considered leisure. The 
distinction is useful, but can be difficult to apply in practice. Especially tasks 
such as caring for children may involve elements of both leisure and unpaid 
labor, which may be difficult to disentangle. 
This difficulty is avoided to some extent by applying the second approach, 
measuring the time spent by others who take over the patient’s unpaid work. 
In that case, however, all tasks that are simply forgone or later compensated 
for remain unvalued, potentially leading to an underestimation of productivity 
loss related to unpaid labor. A solution may be to ask patients how much time 
others would have to spend to perform all lost activities, rather than how much 
time others actually did spend taking over tasks. To date, clear guidance and 
sufficient knowledge on how unpaid labor changes can be best measured is 
lacking, introducing another potential for undesirable variation in measure-
ment.
Indirect estimation
A practical concern related to productivity cost measurement is that collecting 
all required information related to productivity changes might not be feasible. 
Researchers are sometimes fully dependent on retrospective data or data col-
lection within clinical trials that do not include questions concerning patients’ 
productivity. In these situations, occasionally published estimates of previous 
studies are used (if available), but productivity costs seem largely to be ignored 
under such circumstances.(10,43-45,87) One partial remedy is to indirectly estimate 
productivity losses based on other available patient information, especially 
quality of life measures,(19) which have been shown to be significantly associ-
ated with productivity.(19) In a recent exploration of this possibility, the results 
of a study by Krol et al.(55) were promising, but require additional confirmation. 
Applying prediction models to estimate productivity losses in cases where no 
actual data is available may be preferable to ignoring the effect of illness on 
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productivity. Whether it is possible to predict productivity related to unpaid 
work based on quality of life data has not yet been explored.
2.5 Valuation
The valuation of productivity changes, especially those concerning paid work, 
has been most prominently debated in the literature. The following section 
highlights the main issues of debate and indicates where we stand in theory 
and practice. 
Valuation approaches of lost paid work
Valuation methods for productivity have been fiercely debated in the health 
economic literature. Early work on the valuation of reduced productivity was 
based on the theory of human capital (88) whereby, in the case of total unpro-
ductivity due to illness, the relevant value of the production loss was assumed 
to equal the present value of all lost future earnings of the individual. That 
is, income acts as a proxy for the production value of the individual and all 
production not produced by this person is counted as production loss. This 
obviously produces relatively large estimates of productivity costs in case of 
long term absenteeism, disability, and premature death. Consider, for instance, 
a person, who would have retired at age 65, but dies at age 35 from acute heart 
failure. The human capital approach then counts all lost production time (i.e., 
from age 35 to 65) to calculate productivity costs and commonly multiplies it 
with the expected average annual wage rate. For an annual wage of €40,000, for 
example, total value of lost productivity would be 30 x €40,000, or €1,200,000 
(without discounting). 
The very high valuations resulting from the human capital approach induced 
important criticism. (47,56,89,90) The approach was importantly challenged by 
Koopmanschap and Van Ineveld, (90) who argued that an important, implicit 
underlying assumption of this approach is that all markets – including the 
labor market – clear, such that no involuntary unemployment ever occurs. 
In reality, involuntary unemployment is rather common; ill workers are often 
replaced by healthy, (unemployed) persons. In that case, Koopmanschap and 
Van Ineveld argued, productivity losses due to long term absence would be 
limited to the ‘friction period’, or the period it takes to replace the ill worker by 
a formerly unemployed person and, hence, to restore production to its initial 
level. Production losses and transaction costs (related to advertising, hiring, 
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training, etc.) occur during the friction period only. Moreover, since a reduc-
tion in labor time is often assumed to cause a less than proportional decrease 
in production, Koopmanschap et al. (47) originally proposed to apply an elastic-
ity factor of 0.8, which is often used in empirical studies applying the friction 
cost approach. Productivity costs using this method are markedly lower than 
using the human capital approach, especially in the case of long term absence. 
On the basis of an econometric model of a national economy, Koopmanschap 
et al. (47) showed that it is possible to focus on the short term costs incurred 
during the friction period to measure productivity costs. Long term indirect 
costs were estimated to be relatively small in relation to the friction costs, and 
relate to the effects of changes in the number of ill and unemployed persons in 
the population and the corresponding effects, for example, on social insurance 
premiums for unemployment and disability benefits.
The friction cost approach was subsequently criticized by proponents of the 
human capital approach (e.g., (58,91)). Important criticisms were that it lacked 
a sound theoretical underpinning and would render leisure time valueless. 
Although an unemployed person replacing the ill worker sacrifices leisure time 
to perform paid work, the friction cost approach gives it no value. Friction cost 
proponents indicated that leisure was not treated as ‘costless’, but rather that 
gains and losses of leisure at a societal level even out between the sick worker 
and the replacing worker. Moreover, differences in ability to enjoy leisure 
time are commonly valued in terms of quality of life. (57,59) Although the debate 
between proponents of the two approaches is likely to continue, Nyman (23) 
recently concluded on theoretical grounds that “to be consistent with the soci-
etal perspective … frictional accounting of productivity costs should be adopted 
rather than the human capital accounting.”
This recommendation, made especially for the US context, was important, 
since during the debate between proponents of the two approaches in the 
1990s, the US Panel on Cost-Effectiveness in Health(2) implicitly criticized both 
by advocating the inclusion of productivity costs in economic evaluations 
as effects rather than costs. The Panel suggested that the effect of disease on 
productivity is (and should be) valued through a preference-based measure of 
health like the quality adjusted life year (QALY) as health effects. They moreover 
indicated that respondents in health state valuations underlying QALY calcula-
tions would consider effects on productivity and income when valuing health 
states, unless explicitly instructed otherwise. This implies that any additional 
monetary valuation of the impacts on productivity would be double counting. 
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The US Panel method was criticized soon after it was proposed. It was sug-
gested that its estimates would be unreliable, since people may be unable 
to translate a hypothetical health state, described in a health state valuation 
exercise, to an estimate of productivity. Moreover, the link between productiv-
ity and income on an individual level is weak because of private and social 
security systems. (22,31) In spite of the theoretical criticisms of the US Panel 
approach, the suggestion of double counting when also applying the human 
capital or friction cost approach could not be easily rejected. Further empirical 
research followed and is discussed in the next section. 
Empirical evidence and the theoretical debate
The theoretical debates between the three valuation approaches could benefit, 
to some extent at least, from more empirical research. An important issue in the 
US Panel method was the assertion that individual respondents would include 
income consequences of reduced productivity as a result of poor health in their 
valuations of health states, for instance, when answering common time trade-
off (TTO) questions. While such considerations may not (necessarily) result in 
a valid valuation of productivity losses, they could result in (partial) double 
counting. Such partial double counting casts doubts on including productivity 
costs in the numerator of a CE ratio, using either the friction cost or human 
capital approach. This issue initiated empirical studies focusing on whether 
respondents in health state valuations indeed consider income changes and, if 
so, how it affects valuations. 
Recently, Tilling et al. (92) reviewed the seven studies thus far published on 
the topic, which varied substantially in design and approach. Their review 
indicated that, while a non-negligible minority of respondents may indeed 
include income changes in health state valuations when not explicitly in-
structed not to do so, inclusion did not appear to significantly affect health 
state valuations. Tilling et al. (92) concluded that this evidence suggests that the 
US Panel method is not a reliable valuation method for productivity costs. This 
underlines the theoretical criticism it received. Moreover, in terms of the risk of 
double counting, Tilling et al. (92) indicated that: “the evidence seems to suggest 
that population value sets derived using generic instruments such as the EQ-5D 
are not noticeably influenced or ‘polluted’ by income effects and therefore can be 
used alongside monetary valuation methods of productivity costs, as well as in 
contexts where income effects are to be excluded from the analysis completely”. 
Although they indicated that more research is warranted to fully exclude the 
risk of double counting, it seems that a monetary valuation method (human 
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capital or friction cost) is necessary to adequately value productivity costs and 
can be used in combination with conventional health state valuations. Nyman, 
after considering these issues, recently (23) proposed to change US guidelines 
and move away from the US Panel approach. He moreover suggested explicitly 
instructing respondents in health state valuation exercises to assume income 
would not be affected by illness. Since empirical evidence suggests that 
spontaneous inclusion of income effects does not seem to affect health state 
valuations, (92) it is uncertain whether such explicit instruction (which may 
unintentionally over-emphasize income in health state valuations) (68) results 
in ‘better’ health state valuations. Future research is thus required. 
The debate between the proponents of the human capital and friction cost 
approaches has generated less empirical research, partly related to the debates’ 
more fundamental differences that render empirical research difficult at best. 
For example, the existence of involuntary unemployment may be undisputable, 
but it need not be viewed as complete evidence that the friction cost approach 
is appropriate. More empirical research, such as on exactly how firms replace 
ill workers, where they are recruited from, and what it implies for the friction 
period (one period or a chain of periods) would be an important area for future 
research. It is, moreover, important to have estimates of transaction costs of 
replacement of employees, since they can be substantial. (93) In addition, for 
most countries the appropriate friction period to apply is unknown. Without 
establishing (and regularly updating) these data, an accurate calculation of 
productivity costs is hampered.
Other valuation issues
Common standards regarding the appropriate operationalization of valuation 
methods are lacking, resulting in practice variation even between studies 
claiming to use the same method. An important source of variation is the 
exact value attached to lost time from work. In published economic evalua-
tions values have been based on, for example, the employees’ added value to 
the firm, the employees’ gross income, average national gross income, or, less 
frequently, GDP per capita, insurance payments, or doctors’ opinions. Patients’ 
gross wage, however, or the (age and gender-dependent) average national gross 
wage seem the most commonly used valuation sources. (44) Which of the two is 
more appropriate depends on the study sample. Posnett and Jan (49) claim that: 
“Unless the study is designed in such a way that the study population can be 
taken to be fully representative of the population of all potential patients, the 
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results of the evaluation will be more readily generalized if market values for 
potential patients (of wage rates for example) are used (…..).”
An unresolved valuation issue is whether and how to adjust conventional 
productivity cost estimates for compensation mechanisms. Currently, such ad-
justment is uncommon in economic evaluations although estimates using the 
friction cost approach may already include a correction for compensation of 
lost work during normal working hours by factoring in the 0.8 elasticity. What 
this elasticity exactly represents is unclear, however, and to our knowledge its 
appropriateness has not been extensively investigated. If the elasticity indeed 
already represents compensation in normal hours, additionally correcting for 
compensation mechanisms could be a ‘double correction’ that artificially low-
ers productivity cost estimates. Adjusting estimates for multiplier effects is also 
uncommon. Important research questions linger in this area too, like whether 
the influence of one person’s productivity on a team is not yet reflected in his 
wage.
To date, few attempts have been made to directly correct productivity cost 
estimates for either team effects or compensation mechanisms. (15-18) One 
recent study corrected for these effects simultaneously, (80) but how compensa-
tion mechanisms and team effects interact in practice has not been explored. 
Examining this interaction is relevant, since complementary team work could 
increase the opportunity to compensate for a missing member in some cases, 
but lead to larger losses in others.
Valuation of unpaid labor 
Although some attention has been paid to the valuation of unpaid work related 
to informal care (94-99), little attention has been paid to valuing patients’ unpaid 
work. Time spent on unpaid labor such as household work can be considered 
a non-marketed use of time, which is commonly valued by assigning a shadow 
price based on the opportunity cost method or the replacement cost method. 
(7,96) With the replacement cost method (also called the proxy good method), the 
value of unpaid labor is determined by valuing the time it would take others to 
perform the tasks normally performed by the patient, determined by the cost 
of hiring a paid worker to perform the tasks. The value of an hour of household 
work, for example, would be determined by the (average) hourly gross wage of 
a paid household help.
Alternatively, the opportunity cost method could be applied, where the value 
of unpaid work is commonly set equal to the value of competing use of time 
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spent on paid labor. For the employed, the value of net wage could be used as a 
basis for computation; for the unemployed, potential wage.
In practice, most economic evaluations ignore unpaid labor and little atten-
tion is paid to further develop and implement its valuation methods. A lack 
of theoretical attention and practical inclusion, however, are likely to interact. 
An increase in scientific interest in unpaid labor may eventually lead to an 
increase of inclusion of unpaid labor in economic evaluations.
2.6 Productivity costs in practice
So far, debates regarding whether and how to include productivity costs in 
economic evaluation have not led to an increase of their inclusion in economic 
evaluations since the 1980s. As seen in table 2.2, productivity costs related to paid 
work are neglected in the vast majority of cases and their exclusion rate seems 
to be rather stable over time. Productivity costs related to unpaid labor are rarely 
included. Moreover, there is a clear lack of standardization regarding methodol-
ogy when including productivity costs. Exclusion may be partly explained first by 
the fact that half the national health economic guidelines prescribe a health care 
perspective. Second, productivity costs may not always be relevant to include, 
such as those related to paid labor in studies including elderly patients. The 
explanations nonetheless leave a considerable number of cases unexplained. (45) 
Productivity costs seem somewhat randomly included or excluded. Krol et al. 
(45) suggest this may indicate the existence of some kind of perspective selection 
bias; i.e., decisions regarding productivity cost inclusion and exclusion could be 
based on the expected effects on incremental cost-effectiveness outcomes. To 
avoid such bias, decision-making bodies should be more aware of their in- or 
exclusion whenever a societal perspective is (or ought to be) taken.
2.7 Conclusions
Past
A variety of aspects regarding the inclusion of productivity costs in economic 
evaluations have received attention in the scientific literature. The past few 
decades have seen important progress by, for example, acknowledging that 
productivity costs can be identified in cases other than absenteeism, such 
as presenteeism and effects on coworkers’ productivity, and that the costs of 
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health-related productivity changes depend on how they are compensated and, 
subsequently, the costs of the compensation. Numerous productivity costs mea-
surement instruments have been developed over the years. Most of them focus 
on health-related productivity changes in the context of paid work but neglect 
unpaid labor and coworkers’ productivity effects. Productivity cost estimates 
can vary substantially with the instrument, however, and which one provides the 
most accurate estimates has not been established. The valuation of health-related 
productivity changes has been fiercely debated. Empirical research initiated by 
the debate has illustrated that productivity changes are not sufficiently captured 
on the effects side of the cost-effectiveness ratio and therefore are better placed 
on the costs side. Whether productivity costs should be valued according to the 
human capital or friction cost approach remains a matter of debate.
Present
Despite the progress and the substantial amount of scientific research, consen-
sus has not been reached on either the inclusion of productivity costs in eco-
nomic evaluations or the methods used to produce productivity cost estimates. 
Such a lack of consensus has likely contributed to ignoring productivity costs 
in economic evaluations and is reflected in variations in national health eco-
nomic guidelines.(10,43-45,87) Given the current variety in applied productivity cost 
methodology, accurately reporting the methods used to estimate productivity 
costs in economic evaluations is critical to understand the nature of potential 
differences in outcomes. The reported level of detail is often poor. (45) Reported 
outcomes should also consider different types of production losses, such as 
absenteeism, presenteeism, and lost unpaid labor. Reporting productivity 
costs separately from direct costs to enable comparison of outcomes between 
studies, as is sometimes done, is recommended.
Future
Further scientific research is needed to lessen the controversy regarding the 
estimation of health-related productivity costs. In table 2.3 we provide an 
overview of the most topical issues inspired by questions and concerns of pre-
vious sections. The table partly reiterates earlier pleas. (51) The activities in table 
2.3 may serve a number of general objectives: (i) to increase the inclusion of 
productivity costs in economic evaluations whenever (deemed) relevant; (ii) to 
increase scientific research regarding (the inclusion of) health-related changes 
in unpaid labor; (iii) to promote the comprehensive inclusion of the costs of 
health-related productivity changes in paid labor (i.e., absenteeism, presen-
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teeism, and the effects on coworkers productivity); (iv) to increase knowledge 
on how health-related productivity changes lead to societal costs or savings; (v) 
to investigate how employee replacement costs can be measured and included 
in economic evaluations when relevant; and (vi) to explore the theoretical and 
practical potential to transfer societal savings due to productivity increases 
induced by medical treatment into the health care sector.
As has been shown, productivity costs can be substantial and the decision to 
include or exclude them can strongly affect cost-effectiveness outcomes. (9,43-45) 
This implies that if productivity costs are excluded where they are relevant, 
decisions regarding reimbursement of health interventions may be based on 
inaccurate incremental cost-effectiveness ratios. Decision makers aiming to 
make well informed decisions on reimbursement from a societal perspective 
might wish to emphasize the inclusion of productivity costs in future cost-
effectiveness studies.
The ultimate aim would be to develop common standards regarding the 
identification, measurement, and valuation of productivity costs. Although 
consensus on methodology is lacking, more standardization is essential to 
increase the comparability and credibility of economic evaluations taking a 
societal perspective. We hope to stimulate additional research in the important 
area of productivity costs.
Table 2.3 Future research topics
Unpaid labor Further develop and test methods to identify, measure and value relevant unpaid productivity 
changes.
Paid labor: 
Inclusion 
Reduce the lack of standardization and guidance regarding the inclusion of productivity costs.
Paid labor: 
Identification
Explore how health related productivity changes affect coworkers’ productivity and team 
output. 
Develop methods to identify and include these effects in economic evaluations.
Paid labor: 
Measurement
Develop and validate measures of compensation.
Develop and validate measures of multiplier effects.
Investigate the relationship between wages and multiplier effects.
Investigate the robustness and transferability of multiplier effect estimates.
Further investigate whether estimated productivity changes based on quality of life data can be 
useful for productivity cost calculations in cases where direct productivity measurement is not 
feasible.
Paid labor: 
Valuation
Investigate the costs of compensation mechanisms.
Investigate the friction cost period for different countries.
Investigate replacement costs of employees.
Other Explore the actual and potential redistribution (mechanisms) of productivity costs and savings 
within and outside the health care sector.
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Summary
Background: There has been considerable debate on whether productivity 
costs should be captured in the numerator or the denominator of the cost-
effectiveness ratio. That debate cannot be resolved on the basis of theoretical 
arguments alone because the final choice also depends on what is incorporated 
in health state valuations by respondents and how this influences outcomes. At 
the moment, little is known about whether the effects of ill health on income 
are included in health state valuations, and how instructions on including 
or excluding the effects on income influence health state valuations. Aim: To 
conduct an empirical study of health state valuations to test: (i) whether or 
not respondents spontaneously include the effect of ill health on income and 
leisure time; (ii) the impact on the valuation of inclusion (or exclusion) of such 
effects; and (iii) the influence of explicit instructions on this matter. Methods: 
Three questionnaires were developed and administered to the general public. 
Health state valuations were conducted by visual analogue scale scoring of 
three health states of differing severity taken from the EQ-5D. Version 1 had 
no directions regarding inclusion/exclusion of effects of ill health on income. 
Those respondents who spontaneously included effects on income were sub-
sequently asked to value the same three health states again, excluding these 
effects. Version 2 had explicit instructions to incorporate the effects on income. 
Version 3 stated that income was assumed to not change as a result of ill health. 
Respondents for versions 2 and 3 were also questioned about inclusion of 
effects on leisure time. Results: Giving explicit instructions on the incorpora-
tion or exclusion of effects of ill health on income did not lead to significant 
differences in subsequent health state valuations. In the absence of instruc-
tion, 36% of respondents included and 64% excluded effects on income, but 
the health state valuations of the two groups were not significantly different. 
Eighty-four percent of respondents included the effects of ill health on leisure 
activities, and again this had no significant impact on the resulting health state 
valuations. Conclusions: It appears that neither spontaneous differences in 
incorporation of effects on income, nor explicit instructions will yield signifi-
cantly different health state valuations. This may suggest that QALY measures 
are insensitive to concerns regarding effects on income even when these are 
(explicitly) incorporated, and these effects may therefore be best placed on the 
cost side of the cost-effectiveness ratio.
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3.1 Introduction
The inclusion of productivity costs in economic evaluations of health care has 
always been an area of controversy.5 Some have argued that productivity costs 
should not be part of a health economic evaluation, since these costs are not 
relevant for health care decisions, do not fall under the health care budget and 
their inclusion may have adverse distributional consequences (i.e. favoring 
interventions aimed at productive individuals). (12,100-102) Still, the normally 
advocated societal perspective dictates the incorporation of all societal costs 
significantly influenced by the intervention under study, regardless of where 
these costs fall. (2,103) This implies that productivity costs should be captured in 
a health economic evaluation.
Yet, even if we would agree on taking the societal perspective (and a practical 
consensus on this matter seems lacking, judging from the different national 
guidelines; see www.ispor.org), then the debate becomes whether productivity 
costs should be captured in the cost or the effect side of an economic evalua-
tion, especially when effects are expressed as QALYs (8,20-22,31,104,105). Although the 
distinction between costs and effects may be thought of as rather straightfor-
ward, some argue that the consequences of reduced productivity should be, 
and normally are, captured in health state valuations, (2) thus in terms of effects, 
while others argue that these consequences need to be seen and expressed as 
costs in an economic evaluation. (8,22,31,68,91) If one opts to incorporate productiv-
ity costs in terms of costs, a further debate will be whether the human capital 
or the friction cost method is most appropriate to determine productivity 
costs. (47,57-59,102)
In this chapter, we are especially concerned with the debate on whether 
productivity costs should be placed at the cost or effect side of an economic 
evaluation. This debate was stimulated by the publication of the guidelines 
of the US Panel on Cost-Effectiveness in Health and Medicine, which recom-
mended that for “… the reference case analysis, health-related quality of life 
should be captured by an instrument that, at minimum, implicitly incorporates 
the effects of morbidity on productivity and leisure.” (2) Although theoretical 
5  In fact, even the definition of the term productivity costs differs in the literature. Brouwer et al. 
(22) refer to productivity costs as “costs associated with production loss and replacement costs due 
to illness, disability and death of productive persons both paid and unpaid,” while the US Panel on 
Cost-Effectiveness in Health and Medicine refers to productivity costs as “the cost associated with 
lost or impaired ability to work or engage in leisure activities due to morbidity and lost economic 
productivity due to death.” (2)
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objections against this recommendation were put forward, the recommenda-
tions clearly brought to light the fact that currently there is little knowledge 
on which aspects of ill health respondents actually incorporate in health state 
valuations. It is especially uncertain whether respondents include productivity 
costs in terms of income effects in health state valuations. Although income 
losses are not synonymous with the broader concept of productivity costs, they 
are sometimes seen as a proxy for productivity costs related to paid work, (2) 
although this has been disputed.6 (22,68) However, it is clear that if respondents 
incorporate income changes in health state valuations, while recognizing the 
general difference between income losses and productivity costs, this implies 
a clear risk of double counting if productivity costs were also to be counted 
as costs. In the context of this chapter, therefore, we will use the terms inter-
changeably.
Given the recent debate in the literature on whether productivity costs 
should be seen as costs or effects, more knowledge on this issue is essential. 
If it turns out that some respondents do and some do not include income ef-
fects, productivity costs might be underestimated or double counted, depend-
ing on whether productivity costs are placed at the cost or effect side of the 
cost-effectiveness ratio and the effect incorporation of these effects has on 
subsequent health state valuations. Moreover, it has been argued that to be 
sure that all respondents include the same aspects in health state valuations, 
explicit instruction to either include or exclude productivity costs might be 
necessary. (68) Yet, to our knowledge, the effects of such instructions have never 
been investigated.
In this chapter we present the results from an empirical study with the aim: 
(i) to find out whether people include potential income losses (and leisure-
time loss) in health state valuations that are silent on effects of ill health on 
income (and leisure); and (ii) to find out what the effects of explicit instructions 
on including or excluding the effects of ill health on income are on health state 
valuations.
First, we provide some background on the debate on whether productivity 
costs should be in the numerator or the denominator of the cost-effectiveness 
ratio and present the scarce previous empirical studies on whether respon-
dents include health-related income loss in health state valuations. We then 
6  Note that the perspective of the study is relevant here as well. Income losses will be incorporated 
to the extent that the individual experiences them, while from a societal perspective this may not 
be a valid approach to measuring and valuing productivity costs. (22)
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present the study we performed to test the incorporation of effects of ill health 
on income and leisure time in health state valuations and the influence of 
explicit instructions on this matter.
3.2  Productivity costs and health state valuations
In 1996, the US Panel on Cost Effectiveness in Health and Medicine recom-
mended that productivity costs be included in a non-monetary value, such as 
QALYs, on the effect side of the cost-effectiveness ratio. (2) The Panel suggested 
doing this by explicitly mentioning that respondents should include the effect 
of ill health on income in health state valuations, but assumed that silence on 
this subject is enough to make people incorporate income effects. (2,21)
An important objection against the recommendations of the US Panel is 
that measuring the effects of ill health on income through QALY elicitation will 
not lead to accurate measurement of productivity costs. (8,22,31,91) For example, 
individuals who are insured against income losses experience little or no in-
come effects of ill health, while their productivity may be significantly affected. 
Moreover, differences may exist between the societal valuation of production 
loss and an individual’s valuation of income loss. Such differences may arise 
from various factors, for instance, differences in the period considered to be 
relevant for calculating what losses occur, whether gross wages are used to 
reflect the added value of a worker to society, or whether net income is used to 
reflect the outcome of interest for the individual, etc.
Even if it were possible to measure all income effects accurately at the ef-
fect side, these are not the only relevant costs. Indeed, the additional costs for 
the employer (e.g. hiring and training new employees) would still have to be 
calculated at the cost side of the cost-effectiveness ratio, since an individual 
will normally not consider such costs. (2) Such a separation of productivity costs 
(partly incorporated at the effect side and partly at the cost side) can cause 
an increase in the costs of conducting economic evaluations. (31) However, it 
needs to be noted that the loss of the ability to perform (un)paid work is usually 
seen as part of quality of life, for instance in terms of role functioning, but this 
needs to be distinguished from the societal costs resulting from this inability 
to function in a paid job. (22) In this chapter, we only address the latter aspect.
Capturing productivity costs at the cost side of the cost-effectiveness ratio 
(e.g. using the human capital or friction cost approach) (7,102,105) has also been 
criticized. Besides discussion on which of the two methods is superior, an im-
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portant question in this context is whether incorporation at the cost side of a 
cost-effectiveness ratio could lead to double counting. (20) This would happen if 
respondents already take productivity costs into account when valuing health 
states, which is currently largely unknown. From this it follows that costs 
and effects in a cost-effectiveness analysis are complements and one needs 
to ensure that all relevant items are captured on both sides, not leaving out 
anything important and not double counting anything by including the item 
on both sides. (68) This indicates that knowledge of what respondents incorpo-
rate in health state valuations and how this alters results is instrumental for 
correct analysis, as is the knowledge of how to better instruct respondents to 
consistently include or exclude relevant aspects.
To date, there is little empirical evidence on what respondents consider in 
health state valuations. Only two studies have been conducted to find out if 
respondents included the effects of ill health on income in health state valua-
tions. Meltzer et al. (60) tested how giving information about the financial con-
sequences of ill health affected respondents’ valuations using time trade-off 
(TTO) questions. However, they did not give explicit instructions to respon-
dents on what to do with this information. Respondents were asked afterwards 
if they had thought of financial consequences of illness when answering the 
TTO questions. Even in the group in which respondents were informed that 
no form of disability payment existed, <25% of the respondents considered the 
financial consequences of illness. Without any information on income losses, 
<15% thought of the negative effects of ill health on income. Within the group 
without information on income loss, respondents who indicated that they had 
(spontaneously) considered effects on income showed lower TTO scores than 
respondents who did not consider effects of ill health on income.
Sendi and Brouwer (64) recently performed a small sample test among 20 
health professionals to find out whether the effects of ill health on income and 
leisure time were included in health state valuations when no explicit instruc-
tions were provided. Respondents were asked to value a health state on a visual 
analogue scale (VAS). Forty percent of the respondents included the effects 
of ill health on income, whereas 60% did not. The former respondents had a 
significantly lower VAS score than the respondents who did not include effects 
of ill health on income.
Both studies (60,64) show that, without instruction, many respondents do not 
consider effects on income in health state valuations, although a reasonable 
proportion of respondents do consider such effects. To ensure that respondents 
are consistent in including or excluding effects of ill health on income in health 
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state valuations and thus avoid double counts or omissions of important costs 
(regardless of the position one wants to take in terms of where they should 
be placed in the cost-effectiveness ratio), giving people explicit instructions 
in health state valuation exercises has been proposed. (68) Given the theoretical 
debate, two types of explicit instruction appear most relevant. First, one may 
opt to instruct respondents to incorporate all possible effects of ill health on 
income in their valuations (following the recommendations of the US Panel). 
Second, one could instruct respondents to exclude these effects and measure 
all productivity costs in a monetary value (using the human capital or friction 
cost method). Whether such instructions indeed result in changes in health 
state valuations has not been investigated to our knowledge.
Brouwer and Rutten (68) have questioned whether instructing respondents 
not to consider specific costs or effects is feasible, as it resembles instructing 
people not to think of a ‘pink elephant’. It is therefore essential to have more 
information on what respondents do without instruction and what the influ-
ence on health state valuations is of explicit instruction on the inclusion or 
exclusion of income effects of ill health.
In the study by Sendi and Brouwer (64) respondents were also asked whether 
they had considered effects of ill health on leisure time. It transpired that (only) 
75% of the respondents indicated that they had considered these effects. Al-
though in this chapter the main focus is on productivity costs, and despite the 
fact that there is little debate on whether leisure time should be incorporated in 
the QALY measure, (2,20,64,68,91,106) it needs to be noted that it is equally uncertain, 
and therefore worthwhile investigating further, whether respondents in fact 
include leisure time in health state valuations (given the small sample size in 
previous research). (64) If not all respondents include these effects, even though 
we expect them to, it is also important to see what effect this has on subsequent 
health state valuations.
3.3 Methods
To test the effects of including loss of income and leisure time in health state 
valuations, as well as to test the influence of instructions regarding how to 
include such effects, three different questionnaires were developed. In all, 
respondents to the questionnaires were first asked some background ques-
tions about sex, age, income, education and their current health state using 
the EuroQoL descriptive system (EQ-5D) and the EuroQoL VAS. (107)
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Next, the respondents were asked to value on a VAS, three ill-health states 
that differed in severity (see table 3.1). These three health states were chosen 
from 243 possible health state scenarios within the EQ-5D. (108) Our main selec-
tion criterion was to have three distinct health states in terms of severity. A VAS 
was used since it requires a minimum of explanation to respondents and lends 
itself to self-administration. (109)
In version 1 of the questionnaires, respondents did not receive directions on 
whether to incorporate or to ignore the effects of ill health on income. After 
having valued the three health states, the respondents were asked whether 
they included effects on income. If they indicated that they had included these 
effects, they were asked to value the same three health states again, but now 
with the explicit instruction to ignore the effects of ill health on income. In ver-
sion 2, respondents were explicitly instructed upfront to incorporate the pos-
sible effects of ill health on income. In version 3, respondents were instructed 
to assume that income would not change as a result of ill health, and thus to 
ignore the effects of ill health on income. This phrasing was chosen in an at-
tempt to avoid the ‘pink elephant’ trap described in the previous section. In 
all questionnaires, respondents were asked whether they thought being in the 
different health states would decrease their income and, if so, to what extent. 
This was always done after the valuation process, so as not to ‘contaminate’ the 
experiment. In versions 2 and 3, respondents were furthermore asked if they 
thought the described health states would affect their leisure time and whether 
they had included the possible effects on leisure time in their valuations. The 
latter questions were not included in version 1 (with the double health state 
valuations) to limit the size of the questionnaire.
Based on earlier findings and the debate in the literature, we formulated 
several hypotheses that this study sought to confirm:
Table 3.1 Health states described for valuation
Health 
state
EQ-5D 
code
Standard MVH_A1 
score (108) 
Description
1 21211 0.88 Some problems in walking, no problems with self-care, some 
problems performing usual activities, no pain or discomfort, not 
anxious or depressed
2 22221 0.587 Some problems in walking, some problems with self-care, some 
problems performing usual activities, moderate pain or discomfort, 
not anxious or depressed
3 33312 −0.043 Confined to bed, extreme problems with self-care, not able to 
perform usual activities, no pain or discomfort, moderately anxious 
or depressed
MVH = Measurement and Valuation of Health group.
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1. In health state valuations, if respondents do not receive directions on including 
or excluding the effects of ill health on income and leisure, some respondents 
will include while others will exclude these effects in their valuations. (60,64)
2. Respondents who spontaneously include the effects of ill health on income 
in health state valuations give lower valuations than respondents who do not 
include these effects, ceteris paribus (i.e. all other things being equal). (60,64)
3. Similarly, respondents who spontaneously include the effects of ill health 
on leisure in health state valuations give lower valuations than respondents 
who do not include these effects, ceteris paribus.
4. Respondents who include the effects of ill health on income in health state 
valuations without explicit instructions will value the same health states 
higher the second time when asked explicitly to exclude these effects. (64)
5. Respondents who are explicitly asked to include the effects of ill health on 
income in health state valuations value health states lower than respon-
dents who are explicitly asked to exclude the effects.
The study sample was drawn from the general public in 2004 in various public 
places such as people working at a hospital, people travelling by public trans-
port, etc. Respondents were approached and asked whether they were willing 
to participate in this study. If they agreed to participate, the respondents in our 
convenience sample were randomly handed one of the three different versions 
of the questionnaires for self-completion.
Statistical analyses
Categorical variables were compared using the Chi-square test. Continuous 
variables were compared using the t-test, one-way ANOVA or Wilcoxon signed 
rank test where appropriate. We used a multivariate general estimation equa-
tion (GEE) model with a logit link and an unstructured correlation matrix to 
estimate the association between health state, the version of questionnaire 
administered, employment status and education (adjusted for age and sex) 
and the perceived effects of ill health on income by the respondents. A GEE 
model was used to account for the within-individual correlation of the respon-
dents when judging the three health states described. Robust standard errors 
and z-values were used to calculate confidence intervals for odds ratios and 
P-values. A linear mixed-effects model was used to estimate the association be-
tween the valuation of the health states and whether respondents did consider 
effects of ill health on income in version 1 of the questionnaire, employment 
status and education, adjusted for age and sex. Respondents valuing the three 
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health states were treated as random effects to account for within-respondent 
variability and correlation using an unstructured correlation matrix. A linear 
mixed-effects model was also used to evaluate whether there were differences 
in health state valuation between the three versions, adjusted for age, sex, em-
ployment status and education. Income was not included in the multivariate 
analysis. It was considered that income is a function of both education and 
employment status, and that both these variables would lead to a better fit 
than income alone. Moreover, including all three variables did not lead to a 
gain in information, rather to a loss of power. The data were analyzed with use 
of SPSS Statistical Software Package 11.5 and S-Plus 6.2 Professional.
3.4 Results
Sample population
Of the 227 completed questionnaires, 185 were useful for further analysis 
(version 1, n = 59; version 2, n = 64; version 3, n = 62). The exclusion of ques-
tionnaires was based on inconsistencies suggesting that respondents did not 
understand the purpose of the questionnaire. Most of these respondents gave 
all three health states the same value as their own. Some drew several lines 
from the health state description to the scale. The respondents of the excluded 
questionnaires were significantly older (P = 0.01), less educated (P = 0.00) and, 
at a 10% confidence level, of lower income (P = 0.06) than the respondents of 
the questionnaires used for further analysis.
Respondents were more often well-educated and younger than a represen-
tative sample would be expected to be. (110) As seen in table 3.2, the average 
age was 35.2 years (SD 13.1) and did not differ between groups (P = 0.84). The 
average self-reported health of the respondents was 0.81, which did not dif-
fer between the respondents of the different versions of the questionnaire (P 
= 0.92, SD 0.13). Respondents were more often female (54%). There were no 
significant differences between the groups in sex (P = 0.53), employment (P = 
0.84) or income (P = 0.57).
55
Productivity costs in health state valuations
Ch
ap
te
r 3
Table 3.2 Characteristics of respondents by questionnaire group 
Characteristic Questionnaire administered All respondents
Version 1 ( n = 59) Version 2 (n = 64) Version 3 (n = 62) (n = 185)
% Females 59 53 49 54
Mean age [y] (SD) 36.0 (13.7) 34.7 (13.1) 35.0 (12.6) 35.2 (13.1)
% Employment
 No paid work 24 23 18 22
 Fulltime employment 44 41 48 44
 Part-time employment 32 36 35 34
% Education a
 Lower education 12 11 16 13
 Medium education 39 42 28 36
 Higher education 49 47 56 51
% Income b
 Lower income 16 21 17 18
 Medium income 41 29 29 33
 Higher income 43 51 54 49
Mean SAH with VAS (SD) 0.81 (0.12) 0.81 (0.15) 0.80 (0.12) 0.81 (0.13)
a These groups were defined according to the Dutch educational system. The category ‘lower 
education’ comprises elementary school, lower general secondary education (MAVO) and pre-
vocational (VBO). ‘Medium education’ comprises higher general secondary education (HAVO, VWO) 
and senior vocational education (MBO). ‘Higher education’ comprises vocational colleges (HBO) and 
academic education. b Based on net income per month:
low = <€650, medium = €650–1900, high = >€1900, SAH = self-assessed health, 
VAS = Visual Analogue Scale, y = years, SD = standard deviation
Effects of ill-health on income
As shown in table 3.3, 34%, 75% and 88% of the respondents thought that being 
in the health states 1, 2 or 3, respectively, would decrease their income. For all 
health states, a smaller percentage of respondents to questionnaire version 1 
than to version 2 and 3 thought income would decrease (although only the dif-
ferences between questionnaire versions for health state 3 were significant). In 
other words, the group of people that was not triggered upfront to think about 
income through a prior instruction was less likely to think income would de-
crease because of the ill-health states. Respondents stating that the very poor 
health state 3 would not cause income loss were, unsurprisingly, more often 
unemployed (since normally these respondents are not able to lose income 
because of ill health) than the people that did expect a decrease in income (P < 
0.001). These differences in employment were not found between respondents 
that did and did not think health states 1 and 2 would decrease income. This 
might be explained by the fact that working in health states 1 and 2 may still 
be possible, while in health state 3 this is unlikely since one is confined to bed.
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The results in table 3.3 were largely confirmed in the multivariate analysis 
(table 3.4). Health states 2 and 3 were more likely thought to induce income 
losses than health state 1; respondents who received version 2 or 3 (therefore, 
with explicit instructions), and respondents with a full- or part-time job, were 
more likely to think that a certain health state would induce income losses. The 
variable education was on the border of significance at the 5% level (with P = 
0.05), with the odds ratio indicating that people with a higher education were 
less likely to think a health state would induce income losses (perhaps because 
of differences in work type).
The effects of instruction
No instructions
Confirming hypothesis (1) that without instructions some respondents will 
and some will not include the effects of ill health on income in health state 
valuations, 36% of the respondents of version 1 of the questionnaire included 
the effects of ill health on income in their valuations. Although higher than the 
15–25% in the study by Meltzer et al., (60) this result is comparable with the 40% 
Table 3.3 Effects of ill-health on income and leisure time
Health state 
1 decreases 
income
Health state 
2 decreases 
income
Health state 
3 decreases 
income
Included 
effect on 
income
Included 
effect on 
leisure-time
Version 1 (n = 59) [%] 25 69 78 36 -
Version 2 (n = 64) [%] 43 79 90 - 81
Version 3 (n = 62) [%] 33 78 92 - 88
Mean (%) 34 75 88 - 84
P-value a 0.118 0.357 0.012 - 0.258
Mean estimated 
income loss [€] (SD)
298 (324) 473 (426) 737 (573) - -
a Pearson chi-square test
SD = standard deviation
Table 3.4 Multivariate analysis of the effects of health state, version of questionnaire administered, 
employment status and education on the likelihood of believing ill health would affect income, 
adjusted for age and sex
Variable Odds Ratio 95% CI P-Value
Health state 2 vs. 1 12.72 7.68-21.09 <0.001
Health state 3 vs. 1 19.06 11.20-32.41 <0.001
Fulltime vs. no job 3.96 1.70-9.18 0.001
Part-time vs. no job 3.58 1.47-8.72 0.005
Version 2 vs. 1 2.71 1.31-5.61 0.007
Version 3 vs. 1 2.06 1.03-4.10 0.039
Education (high vs. low) 0.50 0.25-1.00 0.050
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in the small sample of Sendi and Brouwer (64) and differences in methods used 
may partly contribute to these differences.
For respondents to version 1 of the questionnaire, the group that did and the 
group that did not consider effects on income in their health state valuations 
did not differ in age, sex, education, employment, net income and self-reported 
present health state. Moreover, there were no significant differences between 
the health state valuations of respondents who considered income effects and 
respondents who did not (table 3.5). These findings contradict the findings of 
Meltzer et al. (60) and Sendi and Brouwer (64) and do not support hypothesis (2) 
that respondents who spontaneously consider effects on income will value 
health states lower than respondents who do not consider these effects.
These results were maintained in a multivariate analysis. Again, whether 
effect on income was considered did not significantly impact health state valu-
ation (table 3.6). The only variable significantly associated with health state 
valuation was the health state presented. The more severe the health state, the 
lower the valuation of that health state by the respondent.
From no instructions to instructions
The respondents to version 1 of the questionnaire who included income in 
their valuations were asked to value the same health states again assuming 
these health states would not influence their income. It was expected that the 
respondents would value the same health states significantly higher the second 
time, similar to the findings of Sendi and Brouwer. (64) The results in table 3.7 
show that changing the instructions did not significantly affect the valuation 
of health state 1, whereas it did change the valuations of health states 2 and 3. 
This is probably best explained by the fact that most respondents stated that 
health state 1 would not affect their income, as seen in table 3.3, whereas most 
did expect that health states 2 and 3 would decrease income (which logically 
translates in the results found). These results largely confirm hypothesis (4) 
that respondents change their valuations if they are asked to not consider a 
Table 3.5 Health state visual analogue scale valuations of respondents to version 1 of the 
questionnaire that spontaneously included or excluded the effects of ill health on income
Group Health state 1
[Mean (SD)]
Health state 2
[Mean (SD)]
Health state 3
[Mean (SD)]
Included effect on income ( n = 21) 0.68 (0.10) 0.53 (0.11) 0.32 (0.12)
Did not include effect on income (n = 38) 0.69 (0.13) 0.49 (0.17) 0.28 (0.12)
P-value a 0.722 0.295 0.261
a  T-test equality of means
SD = standard deviation
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negative aspect of ill health they did consider before, when this is applied to 
the most relevant scenarios (i.e. health states 2 and 3). Despite these significant 
differences, many respondents did not change their original valuation the 
second time, as was the case in the study by Sendi and Brouwer. Fourteen of 21 
respondents valued health state 1 the same, 13 valued health state 2 the same 
and 11 valued health state 3 the same.
Explicit instructions
Table 3.8 shows the average VAS valuations of the three health states of the 
respondents to the three different questionnaires. In contrast to our expecta-
tions, the respondents of version 2 (who were explicitly asked to include the 
effect of ill health on income) did not value the health states lower than the 
respondents of version 3 (who were explicitly asked to exclude these effects). 
As table 3.8 shows, there were no significant differences between respondents 
in the valuations of each of the health states for the different versions of the 
questionnaire. The valuations of the respondents without instruction (version 
1) did not differ from those in the other two groups. Thus, these results seem to 
Table 3.6 Multivariate analysis of the effects of consideration of impact on income, health state, 
employment status and education on health- state valuation in version 1 of the questionnaire, 
adjusted for age and sex
Variable Coefficient SE P-Value
Intercept 0.679 0.058 <0.001*
Included effect on income 0.015 0.029 0.604
Health state 2 vs. 1 -0.183 0.016 <0.001*
Health state 3 vs. 1 -0.394 0.020 <0.001*
Fulltime vs. no job -0.014 0.036 0.706
Part-time vs. no job -0.044 0.041 0.288
Education (high vs. low) 0.000 0.032 0.991
* Significant at P < 0.05
SE = Standard error
Table 3.7 First and second health state visual analogue scale valuations of respondents (n = 21) who 
spontaneously included effects on income the first time and were asked to exclude these effects the 
second time
Health State 1
[Mean (SD)]
Health State 2
[Mean (SD)]
Health State 3
[Mean (SD)]
First valuation 0.68 (0.10) 0.53 (0.11) 0.32 (0.13)
Second valuation 0.70 (0.11) 0.56 (0.10) 0.37 (0.13)
P-value a 0.167 0.027* 0.041*
a  Wilcoxon signed rank test
* Significant at P < 0.05
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imply that instruction does not matter in the sense that it does not change the 
overall results. Again, these results were maintained in a multivariate mixed 
effects model where there were no significant differences in the valuations of a 
given health state between respondents of the three versions of the question-
naire (P = 0.665), when adjusted for age, sex, employment status and education.
As an aside, it is worth noting that the health state valuations in table 3.8 
are different from the EQ-5D MVH (Measurement and Valuation of Health 
group)-A1 scores shown in table 3.1. (108) This need not be surprising or worry-
ing, since the MVH_A1 scores are elicited through TTO exercises, while we used 
VAS valuations, and the latter are known to differ from TTO or standard gamble 
scores. (109) On average the respondents in our sample valued health states 1 
and 2 significantly lower than the corresponding MVH_A1 scores: 0.67 versus 
0.88 and 0.49 versus 0.59, respectively. Health state 3 was valued significantly 
higher: 0.29 versus –0.04. The incongruent valuations of respondents with the 
corresponding MVH_A1 scores might be partly caused by context- and end-
aversion bias related to the use of the VAS. (109) Context bias reflects the fact that 
the VAS score for a health state depends on the number of better and worse 
states presented at the same time. Respondents have the tendency to spread 
their valuations over the scale. End-aversion bias, the reluctance of people to 
use the ends of a scale, is a well-known bias that affects scales scored on a 
continuum. (109) The fact that the MVH_A1 scores are based on a wider scale 
(scores can be below zero) is also of significance.
Regression techniques were used to investigate which variables had a sig-
nificant influence on the valuations of the different health states. The results 
are shown in table 3.9, and as can be seen, age is a significant predictor for 
the valuation of all three health states. Self-reported present health state 
had predictive value for health state 1 and 2, but lost its significance for the 
valuation of (the very poor) health state 3. Education (at P < 0.10) and whether 
respondents think a health state will decrease income (at P < 0.05) is only of 
Table 3.8 Health state visual analogue scale valuations according to version of questionnaire 
administered
Health State 1
[Mean (SD)]
Health State 2
[Mean (SD)]
Health State 3
[Mean (SD)]
Version 1 (n = 59) 0.69 (0.12) 0.50 (0.15) 0.29 (0.12)
Version 2 (n = 64) 0.68 (0.12) 0.49 (0.15) 0.27 (0.16)
Version 3 (n = 62) 0.65 (0.10) 0.48 (0.14) 0.30 (0.15)
Mean 0.67 (0.11) 0.49 (0.15) 0.29 (0.14)
P-value a 0.316 0.671 0.463
a  One-way ANOVA
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influence for health state 1. The version of the questionnaire has no significant 
influence on any of the three health state valuations. This implies that the 
differences in instruction do not appear to lead to differences in health state 
valuations. These findings contradict the findings of Meltzer et al. (60) and Sendi 
and Brouwer (64) who did find differences between groups of respondents based 
on different considerations about negative effects of ill health on income, as-
sessed without explicit instruction. The findings in our study do not support 
hypothesis (5) that respondents who are explicitly asked to include effects 
on income will value health states lower than respondents who are explicitly 
asked to exclude these effects.
Leisure time
The results in table 3.3 show that 84% of the respondents to questionnaire 
version 2 and 3 included the effects of ill health on leisure time, confirming 
the first hypothesis that some respondents do and some do not include leisure 
time in health state valuations. The characteristics age, sex, level of education, 
employment, self-reported present health state and net income did not differ 
between respondents who did and those who did not think of the effects of ill 
health on leisure time in the health state valuations. Thus, even though it is 
usually assumed that respondents incorporate the effects of ill health on leisure 
Table 3.9 Results of regression analyses of visual analogue scale health state valuations (n = 176)
Valuation health state 1 Valuation health state 2 Valuation health state 3
Beta SE P-value Beta SE P-value Beta SE P-value
Constant .068 < .001* .094 .248 .103 .766
Education -.122 .006 .092 .019 .008 .805 .114 .008 .161
Employment .002 .012 .977 -.065 .016 .447 .014 .018 .880
Gender .074 .015 .267 .092 .021 .200 .093 .022 .222
Age .303 .001 .001* .319 .001 .001* .311 .001 .002*
Net income -.017 .008 .865 .049 .011 .646 -.098 .011 .389
Self-reported 
health
.415 .056 < .001* .269 .078 < .001* .088 .081 .248
Version 1 (vs. 2) -.004 .018 .957 -.011 .025 .897 .016 .027 .853
Version 3 (vs. 2) -.057 .018 .455 -.049 .025 .551 .103 .026 .229
Does HS 1 
decrease income
-.150 .016 .028* - - - - - -
Does HS 2 
decrease income
- - - -.081 .025 .265 - - -
Does HS 3 
decrease income
- - - - - - -.072 .036 .377
Adjusted R² .291 .171 .058
* Significant at P < 0.05
HS = health state.
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time in health state valuations, (2,7,68) not all do so. This may lead to omission of 
leisure time effects in economic evaluations. The extent to which this poses a 
serious problem crucially depends on the influence the incorporation of leisure 
in health state valuations has on outcomes. However, interestingly, the health 
state valuations of the two groups (that did or did not incorporate effects on 
leisure time) did not differ significantly. These results therefore do not support 
the hypothesis (3) that respondents who include the effects of leisure time will 
value the health states lower than those who do not include these effects, and 
raises the question of whether leisure is adequately captured in health state 
valuations at the moment. The latter holds, because one might expect varia-
tions in health state valuations between people who do and do not incorporate 
leisure, depending on the relative importance of leisure. In addition, if leisure 
time is to be incorporated at the cost side of the cost-effectiveness ratio and 
has a noticeable effect on total costs, this raises the question of whether leisure 
should not be captured in monetary terms, to avoid ignoring these effects.
Of note, the percentage of respondents considering leisure in our sample 
was slightly higher than the percentage considering leisure time in the small 
sample of Sendi and Brouwer (64) (84% vs. 75%). This could be due to the use 
of the EQ-5D in our questionnaire to describe the ill-health states, as opposed 
to the description of a specific health state in the questionnaire used by Sendi 
and Brouwer, (64) since the EQ-5D focuses explicitly on the ability to perform 
usual activities.
3.5 Discussion
These results show that, without instruction on whether to consider effects of 
ill health on income in health state valuations, some respondents will include 
these effects and some will not. Moreover, our results confirm that respondents 
are inconsistent in including or excluding the effects of ill health on income. 
There are large differences in the perceptions of people as to whether and to 
what extent their income will be influenced by ill health. In light of the debate 
on productivity costs, this means that measuring productivity costs without 
instructing respondents can lead to double counting or underweighting of 
productivity costs. As noted in the introduction, the extent of double counting 
is also related to the extent to which one considers income losses to be a proxy 
for (societal) productivity costs. Therefore, as suggested before in the literature, 
giving explicit instructions to respondents on what to incorporate and what to 
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exclude in health state valuations seems appropriate. However, our results in-
dicate that explicit instructions do not lead to significant differences in health 
state valuations (with the exception of the respondents to version 1, who were 
asked to change their considerations and to exclude a negative aspect of ill 
health they did include before, which in itself likely prompted respondents to 
change their valuations).
What do these results imply? First of all, instructions on the inclusion or 
exclusion of effects of ill health on income do not appear to result in different 
valuations of health states. Our results suggest that respondents seem to give 
little weight to income loss of ill health in health state valuations. Although 
we did not directly assess the relative importance that respondents placed 
on effects on income relative to other aspects in health state valuations (and 
this requires further investigation), our results indicate that valuations are 
determined more by other aspects of ill health. Therefore, incorporating pro-
ductivity costs (partly) in the effect side appears to have no noticeable effect on 
health valuations. Since the incorporation of productivity costs at the cost side 
does have a (clear) influence on the resulting cost-effectiveness ratio, one may 
feel that productivity costs are best placed at the cost side and excluded from 
the effect side of the cost-effectiveness ratio. If our results are also confirmed in 
other samples and using other valuation methods such as TTO, this exclusion 
need not necessarily be explicit, since instructions do not seem to alter the 
final valuations. This would also imply that current valuations (which are nor-
mally based on health state valuations that are silent in terms of incorporation 
of effects on income, for example the much used MVH_A1 scores (108)) can be 
used in combination with monetary valuations of productivity costs without 
risking double counting, even though some respondents may have included 
effects on income.
Our results confirm the results of Sendi and Brouwer (64) in that no differ-
ences in health state valuations were found between respondents who did and 
those who did not include the effects of ill health on leisure. There is consensus 
among health economists that respondents should include effects on leisure 
time in their valuations and it has been noted that without incorporating ef-
fects on leisure time a QALY seems to become a somewhat hollow concept. (91) 
In this light, it is remarkable that differences in including or excluding leisure 
time seem to have no significant influence on health state valuations. More 
research is necessary to understand why the valuations of the 16% who did not 
include leisure time did not differ from the 84% who did. In fact, our results, 
if confirmed in other research, may imply that losses in leisure time may need 
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to be (partly) covered at the cost side of an economic evaluation, unlike cur-
rent standards and practice. In that respect, Brouwer and Rutten (68) recently 
proposed that it may be possible to reserve the QALY measure for the valua-
tion of the mere fact that one is impaired in terms of leisure activities, while a 
monetary value could be attached to each hour in which this is the case. They 
suggest that “the quality of leisure is then captured in terms of the QALY, valuing 
health states using a general indication of impairment, while the quantity of 
leisure is captured in terms of money.”
Study limitations
Some limitations of our study need to be noted. First, 18.5% of the respondents 
did not seem to understand the questionnaire. This suggests that the question-
naire is difficult to understand for a part of the general public (especially for 
older and less educated people). If respondents had received a comprehensive 
oral instruction, the number of questionnaires that could have been used for 
further analyses might have been higher. 
Second, there may be differences between different quality of life measure-
ments in terms of their sensitivity to changes regarding inclusion of effects 
on income. We used a VAS instrument and it is possible that the income in-
sensitivity of this instrument was partly due to scale compatibility. It is well 
known that respondents tend to give more weight to the subject of focus (in 
our case health, since the VAS ranges from the best to the worst attainable 
health state) and therefore might under-weigh other aspects related to ill 
health. (111) Other valuation techniques may be more sensitive to changes in 
income considerations, but this needs confirmation. Although Meltzer et al., (60) 
using TTO questions, found differences in TTO scores of respondents who had 
and those who had not thought about financial consequences of illness, their 
study differs in many ways from ours. Moreover, it needs to be noted in this 
context that in contradiction to our findings, Sendi and Brouwer (64) did find 
some significant differences in health state valuations between respondents 
who had and had not included the effects of ill health on income, also using 
the VAS (although the sample size in that study makes conclusions vulnerable 
to outliers). Differences between that and this study may explain the different 
findings. For instance their respondents were health professionals who might 
expect a greater impact of ill health on income (based on their experience) 
than the general public. Furthermore Sendi and Brouwer (64) asked respondents 
to value a specific disease (multiple sclerosis [MS]), while here we used more 
general health state descriptions without specifying duration or type of illness. 
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The clear chronic nature of MS could have caused respondents to predict 
more income loss or attach a greater weight to it. More research is needed to 
further test the insensitivity of the VAS instrument and to investigate whether 
other QALY elicitation methods are equally insensitive to differences in income 
considerations. The effect of different instructions and information provided 
to the respondents may also be worthy of further investigation.
Another point worth investigating is whether respondents who are explic-
itly instructed to either include or exclude income effects really follow these 
instructions. If they do not, this may explain the fact that we did not find an 
influence of instruction. Moreover, while we have chosen the general public as 
our source of health state valuations (following a societal perspective), it could 
be considered worthwhile investigating whether the influence of income loss 
would be more pronounced in patients affected by illness.
Finally, it is possible that a similar study as the one presented in this chapter 
will lead to different outcomes when conducted in another country. Maybe 
respondents would be more aware of possible income losses due to ill health 
in countries with a less comprehensive social security system than in The 
Netherlands. This may lead to a higher percentage of respondents including 
the effects of ill health on income, a higher weight being given to income con-
siderations in health state valuations and therefore to significant differences 
between the valuations of respondents who include and those who exclude the 
effects of ill health on income.
3.6 Conclusions
It appears that neither spontaneous differences in incorporation of effects on 
income, nor explicit instructions will yield significantly different health state 
valuations. This may suggest that QALY measures are insensitive to concerns 
regarding effects on income even when these are (explicitly) incorporated, and 
these effects may therefore be best placed on the cost side of the cost-effec-
tiveness ratio. Obviously more research (with larger samples and other health 
state valuation techniques) should be conducted to see if the results presented 
in this chapter hold, but it is hoped that this chapter will give new empirical 
impetus to the debate on measuring productivity costs and contribute to in-
creasing the knowledge of what people take into consideration in health state 
valuations and on how to move forward.
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in TTO exercises
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Summary
Objectives: An underexplored question in the debate on incorporating produc-
tivity costs as costs or effects in a cost-effectiveness analysis is whether people 
include effects of ill health on income in health state valuations (HSV). The 
same holds for the actual inclusion in HSV of the effects of ill health on leisure. 
This study aims to test whether respondents to HSV using time trade-off (TTO) 
questions include income and leisure effects without instructions. Moreover, 
it tests the consequences of explicit instructions to include or exclude income 
effects. Methods: Three questionnaires were administered among the general 
public. Respondents were asked to value three distinct EuroQol descriptive 
system health states using TTO. In version 1, respondents were asked after-
wards whether they included income effects. In versions 2 and 3, respondents 
were instructed upfront to include or exclude income effects. They were 
furthermore asked whether they included leisure effects. Results: A total of 
222 respondents completed the questionnaire. In version 1, 64% of the respon-
dents spontaneously included income effects, not resulting in differences in 
mean valuations. In versions 2 and 3, 88% included leisure time, resulting in 
a significantly lower TTO value in one health state. With explicit instructions, 
respondents instructed to include income gave lower HSV for the worst health 
state presented. Conclusions: Respondents in our sample did not consistently 
include income effects and leisure effects. Including income effects only had 
(some) effect on TTO valuations after an explicit instruction. If these results 
are confirmed in future research, this implies that income effects may be best 
captured on the cost side of the cost-effectiveness ratio. Spontaneous inclusion 
or exclusion of leisure time appeared to be more influential.
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4.1 Introduction
Productivity costs remain a controversial cost category in the context of health 
economic evaluations. Not only is their inclusion debated, mostly in relation 
to the perspective chosen in the evaluation (41), also the correct way to estimate 
productivity costs is a much debated topic (12,47,102,105). One of the ongoing de-
bates is whether productivity costs are best measured at the cost or the effect 
side of the cost-effectiveness ratio in a cost-utility analysis (2,7,8,22,31,68,91,105). This 
debate was especially triggered by the publication of the US guidelines on 
cost-effectiveness in 1996 (2), which specified that productivity costs should 
not be valued in monetary terms (and captured at the cost side of the cost-
effectiveness ratio) as is normally the case. Rather, they were to be included 
at the effect side of a cost-effectiveness ratio. To ensure this, respondents in 
health state valuations (HSV) should consider the possible income effects of 
ill health, which, according to the US guidelines, would be the case as long 
as respondents are not explicitly instructed to exclude these effects. Although 
explicit instructions to include income effects could be considered superior, 
silence on this topic would be sufficient to ensure the incorporation of income 
effects by respondents in HSV (2). This recommendation received quite some 
attention and criticism (8,22,31,91,105). One of the main objections to measuring 
the effects of ill health on income through quality adjusted life year (QALY) 
elicitation is that it will not lead to accurate measurement of productivity costs 
(8,22,31,91). Moreover, despite the suggestion of the US Panel to instruct respon-
dents to include income effects, all but one of the most popular multi-attribute 
utility instruments (EuroQol-5D, Health Utilities Index, Quality of Wellbeing 
Scale, Rosser and 15D) remains silent on the matter. Only the Health Utilities 
Index is explicit in this respect and excludes rather than includes these effects 
(112). This, by the way, is consistent with the original instructions for use of 
the time trade-off (TTO) (113). The silence of the other instruments has been 
explained as a deliberate attempt to avoid alluding to income rather than an 
implicit way to include these effects (8). But still, the current silence in most 
HSV exercises does not ensure the exclusion or the inclusion of income effects 
by respondents. This means that to some extent, income effects might be in-
cluded in HSV, which would result in double counting when productivity costs 
are also captured at the cost side of the cost-effectiveness ratio. On the other 
hand, unless all respondents would include correctly estimated income effects 
in HSV, the approach advocated in the US guidelines will not result in an ac-
curate estimation of productivity costs—even apart from other objections (68).
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Unsurprisingly, therefore, it has been suggested that research should be un-
dertaken to find out whether respondents consider income effects of reduced 
health in HSV when these are silent in this respect, whether this affects their 
subsequent valuations, and what effect explicit instructions regarding inclu-
sion or exclusion would have on HSV (112). To date, however, few studies have 
been conducted in this area. The results seem to indicate that a majority of 
the respondents do not include income effects in HSV (60,64,65,67). Moreover, the 
effect of incorporating income effects in HSV appears to be extremely limited 
(65). Still, the available evidence is limited, often used a visual analog scale (VAS) 
as valuation instrument and focused on spontaneous inclusion rather than 
on (the effect of ) instruction. Still, explicit instructions may be considered the 
appropriate way to prevent either an underestimation or double counting of 
productivity costs (7,31,68,91). Given the theoretical debate, two types of explicit 
instruction appear most relevant. First, one could instruct respondents to 
incorporate all possible effects of ill health on income in their valuations (in 
line with the recommendations of the US Panel). Second, one could oppositely 
instruct respondents to exclude these effects and measure all productivity 
costs in a monetary value (using the human capital or friction cost method). 
To our knowledge, the effects of such instructions have been tested only once 
(65). Different explicit instructions on including or excluding the effects of ill 
health on income, or giving no instructions at all, did not lead to significant 
differences in HSV on a VAS. The latter may have been a limitation in estab-
lishing effects of income considerations in HSV because scale compatibility 
(i.e., the tendency of respondents to give more weight to the subject of focus 
in the response scale, potentially underweighting other aspects) may result in 
relative insensitivity of the VAS instrument regarding income effects (65): the 
respondents may have been inclined to focus mainly on health itself instead of 
focusing on other aspects related to ill health.
Although there is debate in this area as well (114), the TTO method currently 
seems to be the preferred valuation technique for health states rather than 
standard gamble techniques, VAS, or person trade-offs, and indeed, much used 
tariffs have been based on TTO elicitations (108,115). It seems especially relevant 
therefore to investigate the extent to which respondents consider income 
changes in TTO exercises and whether the TTO method is equally insensitive 
as the VAS seems to be to differences in explicit instructions on including or 
excluding income effects. This chapter reports on a study investigating this.
Although the main focus is on productivity costs and despite the fact that 
there is little debate on whether leisure time should be incorporated in the 
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QALY measure (2,7,68,91), it needs noting that the amount of empirical research 
on whether respondents in fact include leisure time in HSV is equally limited 
(64,65,67). If respondents do not consistently include these effects on leisure, even 
though we expect them to, it is also important to see what effect this has on 
subsequent HSV. We explicitly highlight the effects of including the negative 
consequences of ill health for leisure time in TTO valuations in this chapter.
The structure of this chapter is as follows. First, we highlight the current 
knowledge in this area. Then, we present the design of the new study. Next, we 
highlight the results and subsequently discuss them.
4.2 Previous studies
As mentioned, few empirical studies have been performed to assess respon-
dents’ income (and leisure) considerations in HSV. To our knowledge, four 
studies have been conducted to find out whether respondents include the 
effects of ill health on income in HSV; the studies of Meltzer et al. (60), Sendi 
and Brouwer (64), Brouwer et al. (67), and the study of Krol et al. (65). The first three 
studies focused on whether respondents include income effects and the latter 
additionally focused on the effect of instructions on including and excluding 
these effects. In the studies of Sendi and Brouwer (64), Brouwer et al. (67), and Krol 
et al. (65), respondents were furthermore asked whether they had included the 
effects of leisure time in their HSV.
Meltzer et al. (60) tested how giving information about the financial conse-
quences of ill health affects respondents’ considerations and valuations using 
the TTO method. Respondents were asked whether they had thought of finan-
cial consequences of illness while answering the TTO questions. Even when 
respondents were informed that no form of disability payment existed, less 
than 25% of the respondents included the financial consequences of illness 
in their valuations. Without any information on income losses, less than15% 
included income effects. Respondents who indicated to have (spontaneously) 
included income, without previous information on income loss, had lower TTO 
scores than respondents who did not consider income changes.
Sendi and Brouwer (64) performed a small sample test among 20 health pro-
fessionals to find out whether the effects of ill health on income and leisure 
time would be included in HSV when no explicit instructions are provided. 
Respondents were asked to value a disease-specific health state on a VAS. 
Forty percent of the respondents included the effects of ill health on income, 
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whereas 60% did not. The respondents who included income effects had a 
significantly lower mean VAS score than the respondents who did not include 
these effects. In the experiment of Sendi and Brouwer (64), respondents were 
also asked whether they had considered effects of ill health on leisure time. 
It turned out that 75% of the respondents indicated to have considered these 
effects. Although the valuations of respondents who had not included leisure 
time were higher than the valuations of those who did, the difference was not 
significant.
Brouwer et al. (67) asked 75 respondents of the general public to value three 
health states on a VAS. The respondents were asked afterwards whether they 
had considered income effects and leisure time effects of ill health. Respec-
tively, 31% included income effects and 61% had included leisure time effects. 
Although income consideration did not result in significant changes in HSV, 
the incorporation of leisure proved to be influential in the valuation, but only 
for the most severe health state.
Krol et al. (65) asked 185 respondents of the general public, divided into 
three groups, to value three health states on a VAS. The first group was asked 
afterwards whether they had considered income effects in their valuations. 
Thirty-six percent spontaneously included income. The second group was in-
structed to consider income effects in their valuations and the third group was 
instructed to assume that income would not change due to ill health. There 
were no differences in the valuations of the three groups of respondents. The 
second and the third group of respondents were furthermore asked whether 
they had included the effects of ill health on leisure time. Eighty-four percent 
included these effects. There were no significant differences between the valu-
ations of respondents who included or excluded effects on leisure time.
The results of the above studies seem to indicate that inclusion of income 
in HSV is inconsistent without explicit instructions. Nevertheless, the results 
of the studies of Brouwer et al. (67) and Krol et al. (65) suggest that inclusion of 
income effects does not change HSV when using a VAS as elicitation method. 
This may reflect that the VAS is rather insensitive in capturing these effects of 
ill health on income. The results regarding the effects of including leisure time 
on HSV are inconclusive.
This study aims to further investigate respondents’ considerations on in-
come and leisure in HSV using TTO, and additionally focuses on the effects of 
explicit instructions regarding the inclusion of income.
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4.3 A new study
To increase the comparability with previous studies, we drew our study sample 
in a similar way as was done in the research of Krol et al. (65) and (with exception 
of the QALY-elicitation method) we used similar questionnaires.
To test the inclusion of income and leisure time as well as the influence of 
instruction, three different questionnaires were constructed. The study sample 
was drawn from the general public in various public places (mainly individuals 
traveling by public transportation). Respondents were approached and asked 
whether they were willing to participate in this study. If they agreed to partici-
pate, the respondents in our convenience sample were randomly handed one 
of the three different versions of the questionnaires for self-completion. A total 
of 240 questionnaires were administered. In all three questionnaires, respon-
dents were first asked some background questions about sex, age, income, 
education, and their current health state using the EuroQol descriptive system 
(EQ-5D) and the EuroQol VAS. Next, the respondents were asked to value three 
ill health states that differed in severity, and were chosen from the 243 possible 
health state scenarios with the EQ-5D, with the standard Measurement and 
Valuation of Health group (MVH)_A1 scores of, respectively, 0.88 (health state 
21211), 0.587 (health state 22221), and -0.043 (health state 33312) to have a 
large spread in health states (table 4.1).
In the study of Krol et al. (65), respondents were asked to value the same three 
health states on a VAS. Now, respondents were asked to value the health states 
with the use of the TTO method. The respondents were asked to state how many 
years of full health they considered to be equally good as living 10 years in the 
given ill health state (see Appendix 4A). Respondents also had the opportunity 
to choose not to give up life years and live the full 10 years in the given ill health 
state. Respondents were informed that the ill health state would remain the 
same the full 10 years and that life would end after these 10 years in ill health 
Table 4.1 The health states presented in the questionnaires 
Health 
state
EQ-5D 
code
MVH_A1* 
score
Description
1 21211 0.880 Some problems in walking, no problems with self-care, some problems 
performing usual activities, no pain or discomfort, not anxious or depressed. 
2 22221 0.587 Some problems in walking, some problems with self-care, some problems 
performing usual activities, moderate pain or discomfort, not anxious or 
depressed
3 33312 -0.043 Confined to bed, extreme problems with self-care, not able to perform usual 
activities, no pain or discomfort, moderate anxious or depressed
* MVH = Measurement and Valuation of Health group
74
 
or the (less than10) years chosen in full health. Respondents were instructed to 
make choices considering themselves and reflecting their own opinion.
In version 1 of the questionnaires, respondents did not receive directions on 
whether to incorporate or to ignore the effects of ill health on income while 
making the trade-offs. The respondents were asked whether they had included 
income effects, after the valuation process. If they indicated they had included 
these effects, they were asked to value the same three health states again, but 
now with the explicit instruction to ignore the effects of ill health on income 
by assuming that their income would not change due to ill health. In version 
2, people were explicitly instructed upfront to assume that income would not 
change due to ill health, and thus to ignore the effects of ill health on income. 
In version 3, respondents were oppositely instructed to incorporate the pos-
sible effects of ill health on income. In all questionnaires, respondents were 
asked whether they thought being in the different health states would decrease 
their income and if so, to what extent. This was always done after the valuation 
process in order not to ‘contaminate’ the outcomes.
In versions 2 and 3, respondents were furthermore asked whether they had 
included the possible effects of ill health on leisure time in their valuations 
and if they thought the three health states presented would affect their leisure 
time. The latter aspect was asked because the differences in the extent to which 
respondents believe that the three ill health states will affect their leisure time 
can be of influence on their valuations. If, for instance, all respondents expect 
that the health states will have no effect on their leisure time, it could be ex-
pected that including or excluding leisure time considerations in the valuation 
process will have no effect on subsequent valuations. In version 1 (with the 
double HSV), the leisure time questions were not included to limit the size of 
the questionnaire.
The questionnaire was designed to confirm the following hypotheses, based on 
theoretical debate and the results of previous studies.
1. Without receiving directions on including or excluding the effects of ill 
health on income or leisure time, some respondents to HSV will and some 
will not include these effects in their valuations (60,64,65,67).
2. Respondents of HSV who spontaneously include the effects of ill health on 
income do not significantly value health states different from respondents 
who do not automatically include these effects (65,67).
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3. Respondents of HSV who include the effects of ill health on income without 
instructions, will value the same health states higher the second time when 
asked explicitly to exclude these effects (64,65).
4. Respondents of HSV who are explicitly asked to include the effects of ill 
health on income value health states not significantly different from re-
spondents who are explicitly asked to exclude the effects (65).
5. Respondents of HSV who include the effects of ill health on leisure time, value 
health states lower than respondents who do not include these effects (67).
Categorical variables were compared with the chi-square test, ordinal vari-
ables with the Mann–Whitney U-test (for two groups) or the Kruskal–Wallis 
test (for more than two groups). Continuous variables are compared with the 
Student’s t test (two groups) and with one-way analysis of variance (two or 
more groups). Simple linear regression models and linear mixed effects (LME) 
models were used to estimate the association between the valuations of the 
health states and other variables such as the version of the questionnaire ad-
ministered and characteristics of the respondents as age, sex, and income. The 
data were analyzed with use of SPSS Statistical Software Package 13.0 (SPSS, 
Chicago, IL) and S-Plus 6.2 Professional (Insightful S-Plus, Seattle, WA).
4.4 Results
Sample population
A total of 222 respondents completed the questionnaire. Eighteen of the 
administered questionnaires were not returned or returned blank. Twelve 
questionnaires were excluded from further analysis based on comments of 
the respondents that they did not understand the TTO method or based on 
evidence that instructions were not followed (e.g., respondents who did not 
trade-off healthy years, but instead wanted more than 10 years in full health in 
return). A total of 210 questionnaires were used for further analysis (version 1; 
n = 72, version 2; n = 75, version 3; n = 63). As seen in table 4.2, the average age 
of the respondents was 34.8 years and did not differ between the versions of 
the questionnaire. Fifty percent of the respondents were female. The average 
self-reported health of the respondents was 0.82 reported on a VAS. Higher 
educated people and those with higher incomes were overrepresented in our 
sample. The respondents with higher incomes were significantly older (P < 
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0.001). The respondents of the different versions of the questionnaire did not 
differ in income, education, sex, employment, or self-reported health.
Effects of ill health on income
As seen in table 4.3, 28% of the respondents stated that ill health state 1 (the 
‘mildest’ state) would decrease their income. Respectively, 71% and 89% ex-
pected income loss in health state 2 or 3. Although especially for less severe 
health states explicit instructions may have induced more respondents to 
expect income changes, these differences were never significant at the 5% con-
fidence level. Respondents who thought that the health states would decrease 
their income were younger than those who did not expect income influence 
(P < 0.01 for all health states). Respondents who stated that health state 2 or 
health state 3 would not change their income were more often unemployed 
(P < 0.01). Respondents who stated that health state 3 would decrease their 
income were better educated (P = 0.05) as opposed to those who did not.
The respondents who expected income loss to occur expected on average 
that health state 1 would lead to a loss of 284 euros per month, while this 
Table 4.2 Characteristics of respondents (SD between brackets)
Characteristic Questionnaire administered  All respondents
Version 1 ( n = 59) Version 2 (n 
= 64)
Version 3 (n 
= 62)
(n = 185)
% Females 54 44 54 50
Age 36.0 (14.4) 35.1 (14.4) 33.0 (14.2) 34.8 (14.3)
% Employment
 No paid work 36 23 29 29
 Fulltime employment 31 43 40 38
 Part-time employment 33 34 31 33
% Education a
 Lower education 11 13 21 15
 Medium education 39 39 41 40
 Higher education 50 48 38 46
% Income b
 Lower income 26 21 25 24
 Medium income 26 34 33 35
 Higher income 47 45 41 45
Mean SAH with VAS (SD) 0.82 (0.14) 0.83 (0.12) 0.82 (0.15) 0.82 (0.14)
a These groups were defined according to the Dutch educational system. The category ‘lower 
education’ comprises elementary school, lower general secondary education (MAVO) and pre-
vocational (VBO). ‘Medium education’ comprises higher general secondary education (HAVO, VWO) 
and senior vocational education (MBO). ‘Higher education’ comprises vocational colleges (HBO) and 
academic education.
b Based on net income per month: low = <€650, medium = €650–1900, high = >€1900, 
SAH = self-assessed health, VAS = Visual Analogue Scale, y = years, SD = standard deviation
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amount was 421 and 787 for health states 2 and 3, respectively. We used regres-
sion techniques to see which variables are associated with expected income 
loss. The valuations of respondents were not significantly associated with the 
expected amount of income loss. A higher income was associated with a higher 
expected income loss, but only in the worst health state 3 (P = 0.05). Other 
demographic variables such as age, sex, and education turned out not to be 
significant for all the three health states.
The effects of instructions
No instructions
Confirming our hypothesis (1) that without instructions, some respondents 
will and some respondents will not include the effects of ill health on income in 
HSV, 64% of the respondents of version 1 automatically included the possible 
effects of ill health on income in their HSV and 36% did not. This percentage 
of inclusion is higher than those found in previous studies, where it never ex-
ceeded 40% (60,64,65,67). The respondents who automatically included the effects 
of ill health on income did not differ from those who did not, in education, 
income, employment, sex, age, or self-reported health.
Although Meltzer et al. (60) and Sendi and Brouwer (64) report differences in HSV 
based on different considerations about negative effects of ill health on income 
(assessed without explicit instruction), our overall results do not show a sig-
nificant influence of including or excluding of the effects of ill health on income 
without instructions on the subject (see table 4.4). These findings support the 
hypothesis (2) that respondents of HSV who spontaneously include the effects 
of ill health on income do not significantly value health states differently than 
respondents who do not spontaneously include these effects. These findings are 
similar to the findings in the studies of Krol et al. (65) and Brouwer et al. (67).
Table 4.3 Effects of ill health on income and leisure-time (SD between brackets)
Health state 1 
decreases income 
Health state 
2 decreases 
income
Health state 3 
decreases income
Included 
income
Included 
leisure time
% Version 1 (n = 72 ) 21 61 88 64 -
% Version 2 (n = 75 ) 32 76 91 - 90
% Version 3 (n = 63 ) 32 77 86 - 85
Mean % 28 71 89 - 88
P-value a 0.228 0.077 0.758 - 0.371
Expected income 
loss (€) 
284 (205) 421 (330) 787 (461) - -
a Chi-Square Test
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Table 4.4 health state valuations
Valuations
Version Group HS1 n HS2 n HS3 N
The effects of instructions
1 All (no instructions) 0.88 72 0.72 72 0.39 71
2 All (excluding income) 0.91 74 0.74 74 0.45 73
3 All (including income) 0.91 62 0.72 62 0.38 60
P-value a (1 vs. 2 vs. 3) 0.329 0.820 0.279
P-value b (1 vs. 2) 0.201 0.537 0.188
P-value b (1 vs. 3) 0.209 0.867 0.911
P-value b (2 vs. 3) 0.985 0.676 0.181
Spontaneous inclusion/exclusion of income 
1 Including income 0.89 45 0.72 45 0.41 45
1 Excluding income 0.86 25 0.70 25 0.35 24
P-value b 0.494 0.752 0.364
Excluding income after spontaneous inclusion of income
1 1st valuation (+ income) 0.88 34 0.73 34 0.39 34
1 2nd valuation (- income) 0.87 34 0.75 34 0.42 34
P-value c 0.343 0.226 0.189
Income affected & income included/excluded
1 Income affected d 0.79 14 0.70 41 0.40 60
1 Income not affected 0.90 56 0.74 28 0.34 9
P-value b 0.008 0.498 0.508
1 Income included + affected d 0.78 6 0.71 24 0.42 40
1 Income excluded + affected d 0.79 8 0.70 17 0.38 20
P-value b 0.955 0.908 0.579
2 Income affected d 0.93 23 0.72 56 0.44 64
3 Income affected d 0.87 19 0.68 43 0.34 50
P-value b 0.173 0.433 0.055
Leisure-time (LT) affected & leisure-time included/excluded
2 & 3 Including LT 0.90 113 0.71 113 0.39 110
2 & 3 Excluding LT 0.94 16 0.84 16 0.48 16
P-value b 0.242 0.037 0.235
2 & 3 LT affected e 0.88 85 0.70 113 0.40 122
2 & 3 LT not affected 0.96 45 0.86 14 0.60 5
P-value b 0.000 0.021 0.123
2 & 3 LT included + LT affected e 0.88 74 0.69 97 0.38 103
2 & 3 LT excluded + LT affected e 0.89 8 0.81 13 0.45 15
P-value b 0.866 0.091 0.387
a One-way ANOVA, b  T-test for equality of means, c  paired sample t-test 
d The valuations of respondents that think the health state will influence income. The valuations of 
respondents who do not think the particular health state will affect income were removed.
e The valuations of respondents that think the health state will influence leisure time. The valuations 
of respondents who do not think the particular health state will affect leisure-time were removed.
79
Breaking the silence
Ch
ap
te
r 4
In table 4.4, the average TTO valuations of the three health states of the 
respondents of the three different questionnaires are presented. Our respon-
dents valued the health states higher than the corresponding MVH_A1 scores: 
0.90 versus 0.88, 0.73 versus 0.59, and 0.41 versus -0.04 for health state 1 to 
3, respectively. The respondents in our sample were reluctant to trade-off life 
years: 58%, 31%, and 12% of the respondents were unwilling to trade-off life 
years for health states 1 to 3, respectively. There were no differences between 
the versions in percentages of respondents who would not make the trade-off. 
Respondents who would not give up time were significantly older than those 
who would in all the three health states. Furthermore, the respondents who 
would not give up years in health states 1 and 2 had significantly higher in-
comes than those who did make the trade-off. This latter difference was not 
found in health state 3.
Instruction after silence
As mentioned, the respondents of version 1 who included income in their 
valuations were asked to value the same health states again, now assuming 
these health states would not affect their income. Although other studies 
(64,65,67) already show that a part of the respondents does not react to a change in 
instructions by changing their valuations, it was expected that overall, the re-
spondents would value the same health states significantly higher the second 
time.
As seen in table 4.4, we found no significant differences between the first and 
second valuations of the respondents. These findings are similar to the findings 
of Brouwer et al. (67) and do not support the hypothesis (3) that respondents 
change their valuations if they are asked to ignore a negative aspect of ill health 
they had included before.
Explicit instructions
Table 4.4 shows that the respondents of version 2 (who were explicitly asked 
to exclude the effect of ill health on income), did not value the health states 
significantly higher than the respondents of version 3 (who are explicitly asked 
to include the effects), similar to the findings of Krol et al. (65). The valuations 
of the respondents without instruction (version 1) moreover did not differ 
from those in the other two groups. These results, thus, seem to imply that 
instruction does not matter in the sense that it does not change the mean TTO 
valuations. Only considering respondents (in versions 2 and 3) who actually 
expected the presented health state to affect income in our analyses, regardless 
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of the instruction given, increases the differences in mean valuations of the 
respondents in the expected direction (respondents of version 2 give higher 
values to the health states). These differences, however, are still insignificant, 
as shown in table 4.4.
Multivariate analysis
A linear regression model was used to estimate the association between the 
HSV of all respondents and the version administered and whether respondents 
expect a health state to affect income, regardless of whether income effects 
were included (interaction term included), corrected for age, sex, income, and 
self-reported health.
As shown in table 4.5, income had a significant positive association with 
the valuations of health states 1 and 2. In health state 1, the interaction term 
of the version of the questionnaire and whether respondents expect that the 
health state would actually decrease income turned out to be significant. Re-
spondents who were handed version 1 or version 3 of the questionnaire and 
expected the relevant health state to decrease income therefore valued that 
health state lower than the respondents in version 2. These interaction terms 
were not significant for the valuation of health state 2; however, for health state 
3 the interaction term of version 3 and expecting income to be affected was 
again significant. These results imply that the different instructions do seem to 
affect respondents’ valuations, but only if respondents expect that the health 
states presented would actually decrease their income. Note that the linear 
regressions have little explanatory power.
Table 4.5 Results of regression analyses (n = 199)
Valuation HS 1. Valuation HS 2. Valuation HS 3.
Beta P-value Beta P-value Beta P-value
Constant 8.057 .000 6,403 .000 2.445 .174
Sex (male = 1, female = 0) -.005 .544 .020 .202 .024 .207
Age -.235 .240 -.661 .052 -.704 .080
Net income .232 .004* .374 .007* .089 .578
Self-reported health .557 .438 -.339 .779 1.533 .288
Version 1 vs. 2 .051 .854 -.457 .527 -1.489 .291
Version 3 vs. 2 .421 .153 .743 .387 2.552 .094
Does HS 1, HS 2 or HS 3 affect income (1 = yes, 
0 = no)
.405 .255 -.378 .574 -.053 .964
Dummy version1*income affect HS 1, 2 or 3 -1.691 .003* .093 .915 1.101 .461
Dummy version3*income affect HS 1, 2 or 3 -1.063 .043* -1.256 .201 -3.594 .027*
Adjusted R² .094 .098 .094
* P < 0.05
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Next, we focused on the effects of explicit instructions (as given in versions 
2 and 3 of the questionnaire). To that end, an LME model was used and re-
spondents of version 1 of the questionnaire were excluded from the analysis. 
The LME model was used to estimate the association between the valuation of 
the health states and explicit instructions, stratified by whether respondents 
thought income would be affected by the respective health state, adjusted for 
age and sex. Respondents valuing the three health states were treated as ran-
dom effects to account for within respondent variability and correlation using 
an unstructured correlation matrix.
Because the interaction term ‘version*income-affected*health state valua-
tions’ in the LME model turned out to be significant (P = 0.048), the effect of 
explicit instruction on HSV was analyzed separately in each subgroup of re-
spondents who expected income to be affected in, respectively, health states 
1, 2, or 3. A linear regression model was used to separately test whether the 
valuations of the three health states were affected by the explicit instructions in 
versions 2 and 3. Covariates were added to the respective univariate model to 
improve the estimate and precision of the effect estimate in case the univariate 
model showed a P-value of 0.1 or less. Furthermore, in all models, a multivari-
ate model was also used as a starting point and the model was then simplified 
to assess the effect of including/excluding covariates to the respective model 
on the main effect estimate of interest. Because the leisure time questions 
were only asked in versions 2 and 3, respectively, they are also included in the 
multivariate model. The multivariate model included the variables age, sex, 
consideration of income and leisure in HSV, and own VAS.
As shown in table 4.6, in the subgroup expecting the health state to affect 
their income, the explicit instruction variable was significantly associated with 
the valuation of health state 3, with lower scores for respondents including 
income. Also the variables sex, expecting the health state to affect leisure, and 
self-reported health were significantly associated with the valuation of health 
state 3.
The results of the subgroup analysis of versions 2 and 3 imply, similar to the 
analyses of the three versions together, that explicit instructions may have an 
effect on valuations of health states, however only in respondents who believe 
their income will be affected by this health state. In other cases, however, 
explicit instruction did not lead to changes in valuations. This means that the 
findings of Krol et al. (65) are largely but not completely reproduced in this study 
and that hypothesis (4) is for most situations, but not for all, confirmed. The 
picture is less uniform than in previous studies therefore.
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Leisure time
Eighty-eight percent of the respondents of versions 2 and 3 included the effects 
of ill health on leisure time while trading-off time versus health. Even though 
respondents are assumed to include leisure time (2,68,91), 12% of the respondents 
in our convenience sample did not. This supports hypothesis 1, that without 
instructions, some respondents will and some will not include these effects. 
The percentage of respondents who included leisure time is comparable with 
the 84% of the study of Krol et al. (65). It is, however, higher than the percentage 
found in previous studies by Sendi and Brouwer (64) (75%) and Brouwer et al. (67) 
(61%).
The 88% of the respondents who included leisure time in their valuations 
had a lower income than the 12% who did not include leisure time (P = 0.03). As 
shown in table 4.4, respondents including leisure time gave lower TTO values 
to the three health states than respondents who had not included leisure time. 
The differences, however, were only significant for health state 2. These results 
can therefore not completely support the hypothesis (5) that respondents who 
include the effects of leisure time will value the health states lower than those 
who do not include these effects. These findings are similar to the findings of 
Brouwer et al. (67), who also found significant differences for only one health 
state (the worst health state in that case).
As mentioned, we asked the respondents whether they expected the three 
health states presented to affect their leisure time. Sixty-five percent, 89%, and 
96% of the respondents believed that, respectively, health states 1 to 3 would 
Table 4.6 The effect of instruction on health state valuation stratified by whether respondent thinks 
health state affects income (TTO)
Univariate model Multivariate model*
HS Income 
affected
variable Coefficient SE P-value Coefficient SE P-value
1 Yes Version 3 v 2 -.620 .447 .173
1 No .427 .287 .140
2 Yes -.387 .492 .433
2 No .394 .866 .652
3 Yes Version 3 v 2 -.975 .522 .064 -1.062 .500 .036**
Sex -1.479 .499 .004**
Leisure affected -6.507 2.606 .014**
Self-reported health 4.116 2.052 .047**
3 No Version 3 v 2 1.7381 1.9602 .3942
* R² 0.16, P-value of multivariate model = < 0.001
** P < 0.05
SE = Standard error
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affect their leisure time. We excluded the respondents who thought that the 
health states would not affect their leisure time. Next, we tested again whether 
including or excluding leisure time leads to differences in valuations to see if 
the differences would have increased. Opposite from what we expected, the 
differences between the valuations of respondents including and excluding in-
come decreased after correcting for thinking a health state would or would not 
affect leisure time, as shown in table 4.4. The correction causes the difference 
earlier found in health state 2 to lose its significance. Interestingly, whether 
a respondent thinks the health state will affect leisure time is (regardless of 
whether a respondent included or excluded leisure time effects) of significant 
influence on respondents’ valuations for health state 1 and health state 2, 
though not for health state 3. The latter result, also given that the difference 
between the groups grows with the severity of the health state, is probably due 
to lack of power given the low number of respondents thinking that leisure 
would not be affected. Indeed, in the study of Brouwer et al. (67), the fact that 
leisure was affected was most influential as well, although, after correction for 
other variables, it was only for the most severe health state that a significant 
difference was found between respondents who believed leisure to be affected 
and those who did not (in the expected direction).
4.5 Discussion and conclusions
This chapter has reported on the first study aimed at investigating the effects of 
explicit instructions regarding the inclusion or exclusion of income and leisure 
in HSV using TTO. In this study, five hypotheses were sought to be confirmed. 
In line with the results from previous studies, our study confirmed the first hy-
pothesis that without instructions, respondents do not consistently include or 
exclude the effects of ill health on income. Given the high inclusion of income 
in this study relative to previous studies, the TTO method may be more sensi-
tive to inclusion of income effects than the VAS. Scale compatibility may be an 
explanation for this (109). On the other hand, Meltzer et al. (60) used TTO questions 
(and even triggered respondents to consider income effects by giving specific 
information about disability payments) but report lower percentages of inclu-
sion of income by respondents. Differences in sample population, country, and 
methodology may have contributed to these differences.
Our second hypothesis was also confirmed. The respondents spontaneously 
including the effects of ill health on income did not value the three health states 
84
 
significantly different when compared to respondents not including these ef-
fects. Surprisingly, for all three health states, respondents including income 
gave higher valuations, although these differences were insignificant.
Hypothesis 3 was not confirmed. Respondents who, without instructions, in-
cluded income effects did not value the three health states significantly higher 
the second time when asked explicitly to exclude these effects. Nevertheless, 
the valuations of the more severe health states 2 and 3, where potential effects 
of differences in including or excluding income effects would be strongest, did 
change in the expected direction.
Results regarding the fourth hypothesis were mixed. In most cases, explicit 
instructions on including or excluding income had no significant effect on HSV; 
although the group instructed to include income elicited lower valuations 
of health states 2 and 3. The effect of explicit instruction on the HSV was only 
significant in some cases where respondents actually expected an income effect.
For the final hypothesis, results were also mixed. Respondents spontane-
ously including leisure time effects gave lower HSV than respondents exclud-
ing leisure. The differences in valuation were however only significant for one 
of the three health states.
Before discussing the implications, some important limitations of this study 
need to be stressed. First of all, our study is based on a relatively small conve-
nience sample of respondents. Some of the differences in HSV between groups 
may have been insignificant because of lack of statistical power, especially in 
cases where differences in the expected direction were observed but did not 
reach conventional levels of significance (e.g., for hypotheses 3, 4, and 5). 
Therefore, repeating this study in a larger sample remains important. Using a 
wider variation in valued health states in such studies may also be informative. 
Second, the format of our TTO questions might have leaded some respondents 
to believe that the minimum trade-off they could make was 1 year. The re-
spondents indeed did only trade-off whole or half years. This may have caused 
respondents willing to trade-off some time, but less than a year, to choose to 
not give up years at all. The respondents in our sample indeed were reluctant 
to trade-off life years, although the reluctance to trade-off life years is com-
mon (116). Potential bias caused by our TTO framing would be strongest in the 
mildest health state. It is however not expected to affect potential differences 
in valuations between the three health states and our focus was not on finding 
the ‘right’ TTO values, but on finding the effects of instructions on income in 
HSV. Third, the results of our study may be country-specific. In countries with a 
less comprehensive social security system than The Netherlands, respondents 
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might be more inclined to consider income and ill health may affect income 
more strongly, leading to more respondents including the effects of ill health on 
income or perhaps even to significant differences in HSV between respondents 
including and excluding income effects. This could be investigated further. A 
fourth limitation of our study is that we did not ask the respondents afterwards 
whether they acted according to the instructions given. It could be that a part 
of the respondents ignored the instructions. Furthermore, it is possible that 
through the instruction to ignore possible income effects, respondents are 
actually triggered to do think of income (‘the pink elephant effect’ (68)). It is also 
possible that any explicit instruction places too much emphasis on income, 
causing respondents to overweigh possible income effects in the HSV. This 
forms a potential bias if we, in daily practice, consider instructing respondents 
to HSV on including or excluding income. Finally, we asked the respondents 
the extent to which they believed that the ill health states would affect their 
income. It, however, remains questionable whether respondents can make 
realistic estimations of income losses due to illness (67). This idea is strength-
ened by the high number of missing values when a specific amount of expected 
income loss is asked (missing values health state 1: 35%, health state 2: 33%, 
and health state 3: 40%). One way to circumvent this lack of knowledge is to 
include explicit information on reasonable estimates of income losses due to 
certain health states. A similar procedure was followed by Meltzer et al. (60).
In conclusion, our results are generally in line with earlier studies and in-
dicate that silence regarding inclusion of income and leisure does not ensure 
consistency in this respect in HSV. Some respondents will include these effects 
while others exclude them. Moreover, the extent to which respondents expect 
health states to affect their leisure and income varies substantially across 
respondents. Still, as found in some previous studies, spontaneous inclusion 
or exclusion of income effects did not result in different valuations of health 
states. The influence of explicit instructions regarding inclusion of income ef-
fects appears to be limited, but still, in contrast to earlier findings does appear 
to matter. Because we do find some effects of including income after an explicit 
instruction on the matter, the TTO method may be more sensitive in picking up 
income effects than the VAS. Especially when respondents believe that income 
is indeed affected (which is more often the case in severe health states), explicit 
instruction to exclude income may lead to higher valuations. For leisure, the 
percentage of respondents including leisure time was relatively high in our 
study. Still, like in other studies, a substantial part of the respondents do not 
include leisure time in their valuations although they are normally expected 
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to do so. We find no clear evidence that inclusion as such leads to differences 
in valuations. Expecting leisure to be affected seems more influential than the 
indicated inclusion of leisure in HSV, which may indicate simply a difference in 
perception of the severity of the health states between respondents.
What do these results imply then for productivity costs and leisure? First of 
all, it is important to realize that, given the limitations of our study and the 
previous studies conducted, it is premature to draw definite conclusions. There 
is a clear need for more research in this area using larger samples to further 
explore this important topic.
Notwithstanding this, it is clear that currently, most HSV methods include no 
instructions to the respondent regarding the inclusion or exclusion of income 
effects. In this case, respondents spontaneously include or exclude income. As 
we have seen, spontaneous inclusion or exclusion of income changes does not 
appear to result in noticeable differences in HSV even when such changes are 
expected to be large. If this finding is confirmed in future research, this casts 
empirical doubts on recommendations to include income changes in health-
related quality of life, next to theoretical objections one may have against it 
(e.g. (22)). In that case, it would imply that it is best to include productivity costs 
on the cost side of the cost-effectiveness ratio, where they do have a measur-
able effect. If one actively wants to preclude income effects in HSV, explicit 
instructions to exclude income changes due to ill health may be considered 
appropriate. It must be noted, however, that such instructions may involve po-
tential biases, like overweighting income, due to an active, although negative, 
emphasis on income considerations. Rather than telling respondents what not 
to consider, and thus risking that they will consider it, it may be better to tell 
them what to consider; i.e., they should consider that they are covered by full 
health insurance and salary continuation insurance (113). More research here 
would clearly be useful. For now, silence on the matter may be considered the 
best solution, because it is unclear whether a move away from silence, and 
what kind of a move, is for the better or the worse.
Although in all the empirical studies on leisure time in HSV (including ours) 
small samples were used, it seems clear that most people include this in HSV. 
Not all respondents, however, automatically include these effects, and there-
fore, it may be necessary to explicitly instruct respondents to include these 
effects. But even then, more research in this area seems worthwhile because 
it remains unclear whether including leisure results in an adequate valuation 
of lost leisure. Silence may not be golden therefore, but how to break it best 
remains open for debate.
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Appendix
4 A The TTO exercise
In this part of the questionnaire subsequently three health states are described. 
You are asked to value these health states. We are interested in your opinion and 
the choices you would make for yourself. 
Imagine that the health states remain unchanged for ten years en that life ends 
after this period. You are asked to state how many years in full health for you 
would be equal to 10 years in the given health states. You also have the choice 
to state you would rather live 10 years in the given (less than perfect) health state 
instead of given up life years for better health.
Health state 1.
Some problems in walking
No problems with self-care
Some problems performing usual activities
No pain or discomfort
Not anxious or depressed
Mark and give your opinion on the dotted line
Ten years in health state 1 is equal to……………years in full health
Or, if this is your preference, mark:
I rather live 10 years in health state 1, than giving up life years for full-health 

5. 
Does the EQ-5D ref﻿lect lost earnings?
Based on: Tilling C, Krol M, Tsuchiya A, Brazier J, Exel J, Brouwer W. 
Does the EQ-5D reflect lost earnings? 
Pharmacoeconomics 2012 Jan;30(1):47-61.
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Summary
Background: An important methodological issue in economic evaluations of 
health care is how to include productivity costs (the costs related to reduced 
productivity due to illness, disability and premature death). Traditionally, they 
were included in the numerator of a cost-effectiveness analysis, through either 
the human capital or the friction cost method. It has been argued, however, 
that productivity costs are already included in the denominator (i.e. in the 
QALY measure) because respondents consider the effect a given health state 
will have on their income when valuing health states. If that is the case, many 
previous economic evaluations might have double counted productivity costs 
by including them in both the numerator and the denominator. Aim: The aim 
of this study was to determine whether respondents valuing EQ-5D health 
states using the time trade-off (TTO) method spontaneously consider income 
effects, whether this consideration influences subsequent valuations and 
whether explicit ex post instructions influence valuations. Methods: Through 
an online survey, we asked 321 members of the Dutch general population to 
value four EQ-5D health states through three different TTO exercises. The first 
exercise was a standard TTO question. Respondents were then asked whether 
they had included income effects. Depending on their answer, the second TTO 
exercise instructed them to either include or exclude income effects. The third 
TTO exercise provided explicit information regarding the income loss associ-
ated with the health state. Results: Data were available from 321 members of 
the Dutch general public. Of these respondents, 49% stated they had spontane-
ously included income effects. Twenty-five percent of the sample did not trade 
any time in any of the TTO exercises and these respondents were excluded 
from the analysis. Results of t-tests showed there were only weakly significant 
differences in valuations for one health state between those who spontane-
ously included income effects and those who did not. Explicit instruction 
led to some significant differences at the aggregate level, but the effect was 
inconsistent at the individual level. When explicit information on the amount 
of income loss was provided, all states were valued lower when associated with 
a larger income loss. Conclusions: This study offers further evidence indicating 
that income losses do not significantly affect health state valuations.
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5.1 Background
Economic evaluation is increasingly used to inform the allocation of scarce 
health care resources. Many national decision-making bodies, such as the 
National Institute for Health and Clinical Excellence (NICE) in the UK (72) and 
the Dutch Health Insurance Board, (74) require or encourage these economic 
evaluations to take the form of a cost-utility analysis, with the QALY as the 
measure of health benefit. The QALY assigns a ‘utility’ value, representing aver-
age preferences, to a given health state. The values range from 0 to 1, where 
1 represents ‘perfect health’ and 0 represents ‘dead or equivalent’. Values less 
than zero can be used to represent states considered to be ‘worse than dead’. 
The number of QALYs over a given period of time is then calculated by multi-
plying the utility values of the relevant states with the duration of these states. 
The quality adjustment in the QALY is commonly informed by national popu-
lation value sets. Most of these value sets measure changes in health status on 
the EQ-5D7 descriptive system and use the time trade-off (TTO)8 method of 
preference elicitation (e.g. in the UK, (108) the Netherlands (115), the US (117) and 
Germany (118)).
A potentially important component in economic evaluations is productivity 
costs, defined as ‘‘costs associated with production loss and replacement costs 
due to illness, disability and death of productive persons, both paid and unpaid.’’ 
(8) In some countries, guidelines recommend the exclusion of such costs from 
economic evaluations (e.g. the UK (72)), while in other countries the inclusion of 
these costs is advocated (e.g. the US (2) and the Netherlands (74)). This relates to 
the perspective encouraged in such guidelines (i.e. a broad societal perspective 
or a narrower health care perspective).
In a recent review, Tilling et al. (92) discussed the various different methods 
for including productivity costs in economic evaluations. These costs are nor-
mally included in the numerator of the cost-effectiveness ratio, using either 
the human capital approach (88,119) or the more recently developed friction cost 
7 The EQ-5D descriptive system has five dimensions and three levels per dimension, giving a total 
of 243 health states. For example, 22322 describes the following state: some problems with walk-
ing about, some problems with washing and dressing, unable to perform usual activities, some 
pain or discomfort and moderate anxiety and depression.
8 The TTO method typically asks respondents to make a choice between living in a less-than-per-
fect state of health for 10 years and living in full health but for a shorter period of time. Common-
ly, a point of indifference is obtained through an iterative process. If an individual were indifferent 
between living for 10 years in poor health and for 6 years in full heath, the QALY adjustment for 
that health state would be 6/10 = 0.6.
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method. (90) The latter commonly produces lower estimates of productivity costs 
by allowing for the replacement of sick individuals by previously unemployed 
individuals. The practice of valuing productivity costs in monetary terms was 
challenged in 1996 by the ‘Washington Panel’. (2) In its influential guidelines, 
the panel recommended measuring and valuing most of the productivity costs 
in terms of quality of life, thus including them in the denominator of the cost-
effectiveness ratio. Changes in income are then used as a proxy for productivity 
costs. In other words, the panel assumed that when people value health states, 
they take into account the effect of ill health on their ability to work and hence 
on their subsequent income (even when the question is silent on the issue). 
If this assumption holds, health state valuations, and consequently national 
value sets for measures such as the EQ-5D, already (to some extent) incorpo-
rate the impact of ill health on productivity. The panel, therefore, argued that 
to include changes in productivity in the numerator as well would constitute a 
form of double counting.
Regardless of whether an economic evaluator wishes to include productiv-
ity costs, and regardless of the method of inclusion, a key question must be 
answered to establish confidence in the accuracy of economic evaluations: do 
health state valuations, and therefore the published national value sets for the 
EQ-5D, reflect the impact of lost earnings due to ill health? If they do, previous 
studies including productivity costs in the numerator of the cost-effectiveness 
ratio might have double counted these costs. Alternatively, studies wishing to 
exclude these costs (e.g. in taking a strict health care perspective) might have 
implicitly included them through the use of ‘polluted’ value sets.
The review by Tilling et al. (92) outlined the existing empirical studies that have 
attempted to establish whether or not respondents in health state valuation 
exercises consider the potential impact of lost earnings. The review identified 
eight studies; (60-67) four of the studies used the EQ-5D (63,65-67) and three of these 
found that the majority of respondents did not spontaneously include income 
effects. (63,65,67) No firm conclusions can be drawn from the four studies on the 
effect of spontaneous inclusion on valuations or on the effect of explicit in-
structions, although the influence of considering income appears to be limited. 
The remaining four studies asked respondents to value blindness using TTO, (60) 
multiple sclerosis using a visual analogue scale (VAS), (64) carpal tunnel syn-
drome using standard gamble (61) and visual impairment using TTO. (62) Three of 
these studies found the majority of respondents did not spontaneously include 
income effects. (60,61,64) They also found evidence that spontaneous inclusion 
of income effects significantly affected valuations. However, these studies 
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were hampered by small numbers of respondents, mostly from convenience 
samples. The differences in results among the studies make it difficult to draw 
firm conclusions regarding the inclusion of income effects and the potential 
effects this may have on health state valuations.
The study presented here adapted the study design used to generate popula-
tion value sets for the EQ-5D, as first used in the Measurement and Valuation 
of Health (MVH) study (108), and carried out valuations of hypothetical EQ-5D 
states using TTO exercises through an online survey administered in the 
Netherlands. The study used a number of different TTO questions to explore 
the impact of losses in income on the valuation of hypothetical health states. 
Specifically, our objectives were to (i) examine whether EQ-5D health state 
values, obtained through online TTO exercises, reflected losses in income due 
to ill health; (ii) examine the impact on the health state values of including 
specific ex post instructions to consider, or not to consider, income changes 
when hypothetical EQ-5D states are valued; and (iii) examine how the impact 
on the health state values was distributed across the five different dimensions 
of the EQ-5D.
5.2 Methods
Sampling
Data were gathered through an online self-complete questionnaire, presented 
in Dutch, in the Netherlands. Invitations were sent out to potential respon-
dents, within an existing Internet panel, in order to obtain a representative 
sample (in terms of age, sex and level of education) of 300 members of the 
Dutch general public between the ages of 18 and 65 years. This age range was 
chosen since health changes in people within this age range are most likely 
to affect their income. An online market research company (Survey Sampling 
International; www.surveysampling.com) performed the data collection.
Background, ranking and visual analogue scale
All respondents were asked a number of background questions regarding age, 
sex, education, marital status and occupation. In addition, the number of chil-
dren, net personal income and net household income were included to help 
us understand the effect that dependents and personal income have upon the 
propensity to include income effects. Furthermore, to ensure representative-
ness, ethnic origins and religion were included to capture the diverse nature of 
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Dutch society. Following the questions regarding background characteristics, 
respondents were asked to describe their own health through the EQ-5D 
descriptive system. Respondents were next asked to rank four hypothetical 
EQ-5D health states (see The Health States section for details), in addition to 
the following states: (i) full health; (ii) dead; and (iii) ‘your own health today’. 
They were then asked to place the same seven states on a standard EQ-5D VAS.
The time trade-off exercises
The TTO format used a 10-year time horizon. No iterative process was used. Respon-
dents were simply asked how many years living in full health was equivalent to 10 
years living in health state X. No visual aid was used. The main part of the survey 
consisted of a number of different TTO questions, as outlined in Appendix 5A.
Three versions of the questionnaire were used, with allocation of respondents 
being determined randomly. The versions differed only in terms of the levels of 
income loss (20%, 40% and 60%) used in the third TTO question, TTO3. Respon-
dents first valued the four hypothetical EQ-5D health states through the first TTO 
question, TTO1 (the states were the same as those the respondents encountered 
in the VAS and ranking exercises). They were then asked a follow-up question on 
whether they had considered income effects in these valuations. Depending on 
their answer, in the second TTO question, TTO2, respondents were given instruc-
tions to either include or exclude income effects. In TTO3, respondents were given 
information about the specific level of income loss they would incur in the health 
state; after they valued each state in TTO3, they were asked if they thought the 
given health state would reduce their income and, if so, by how much.
Two further TTO exercises were included, but analysis of these questions is 
not included in this chapter; the first of these two questions asked respondents 
to trade-off length of life to avoid an income loss with health remaining con-
stant at perfect health, while the second asked respondents to trade off length 
of life to achieve an income gain. Responses to these questions were only used, 
along with the other TTO responses, to inform the exclusion of ‘extreme non-
traders’ (see Background Characteristics and Non-Traders section). Including 
these questions, each respondent had a total of 14 TTO exercises to complete 
(four health states were valued for each of the three main TTO exercises, and 
one income level was valued for each of the two further questions). This may be 
considered a large amount but it is not uncommon (e.g. both studies inform-
ing the Dutch (115) and Japanese (120) EQ-5D value sets asked each respondent to 
value 17 different states). Given a sample size of 300, we had 300 responses per 
state for TTO1 and TTO2, and 100 responses per questionnaire version.
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The standard TTO question (TTO1) provided a baseline against which the 
later TTO questions could be compared. Directly following TTO1, respondents 
were asked a number of follow-up questions: they were asked if they had 
considered the effect the states would have on their ability to work, on their 
income, on their friends and relatives, and on their leisure time. The first null 
hypothesis was that the majority of respondents, when there is no mention 
of income, will not take income considerations into account; the second null 
hypothesis was that the valuations of those who do and do not spontaneously 
include income effects will not differ.
TTO2 was an ex post inclusion/exclusion question. Those respondents who 
stated they had not spontaneously included income effects in TTO1 were asked 
to repeat the exercise, this time including these effects (‘ex post inclusion’). 
Those respondents who stated they had spontaneously included income 
effects in TTO1 were asked to repeat the exercise, this time excluding these 
effects (‘ex post exclusion’). The ex post inclusion approach was used by Sendi 
and Brouwer (64), while Krol et al. (65,66) used the ex post exclusion approach; 
therefore, we were able to compare our results with these studies and further 
test the effect of explicit instructions. The third null hypothesis was that valua-
tions will not change at the aggregate level following explicit instructions.
TTO3 specified the level of income losses that would be associated with the 
given health state. Meltzer et al. (60) also provided respondents with specific 
information, but they asked respondents to value blindness and back pain, so 
our results were not directly comparable with theirs. The fourth null hypoth-
esis was that the valuations of the four health states in TTO3 will not differ 
depending on the level of income loss they are paired with.
The health states
Four EQ-5D health states were valued as follows: (i) 11112; (ii) 22211; (iii) 11222; 
and (iv) 22322 (see Appendix 5B for a description of the four states). The health 
states were presented in this order, from best to worst, to all respondents in 
the TTO exercises. In the VAS exercise, the ordering was randomized. We chose 
these particular health states in order to have variation in the severity of the 
health states, as well as in levels of impairment of the different domains. This 
may be particularly important for the ‘usual activities’ dimension (middle 
dimension) since it is perhaps most closely related to the ability to work.
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Analysis
In order to convert data to utility scores, the number of years living in full 
health that a respondent gave as being equivalent to 10 years living in health 
state X was divided by ten. Therefore, if 6 years living in full health was deemed 
equivalent to 10 years living in health state X, then this response was coded as 
0.6 (6/10). No protocol was included for states worse than dead, as we felt this 
would be too complicated for a self-complete questionnaire. A zero discount 
rate was assumed for this 10-year period, which is common, although results in 
a downward bias in values. (121) The smallest unit of trade was 1 month.
Some respondents (extreme non-traders) were unwilling to trade any time in 
any of the 14 TTO exercises. Chi-square tests were used to compare background 
characteristics between extreme non- traders and the rest of the sample. TTO1 
valuations of respondents who did and did not spontaneously include income 
effects were compared through unpaired t-tests. Valuations before and after 
instructions were compared through paired t-tests.
Ordinary least squares (OLS) and random effects (RE) generalized least 
squares (GLS) regressions were used to show the effect of background charac-
teristics on TTO1 and TTO3 valuations. A probit regression was used to show 
the effect of background characteristics on the propensity to spontaneously 
include income effects in TTO1. Data analysis was performed using Stata sta-
tistical software, Version 9.
5.3 Results
Background characteristics and non-traders
Data were available from 321 members of the Dutch general public who par-
ticipated in the online survey. Preliminary data examination showed that 25% 
of respondents were unwilling to trade any time in any of the 14 TTO exercises. 
Table 5.1 shows the background characteristics, first for the entire sample and 
then for those who traded in at least one of the TTOs and for those who did not 
trade any time in any of the 14 TTOs (i.e. extreme non-traders). The full sample 
had slightly more males than females. Forty-two percent of the sample were 
not employed and these respondents are perhaps less likely to have considered 
income effects. More than half of the sample had children, and these respon-
dents are more likely to have considered income effects as more people are 
dependent upon that income. Just under half of the sample were married and 
the mean VAS score for own health was 0.76.
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Table 5.1 Background characteristics by traders and non-traders a
Variable All Traders Extreme 
non-traders
Chi-square test (P-values), 
traders vs. non-traders
N 321 241 80
Sex
 male 51.0 52.0 54.0 0.350
 female 49.0 48.0 46.0
Age (y)
 average (SD) 44.0 
(13.1)
43.2 
(13.2)
46.6 (12.4)
 18–35 29.0 32.0 21.0 0.148
 36–50 32.0 31.0 33.0
 51–65 39.0 37.0 46.0
Educated beyond min school-leaving age
 yes 67.0 66.0 70.0 0.507
 no 33.0 34.0 30.0
Educated to degree level
 yes 31.0 32.0 29.0 0.592
 no 69.0 68.0 71.0
Employment
 employed 52.5 53.5 50.0 0.874
 self-employed 5.5 5.0 7.5
 housewife/house husband 13.0 12.5 15.0
 pensioner 6.5 7.0 5.0
 seeking work 3.0 3.0 2.5
 unable to work 11.5 10.0 16.0
 student 8.0 9.0 4.0
Net personal monthly income (€)
 <1000 39.0 38.0 41.0 0.873
 1000–1499 22.0 21.5 24.0
 1500–1999 18.0 19.0 16.0
 >2000 21.0 21.5 18.0
Children
 yes 54.0 49.5 67.5 0.005
 no 46.0 50.5 32.5
Marital status
 married 46.5 42.5 59.0 0.118
 single/never married 21.0 22.5 16.0
 divorced 10.0 12.0 4.0
 widowed 2.0 2.0 1.0
 living together 17.5 18.0 17.5
 other 3.0 3.0 2.5
Mean self-reported health on the EQ-5D 
VAS b
0.76 0.75 0.80 0.073
Spontaneously included income in TTO1
 yes 49.0 42.5 70.0 <0.001
 no 51.0 57.5 30.0
a All values are presented as % unless otherwise indicated, b The sample sizes for this variable were 
as follows: all, n = 280; traders, n = 213; non-traders, n = 67. min = minimum; TTO1 = first time trade-off 
question; VAS = visual analogue scale.
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Two variables were highly significantly correlated with whether or not 
respondents were prepared to trade any time in any of the TTO exercises. 
Extreme non-traders were more likely to be parents than non-parents. Extreme 
non-traders were also more likely than traders to spontaneously consider 
income effects. Forty-nine percent of the whole sample spontaneously con-
sidered income effects, compared with 70% of the extreme non-traders alone. 
Self-reported health on the VAS was weakly correlated with whether or not 
respondents traded, with non-traders being in better health than traders.
The presence of more parents among the extreme non-traders does suggest 
that these may be meaningful preferences rather than strategic responses. 
However, the aim of our study was to compare changes in valuations depend-
ing upon income effects, not to generate health state valuations comparable 
with existing value sets. Responses of non-traders did not help us achieve this 
aim; instead, they may have diluted the more meaningful responses of trad-
ers. We chose to exclude these extreme non-traders from our analysis, which 
reduced the sample size from 321 to 241. Furthermore, 41 respondents gave 
negative VAS valuations of own health (13 of whom were extreme non-traders). 
It seems unlikely that someone in a state of health worse than dead would be 
able to complete an online questionnaire. Examination of these responses sug-
gested that they were not meaningful and were predominantly caused by very 
high valuations of dead as a given health state. Comparison with their EQ-5D 
valuations showed that these respondents were generally in good health. These 
respondents were excluded from analysis involving VAS of own health (reduc-
ing the sample size to 213), but were included in all other analyses.
Results of the chi-square tests showed that the background characteristics 
did not differ significantly across the three versions of the questionnaire. 
Only employment was weakly significantly different across the versions, with 
a smaller proportion of respondents in the 40% income-loss version being in 
employment than in the other two versions. Further subgroup analysis was 
performed to study the propensity to spontaneously include income effects 
by background characteristics. Respondents who had been educated beyond 
the minimum school-leaving age (significant at 10%) and who had a degree 
(significant at 5%) were less likely to spontaneously include income effects.
Spontaneous inclusion/exclusion
Table 5.2 shows the results for the standard TTO1 (as used in the MVH study) 
and for TTO2 (ex post inclusion/exclusion question), first for the main sample 
(n = 241) and then by response to the follow-up question of whether or not 
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respondents spontaneously included income effects. Two-sided t-tests directly 
compared the mean results of those who did and did not spontaneously include 
income effects. The first observation was that respondents consistently valued 
state 22211 higher than state 11222, which suggests they considered pain and 
depression to be worse than problems with mobility and self-care. Values for 
spontaneous inclusion were lower than those for spontaneous exclusion [(1) 
vs. (2) in table 5.2] for only one of the four states. The t-tests suggested that the 
differences in valuations were only weakly significant for the most severe state 
(22322) and, in this case, spontaneous inclusion gave a higher result, contrary 
to expectations.
Ex post instructions
When those who spontaneously included income effects were asked to exclude 
these effects [(1) vs. (3) in table 5.2], the valuations of all four health states 
went up at the aggregate level. These changes were only significant for the 
first two states, but the statistical significance was weak and the magnitude 
of the change was small. When those who did not spontaneously include in-
come effects were instructed to include these effects [(2) vs. (4) in table 5.2], 
the valuations of all four health states went down at the aggregate level. These 
Table 5.2 Time trade-off (TTO) results from the first and second TTO questions (TTO1 and TTO2) both 
including and excluding income effects
Question and subgroup Health state [mean (SD) median]
11112 22211 11222 22322
TTO1 (MVH based)
All (n = 241) 0.92 (0.18) 1.00 0.86 (0.21) 0.97 0.82 (0.22) 0.90 0.68 (0.28) 0.73
(1) Spontaneously included income 
effects (n = 102)
0.93 (0.16) 1.00 0.85 (0.22) 0.95 0.84 (0.21) 0.90 0.72 (0.26) 0.80
(2) Spontaneously excluded income 
effects (n = 139)
0.91 (0.19) 1.00 0.86 (0.21) 0.98 0.81 (0.23) 0.90 0.65 (0.29) 0.70
TTO2 (ex post instruction)
All (n = 241) 0.92 (0.17) 1.00 0.85 (0.21) 0.91 0.81 (0.22) 0.90 0.67 (0.28) 0.70
(3) Explicitly instructed to exclude 
income effects (n = 102)
0.95 (0.12) 1.00 0.89 (0.17) 0.94 0.85 (0.17) 0.90 0.73 (0.25) 0.80
(4) Explicitly instructed to include 
income effects (n = 139)
0.90 (0.20) 1.00 0.83 (0.23) 0.90 0.78 (0.24) 0.87 0.63 (0.29) 0.66
T-test P-values
Including vs. excluding a (1 vs. 2) 0.270 0.698 0.289 0.051
Ex post exclusion instruction b (1 vs. 3) 0.056 0.029 0.598 0.618
Ex post inclusion instruction b (2 vs. 4) 0.242 0.004 0.037 0.340
a Unpaired t-tests, b Paired t-tests.
MVH = Measurement and Valuation of Health.
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changes were statistically significant for states 11222 and 22211, but again the 
magnitude of the change was limited.
Table 5.3 shows the number of respondents who increased and decreased 
their valuations for each of the four health states in TTO2, following explicit 
instructions to either include or exclude income effects. Among the group who 
were in structed to exclude income effects, in three of the four states more 
respondents increased their valuations than decreased them. Mean increases 
were larger than mean reductions for all four states, resulting in positive overall 
mean changes in valuations. More respondents changed their valuations as the 
health state became more severe (e.g. state 11222 elicited more changes than 
22211). We expected the valuations made by the group instructed to include 
income effects to be revised downwards. More respondents revised their valu-
ations downwards for all four health states, but a relatively large number of re-
spondents revised their valuations upwards. Mean reductions were larger than 
mean increases for three of the four health states, but mean overall changes 
were negative for all four states. More respondents changed their valuations as 
the health state became more severe and, once again, state 11222 elicited more 
changes than state 22211.
Background characteristics were compared against whether or not respon-
dents increased, decreased or did not change their valuation of state 22322, 
Table 5.3 Number of respondents who changed their valuations following explicit instructions to 
either include or exclude income effects
Variable Health state
11112 22211 11222 22322
Spontaneously included income effects (instructed to exclude in TTO2) [n = 102]
No. who increased 
valuation
17 27 28 31
Mean increase 0.172 0.206 0.169 0.163
No. who reduced valuation 12 22 31 29
Mean reduction −0.061 −0.094 −0.126 −0.147
Mean change [mean (SD) 
median] a
0.076 (0.20) 0.025 0.071 (0.01) 0.221 0.014 (0.21) −0.008 0.013 (0.20) 0.025
Spontaneously excluded income effects (instructed to include in TTO2) [n = 139]
No. who increased 
valuation
25 25 30 35
Mean increase 0.118 0.114 0.161 0.199
No. who reduced valuation 29 44 48 55
Mean reduction −0.160 −0.188 −0.195 −0.169
Mean change [mean (SD) 
median] a
−0.031 (0.25) 0.196 −0.079 (0.10) 0.216 −0.058 (0.24) −0.075 −0.026 (0.26) −0.05
a Excluding those who did not change their valuation.
TTO2 = second time trade-off question.
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following explicit instructions both to include and to exclude income effects. 
The only significant (5%) characteristic was age for those instructed to include 
income effects. Of those who reduced their valuations, 49.1% were aged 18–35 
years, compared with 37.1% for those who increased their valuations and 
20.4% for those who did not change their valuations. Also, more people in the 
oldest age category (51–65 years) counter-intuitively increased their valuations 
following instructions to include income effects.
Regression analysis
Table 5.4 shows the results of multivariate regression analysis. The four OLS 
columns show results from OLS models in which the dependent variables 
are the valuations of the four health states through the standard TTO1. The 
explanatory variables are background characteristics, whether or not respon-
dents spontaneously included income effects, whether or not they thought the 
given health state would reduce their income, and whether or not they thought 
about their family and friends when answering the questions. An interaction 
term indicating whether respondents had children and thought about their 
family was also included. The results suggest that having children significantly 
increased valuations for three of the four states; that is, having children re-
sulted in fewer life years sacrificed in order to regain full health. Being married 
significantly reduced valuations for the most severe health state. Spontaneous 
inclusion of income led to significantly higher valuations for the most severe 
state only. Uncertainty about income insurance also led to significantly higher 
valuations for the most severe state. The only variable that was significant for 
all four states was whether respondents thought the given health state would 
reduce their income. Respondents who thought the state would reduce their 
income gave significantly lower valuations.
The RE GLS column of table 5.4 shows the results of a pooled (long dataset) 
RE GLS regression that includes valuations of all four health states. There were 
a number of significant variables in this model, suggesting that (i) older people 
give slightly higher valuations; (ii) married people give lower valuations; (iii) 
parents give higher valuations; and (iv) people who think the state will reduce 
their income give lower valuations. Three dummy variables were included to 
show the effect of health state severity on valuations. As expected, states 22211, 
11222 and 22322 all elicited significantly lower valuations when compared 
with state 11112. The sizes of the coefficients were consistent with the raw data 
presented in table 5.2 (i.e. state 11222 elicited lower valuations than 22211, and 
22322 elicited the lowest valuations).
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The final column of table 5.4 shows the results of a probit model in which the 
dependent variable was whether or not respondents spontaneously included 
income effects. Those with income insurance were more likely to spontane-
ously include income effects, as were those who thought about their family. 
For the four health states 11112, 22211, 11222 and 22322, the percentage of 
respondents who thought their income would fall was 13%, 42%, 39% and 54%, 
respectively. It is interesting to note that, although state 11222 was valued lower 
than state 22211, more respondents thought 22211 would affect their income. 
For all health states except 11112 (the mildest state), age had a significant 
negative impact on the likelihood of thinking the states would reduce income. 
Again, for all but the mildest state, being in employment highly significantly 
increased the likelihood of thinking a state would reduce income. This is un-
surprising, given that the incomes of those not in work would not be affected if 
ill health hindered their ability to work. Having income insurance significantly 
reduced the likelihood of thinking two of the four states would reduce income.
An explicit level of income loss
Table 5.5 shows the valuations of the four health states combined with the 
three different levels of income loss (20%, 40% and 60%) that were given to 
respondents in TTO3 depending on which version of the questionnaire they 
received. The valuations of the four health states in all three versions of the 
questionnaire were in order from best to worst (the same order as in TTO1): 
11112, 22211, 11222 and 22322. This holds in all but one case: for 60% income 
loss, states 11222 and 22211 had the same mean values. A key finding was that 
all states were valued lower as the amount of income loss increased. These dif-
ferences were significant once (for state 11112) when 20% loss was compared 
with 40% loss, once (for state 22211) when 40% loss was compared with 60% 
loss, and for three out of the four states (for all states except 22322) when 20% 
loss was compared with 60% loss. Comparison with TTO1 valuations showed 
that all TTO3 valuations were lower. These differences were significant in all 
but two cases (20% loss for states 22211 and 22322).
Table 5.6 outlines results, by questionnaire version, from RE GLS regressions 
showing the effect of background characteristics on TTO3 valuations. For 
all three versions of the questionnaire, thinking a given health state reduces 
income led to significantly lower valuations. For 20% and 40% income loss, 
if a respondent had a partner with an income over 999 euros per month, 
they were likely to give a higher TTO valuation. For 20% income loss, having 
spontaneously included income in TTO1 led to higher valuations in TTO3; 
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having children also led to higher valuations for 20% income loss. The health 
state dummies showed that states 11222 and 22322 elicited significantly lower 
valuations than state 11112 for all three income-loss levels. Health state 22211 
elicited significantly lower valuations than state 11112 only for the largest 
income-loss level (60%).
5.4 Discussion
The results from this study can help to shed light on a number of questions 
regarding what people consider in TTO valuations.
First, do people consider income losses when completing a standard MVH 
study TTO exercise? Our results show that, for the whole sample, 49% of 
Table 5.6 Random effects (RE) generalized least squares (GLS) regressions showing the effect of 
background characteristics on valuations from the third time trade-off (TTO) question (TTO3) by 
questionnaire version a
Variable RE GLS (dependent variable = TTO3 valuations)
20% income loss (n 
= 276) R2 = 0.332
40% income loss (n 
= 276) R2 = 0.198
60% income loss (n 
= 300) R2 = 0.216
Intercept 0.651*** 0.396* 0.670***
Sex: male = 1, female = 0 −0.048 0.070 0.046
Age 0.000 0.003 0.001
Married = 1, other = 0 −0.018 −0.054 0.020
Educated beyond min school-leaving age 0.000 −0.119 −0.030
Have a degree 0.008 0.090 0.009
Working = 1, not working = 0 0.096 0.030 0.091
Have children 0.214** −0.024 0.119
Thought about family b 0.044 −0.003 0.076
Have children, thought about family b −0.151 0.017 −0.178
VAS own health −0.080 0.167 −0.088
Income over €999 per month 0.039 −0.013 −0.076
Partner’s income over €999 per month 0.125* 0.244* 0.050
Included income effects in TTO1 0.093* −0.078 0.077
Think given state will reduce income −0.107*** −0.084*** −0.110***
Income insurance: no/don’t know = 0, 
yes = 1
−0.010 0.032 0.055
Income insurance: no/yes = 0, don’t know 
= 1
0.068 0.024 −0.129
State 22211 vs. state 11112 −0.041 −0.024 −0.049**
State 11222 vs. state 11112 −0.089*** −0.066*** −0.048**
State 22322 vs. state 11112 −0.170*** −0.165*** −0.143***
a Values presented are coefficients. b Thought about their family and friends when answering the 
questions. min = minimum, TTO1 = first time trade-off question,  VAS = visual analogue scale, .
 P ≤ 0.1, ** p ≤ 0.05, *** P ≤ 0.01.
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respondents claimed to have spontaneously included income effects. This is 
lower than one of the two studies using TTO valuation of EQ-5D health states 
(66), which produced a value of 64%; however, it is higher than the other study 
(63), which found that only 6% of respondents spontaneously included income 
effects. It is possible that respondents might have considered these effects for 
some states but not others. However, we could only ask respondents whether 
they had taken income effects into account after valuing all four health states, 
in order to avoid contaminating the exercise.
Second, does spontaneous inclusion of income effects affect valuations? Our 
findings support the findings of three existing studies valuing EQ-5D states 
(65-67) that spontaneous inclusion of income effects does not significantly affect 
health state valuations at the aggregate level. We had expected values for spon-
taneous inclusion to be lower than those for spontaneous exclusion. However, 
this was only the case for one of the four states, and in this case the t-test was 
not significant. Comparisons in table 5.2 show only weakly significant differ-
ences in valuations in the case of state 22322, and in this case the value for 
spontaneous exclusion was lower. Regression analysis in table 5.4 confirmed 
this finding. This suggests that previous cost-effectiveness studies using either 
the human capital or the friction cost method to value productivity costs in the 
numerator of the cost-effectiveness ratio have not double counted these costs. 
Similarly, from the current NICE perspective, the results suggest that economic 
evaluations explicitly not including productivity costs have not included these 
costs implicitly through the health state valuation exercise either.
Third, does explicit instruction on the inclusion of income lead to statisti-
cally significant differences in valuations? The results contradict the findings 
of one study by Krol et al., (66) but support the findings of another study by Krol 
et al. (65) by finding that explicit instruction led to statistically significant differ-
ences in valuations in some cases. Significant differences were found for two 
states each when comparing spontaneous exclusion with explicit inclusion, 
and when comparing spontaneous inclusion with explicit exclusion. However, 
table 5.3 shows that many respondents did not change their valuations, and 
even among those who did, many changed them in a counter-intuitive fashion. 
Following explicit instructions to exclude income effects, for one of the four 
health states, more respondents decreased their valuations than increased 
them. This suggests that explicit instructions may not always have the ‘desired’ 
effect at the individual level.
In the case of explicitly stating a specific level of income loss, table 5.5 shows 
that this led to significant differences when compared with TTO1 for 10 of 12 
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cases. A comparison among the different income-loss levels shows there were 
generally only significant differences in valuations if the differences in income-
loss levels were large (e.g. 20% vs. 60%).
Study limitations
Some weaknesses of this study need to be noted. The large number of extreme 
non-traders is not ideal. For some respondents this may have been a genuine 
representation of preferences but we suspect that many of these respondents 
strategically chose not to trade. Respondents were selected from a database 
of individuals who had signed up to complete online surveys of this nature. 
Therefore, they may have deduced that the quickest way to complete the 
exercise was by choosing not to trade. The sooner respondents completed 
the exercise, the sooner they were awarded a given amount of money to be 
donated to a charity of their choice and the chance to win a prize themselves. 
Van Nooten et al. (122) also found numerous respondents opted not to trade any 
time in TTO exercises in their online questionnaire.
The use of an online self-complete survey may not be appropriate for a large 
number of different TTOs, as suggested by the number of non-traders in this 
study. Ideally, this study would be replicated using an interview method of 
administration (as used to generate commonly used value sets), which would 
allow continual guidance and explanation and would also enable qualitative 
feedback from respondents to be gathered, which may enable researchers to 
further understand respondents’ thought processes. An interview-based study 
would also allow an iterative TTO procedure with a visual aid to be used, which 
may improve the accuracy of valuations.
Our results show that employed people were more likely to think a given 
health state would reduce income. Therefore, since only 58% of our respon-
dents were employed, we cannot rule out the possibility that spontaneous 
inclusion of income effects may have caused significant differences in valua-
tions if our sample had contained a greater number of employed persons. This 
finding also casts some doubts as to the generalizability of the results of some 
previous studies using, for instance, student samples (61,63) or samples consist-
ing of employed individuals only. (64) The high level of unemployment may have 
been caused by the sample selection method. An existing Internet-based panel 
of respondents was used, and this panel may attract people who have relatively 
more time to complete surveys than the employed.
This study may be slightly underpowered. Assuming a standard deviation in 
TTO valuations of 0.16 (the lowest standard deviation generated by TTO1) and 
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an alpha of 0.05, we can detect a difference of 0.1 with power 0.998. However, 
assuming a standard deviation of 0.29 (the highest standard deviation in table 
5.2), we can only detect a difference of 0.1 with power 0.753. This is just below 
conventional thresholds for power. Future studies need to be appropriately 
powered as well. This may be difficult if the interview method of administra-
tion is used, due to the time-intensive and costly nature of this approach.
This study did not have a protocol for states worse than dead. We felt that 
since respondents completed the tasks independently and without guidance, 
it may become too complicated and time-consuming to include a protocol for 
states worse than dead. Given that the worst health state (22322) has a value 
on the Dutch tariff of 0.092 (115), we were concerned that a significant propor-
tion of respondents might have valued this state as worse than dead. In fact, in 
TTO3 with the highest income-loss level of 60% (which should elicit the lowest 
values), only seven, four, five and seven responses (out of 83) were zero for the 
four health states (11112, 22211, 11222 and 22322, respectively). However, if 
this study were to be repeated, it may be worth including a protocol for states 
worse than dead.
One potential problem was that we paired all health states with all levels of 
income loss in TTO3, and some respondents might have considered it unreal-
istic for state 11112 to cause a 60% loss in income. Excluding the extreme non-
traders, a total of 30 of 83 respondents did not trade any time in this exercise 
(compared with 13 of 83 when state 22322 was paired with a 60% income loss).
Results from this study cannot be generalized to other countries. The social 
security system in the Netherlands may be more generous than in some other 
countries, which will obviously influence the effect a given health state might 
have on income. In order to inform the appropriate method of economic 
evaluation within a specific country, work of this nature needs to be carried 
out in that jurisdiction.
5.5 Conclusions
It appears that income losses are not consistently included in health state valu-
ations and, when they are included, they have a negligible impact on results. 
Within the debate on whether to include productivity costs in the numerator 
or the denominator of a cost-effectiveness analysis, one should consider that 
even if income losses are included in health state valuation exercises they may 
not be an accurate proxy for productivity costs. For example, income insur-
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ance may reduce the loss to the individual in the event of illness, but it does 
not reduce the loss to society. Explicit instruction may potentially be able to 
change valuations, but whether these amended valuations accurately reflect 
productivity costs is quite dubious in light of theoretical concerns and also 
given the results presented here. This chapter therefore offers further evidence 
to challenge the controversial recommendations of the Washington Panel. We 
argue that, for economic evaluators wishing to adopt the societal perspective 
in their evaluation, inclusion of productivity costs in the numerator of the cost-
effectiveness ratio may represent the most suitable option.
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Appendices 
5 A The TTO exercises
TTO Version
A B C
1 Standard MVH TTO 
question
“You can live for 10 years in health state X or a 
shorter period of time in full health.” 
Follow Up: “Did you consider the effect these 
states might have on your income?” 
4 states ** 4 states 4 states
2 Repeat of TTO1 with 
instruction to include 
or exclude income 
effects*
“You can live for 10 years in health state X or 
a shorter period of time in full health. Please 
include/exclude any effect the state might have 
on your income.” 
4 states 4 states 4 states
3 Respondents 
explicitly told how 
much income they 
will lose in the given 
health state
“You can live for 10 years in health state X or 
you can live for a shorter period of time in full 
health. In state X your ability to work will be 
impaired and your current income will fall by 
20% [or 40% or 60%].” 
4 states, 20% 
income loss
4 states, 40% 
income loss
4 states, 
60% 
incomes 
loss
* Determined by follow-up to TTO 1
** The four EQ-5D states valued in all versions of TTO1, TTO2 and TTO3 were: 11112, 22211, 11222, 
22322
5 B Descriptions of the four EQ-5D health states used in the study
11112 
I have no problems in walking about 
I have no problems with self-care 
I have no problems performing my usual activities 
I have no pain or discomfort 
I am moderately anxious or depressed 
22211 
I have some problems with walking about 
I have some problems with self-care 
I have some problems with performing my usual activities 
I have no pain or discomfort 
I am not anxious or depressed 
11222 
I have no problems in walking about 
I have no problems with self-care 
I have some problems with performing my usual activities 
I have moderate pain or discomfort 
I am moderately anxious or depressed 
22322 
I have some problems with walking about 
I have some problems with self-care 
I am unable to perform my usual activities 
I have moderate pain or discomfort 
I am moderately anxious or depressed
6. 
Do productivity costs matter? 
The impact of including productivity costs 
on the incremental costs of interventions 
targeted at depressive disorders
based on: Krol M, Papenburg J, Koopmanschap M, Brouwer W. 
Do productivity costs matter? The impact of including productivity costs on the 
incremental costs of interventions targeted at depressive disorders. 
Pharmacoeconomics 2011 Jul 1;29(7):601-619.
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Summary
Background: When guidelines for health economic evaluations prescribe that a 
societal perspective should be adopted, productivity costs should be included. 
However, previous research suggests that, in practice, productivity costs are often 
neglected. This may considerably bias the results of cost-effectiveness studies, 
particularly those regarding treatments targeted at diseases with a high incidence 
rate in the working population, such as depressive disorders. Objectives: This study 
aimed to, first, investigate whether economic evaluations of treatments for depres-
sive disorders include productivity costs and, if so, how. Second, to investigate how 
the inclusion or exclusion of productivity costs affects incremental costs. Methods: 
A systematic literature review was performed. Included articles were reviewed to 
determine (i) whether productivity costs had been included and (ii) whether the 
studies adhered to national health economic guidelines about the inclusion or 
exclusion of these costs. For those studies that did include productivity costs, we 
calculated what proportion of total costs were productivity costs. Subsequently, 
the incremental costs, excluding productivity costs, were calculated and compared 
with the incremental costs presented in the original article, to analyze the impact 
of productivity costs on final results. Regression analyses were used to investigate 
the relationship between the level of productivity costs and the type of depressive 
disorder, the type of treatment and study characteristics such as time horizon used 
and productivity cost valuation method. Results: A total of 81 unique economic 
evaluations of treatments for adults with depressive disorders were identified, 24 
of which included productivity costs in the numerator and one in the denomina-
tor. Approximately 69% of the economic evaluations ignored productivity costs. 
Three-quarters of the studies complied with national guidelines regarding the 
inclusion of productivity costs. For the studies that included productivity costs, 
these costs reflected an average of 60% of total costs per treatment arm. The inclu-
sion or exclusion of productivity costs substantially affected incremental costs in a 
number of studies. Regression analyses showed that the level of productivity costs 
was significantly associated with study characteristics such as average age, the 
methods of data collection regarding work time lost, the values attached to lost 
work time, the type of depressive disorder, the type of treatment provided and the 
level of direct costs. Conclusions: Studies that do not include productivity costs 
may, in many cases, poorly reflect full societal costs (or savings) of an intervention. 
Furthermore, when comparing total costs reported in studies that include produc-
tivity costs, it should be noted that study characteristics such as the methods used 
to assess productivity costs may affect their level. 
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6.1 Introduction
Scarce resources in the health care sector have caused economic evaluations 
to become increasingly important in reimbursement decisions. These evalua-
tions inform decision makers on the amount of health an intervention gener-
ates and at what costs. In many countries, including the Netherlands, Belgium 
and France, it is mandatory (at least in some instances) to present information 
on the cost-effectiveness of treatments to be considered for reimbursement. 
(123) Common types of economic evaluations used to help define basic ben-
efit packages are cost-effectiveness analysis (where benefits are expressed in 
natural or clinically relevant effect measures) and cost-utility analysis (where 
effects are expressed as QALYs). In both types, the incremental costs and effects 
or QALYs of an intervention compared with some relevant alternative(s) are 
calculated.
Although several important handbooks on the methodology of cost-effective-
ness studies have been written to give guidance in conducting these studies, (2,7) 
some methodological issues remain unsolved. One important area of debate is 
the inclusion of productivity costs. These costs can be seen as ‘‘Costs associated 
with production loss and replacement costs due to illness, disability and death of 
productive persons, both paid and unpaid.’’ (8) The inclusion of productivity costs 
remains controversial, as does the question of how to best include them. (11)
Although little research has been conducted on this topic, and the percentage 
of studies that actually include productivity costs remains largely unknown, it 
has been suggested that less than 10% of economic evaluations include them. 
(10) Given that these costs may sometimes account for a large proportion of total 
costs (sometimes even more than 50% (11)), their exclusion could significantly 
misrepresent total societal costs. The extent to which this is the case is unclear, 
yet misrepresenting societal costs may ultimately lead to suboptimal decisions.
This review investigated the impact of productivity costs on incremental 
costs, focusing on economic evaluations of treatments for depression. It is 
expected that productivity costs are particularly relevant in this disease. The 
aims of this review were to (i) observe how often economic evaluations of 
treatments for depression actually include productivity costs (investigated via 
a systematic literature review); (ii) assess the impact of productivity costs on 
incremental costs9 (assessed through the selection and investigation of studies 
9  The effect of in- or exclusion of productivity costs on incremental costs obviously translates in an 
effect on incremental cost-effectiveness ratios. The precise influence depends on the incremental 
effects and the outcome measures used.
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that included productivity costs, highlighting the impact on final results); and 
(iii) to assess the extent to which disease, treatment and study characteristics 
(e.g. methods of valuing productivity loss) affect the level of per-patient pro-
ductivity costs.
6.2 Background
The debate on inclusion of productivity costs in economic evaluation revolves 
around two main questions: (i) whether productivity costs should be included 
in economic evaluations; and (ii) conditional on an affirmative answer to the 
first question, how these costs could best be included. There is no current 
consensus regarding these two questions.
Should productivity costs be included?
Debates regarding the first question have focused on two aspects: (i) the 
appropriate perspective to take in economic evaluations; and (ii) ethical 
concerns regarding the inclusion of productivity costs. It is clear that the inclu-
sion of productivity costs in economic evaluations may lead to the favoring of 
treatments targeted at the (paid and unpaid) working population, potentially 
at the expense of other groups such as the elderly. (13) On the other hand, ex-
cluding these costs implies that actual societal costs are ignored, which may 
lead to welfare-damaging decisions. (12,13,41,100) Inclusion of productivity costs 
immediately relates to the former issue, i.e. that of the appropriate perspec-
tive. While leading health economic text-books advocate adopting a broad 
(societal) perspective (2,7) (consistent with the welfare theoretical roots of eco-
nomic evaluations, e.g. Brouwer and Koopmanschap (104)), in practice, many 
economic evaluations deliberately take a narrower, most notably a health care, 
perspective. Indeed, this perspective is prescribed in many national health 
economic guidelines. Justification for this narrower perspective is commonly 
that economic evaluations need to aid health care decision makers in spending 
a fixed health care budget in line with the goal set for these decision makers 
(which may be something like maximizing or optimizing health). Therefore, 
costs and savings that fall outside the narrower scope relevant for this deci-
sion maker may be deemed irrelevant and ignored. Brouwer et al. (41) suggested 
an intermediate position, using a two-perspective approach as a standard in 
health economic guidelines. Differences in position in these matters have led 
to a large variety in the content of guidelines throughout Europe, decreasing 
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the transferability of research beyond national borders. To illustrate, of the 21 
European guidelines gathered on the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) website, (124) only nine (among them, 
guidelines for the Netherlands, Austria and Finland) stipulate a societal per-
spective. The Italian guidelines state that economic evaluations should take the 
societal and the health perspective. Five guidelines (i.e. the UK, Belgium and 
the Baltic states) prescribe the health care payer perspective and seven guide-
lines (including Denmark, Hungary and Switzerland) do not clearly specify the 
perspective to be adopted. Although very little research has been conducted 
on the extent to which productivity costs are actually included in economic 
evaluations, Stone et al. (10) found that they were presented in only 8% of the 228 
cost-utility analyses they examined. To some extent, this lack of inclusion may 
also reflect the lack of consensus on how productivity costs should be included 
in economic evaluations.
How can productivity costs be included?
Three valuation approaches
Consensus is lacking regarding the question of how productivity costs should 
be included. Three important approaches for valuing productivity costs can 
be distinguished. The first two, the human capital approach (HCA) and the 
friction cost approach (FCA), value productivity costs in monetary terms so 
that they may be included in the numerator of the cost-effectiveness ratio. 
Simplified, the HCA values ‘all working hours lost due to health problems and 
related treatments times the gross hourly wage’, (88) irrespective of the period 
of absence. The FCA is based on the idea that, in long-term absenteeism, an 
ill worker can be replaced by a previously unemployed individual, so that the 
initial production level will be restored after replacement. Therefore, with 
the FCA, productivity costs are only included for the duration of the ‘friction 
period’ (i.e. the time it takes to hire and train a new worker). (47,56,90) As a result, 
productivity costs calculated according to the HCA are usually higher than 
those calculated according to the FCA, especially when considering long-term 
absence. The third approach, the so-called Washington Panel approach (WPA), 
values productivity costs in terms of quality of life (QALYs), so that they can be 
included in the denominator of the cost-effectiveness ratio. (2) The Washington 
Panel assumed that, during the valuation process, respondents in health state 
valuations will already account for negative income effects due to ill health and 
therefore productivity costs will be an integral part of QALY weights attached 
to health states. Consequently, also valuing these costs on the cost side would 
116
 
result in double counting. All three approaches, especially the WPA, have gen-
erated criticism in the literature (for a review on the approaches and the theo-
retical debate see, for example, Tranmer et al. (11)). The theoretical differences of 
opinion are reflected in national (European) guidelines: 15 of 21 guidelines at 
least mention the measurement of productivity costs (five prescribe the HCA, 
two the FCA and eight do not give clear direction on the methodology to be 
used). (124)
The impact of including productivity costs at the cost or effect side
Over the last decade, the theoretical debate has moved on to a more empirical 
discussion. One important question resulting from the debate regarding the 
WPA was whether respondents in health state valuations do in fact (noticeably) 
include income losses in health state valuations. Several attempts have been 
made to investigate whether and how respondents take income effects into 
account. (31,61-66) It seems clear that respondents do not consistently include or 
exclude these effects. The percentage of respondents including productivity 
costs ranged from 6% (63) to 64% (66) across studies and, although the empirical 
evidence is inconclusive, it generally seems that the effects of (alleged) inclu-
sion of income losses in health state valuations do not (significantly) alter 
health state valuations. This suggests that health state valuations are rather 
insensitive to capturing income effects and that ‘inclusion’ of productivity 
costs at the effect side by simply stating that respondents will have considered 
income will not significantly affect outcomes. On the other hand, it is clear that 
including productivity costs on the cost side will have a noticeable impact on 
total costs and on the cost-effectiveness ratio. However, little is known about 
the exact impact on incremental costs and subsequently on final outcomes. 
Obviously, this will depend on many factors, such as treatment, disease and 
patient population. To our knowledge, only two studies have focused on 
quantifying the effect of including productivity costs on final outcomes of an 
economic evaluation. (9,42)
Koopmanschap and Rutten (9) investigated the impact of productivity costs 
on the cost-effectiveness outcomes of eight health care programs targeted at 
different diseases. Productivity costs were restricted to paid labor, and costs 
were calculated using the FCA (using a friction period of approximately 3 
months). The total incremental costs of the different programs changed with 
the inclusion of productivity costs: from a decrease of 18% to an increase of 
52%. One program moved from ‘positive costs’ to ‘savings’. Given the diversity 
in impact of the inclusion of productivity costs, Koopmanschap and Rutten 
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(9) concluded that, in general, a significant effort should be made to calculate 
productivity costs when (i) treatments produce health effects in the short run; 
(ii) there is a strong impact on ability to work in the short run; and (iii) a large 
proportion of the study population is in paid work when the health effects oc-
cur.
Lindholm et al. (42) investigated, by means of a case study of different inter-
ventions aimed at preventing cardiovascular diseases (CVD), the impact of 
taking either the health care or the societal perspective for reimbursement 
decisions with a given budget constraint. The cost-effectiveness of treatments 
for several target groups was calculated from each perspective. The outcomes 
were put in two QALY rank tables and, fictively, the health care budget for CVD 
prevention was spent, starting with treatments for the groups with the lowest 
cost-effectiveness ratio. Adopting either perspective, 10% of the target groups 
would not receive preventive care. When taking the health care perspective, 
this 10% not receiving CVD prevention were mainly middle-aged men, while, 
when taking the societal perspective, it was mainly elderly women. This high-
lights the distributional consequences of adopting different perspectives.
Productivity costs in economic evaluations of treatments for 
depressive disorders
Even though Koopmanschap and Rutten (9) and Lindholm et al. (42) make clear 
that the inclusion or exclusion of productivity costs will affect cost-effective-
ness outcomes and allocation of resources across groups, it is also clear that 
the importance of including productivity costs depends on the disease under 
study. For instance, treatments mainly targeting diseases affecting the elderly 
are not likely to generate much productivity savings or costs, at least not those 
related to paid work (on which we focus here), while interventions that have 
a strong effect on the productivity of the working population may produce 
productivity costs that reflect a large part of total costs.
The importance of including productivity costs in economic evaluations of 
treatments for depression was emphasized over 10 years ago, given the high 
incidence of depression among people of a working age. (125) In total, 5–12% 
of men and 10–25% of women have a major depressive episode during their 
lifetime. (126) In 2002, the 12-month prevalence of major depressive disorders 
was estimated as 6.6% in the US. According to the WHO, depression will be the 
highest ranking cause of burden of disease in the Western world by the year 
2020. According to Bostwick and Pankratz, (127) around 2–9% of patients with 
depressive disorders eventually commit suicide, compared with <0.5% of those 
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without affective disorders. The incidence of depression is highest in middle-
aged individuals, which may indicate that it strongly affects society’s produc-
tivity, especially in light of the recurrent nature of the disease. (128) Kessler et al. 
(129) found that employees with depression had 1.5–3.2 more short-term dis-
ability days per month than those without. In 2000, the total economic burden 
of depression in the US was estimated to be $US 51.5 billion, of which 62% 
was reflected by workplace costs. (130) Such figures highlight the need to further 
investigate the influence of productivity costs on outcomes of economic evalu-
ations regarding treatments for depressive disorders.
6.3 Methods
Literature review
A systematic review was performed to identify original economic evaluations 
of treatments for depression that included productivity costs, in order to 
investigate the impact of such costs on incremental costs. By recalculating in-
cremental costs after excluding productivity costs, the effect of including them 
in economic evaluations on outcomes is illustrated. The systematic review was 
performed using the Cochrane Library and PubMed databases. A publication 
date limit of January 1997 to May 2008 was chosen because standardization of 
cost-effectiveness studies became increasingly common from the late 1990s. 
Some publications, such as the influential US guidelines (2) and the textbook by 
Drummond et al. (7) made important contributions to this development.
The queries used for the database search were ‘depression’ AND ‘cost’ OR 
‘costs’ AND ‘effectiveness’. To identify relevant economic evaluations, the 
following inclusion and exclusion criteria were used. Only unique scientific 
articles in peer-reviewed journals using the English language were considered; 
articles needed to focus on the estimation of incremental cost-effectiveness 
of therapeutic interventions for depression; abstracts were excluded and ar-
ticles had to be available in the Netherlands or in the British Library. Although 
reviews were excluded, the references used in reviews were hand searched to 
identify any missing relevant economic evaluations. Only articles with at least 
a part of the patient population aged between 18 and 65 years were included, 
since productivity costs related to depressive disorders are most relevant in this 
age category. Cost items had to be reported separately in order to (re)calculate 
incremental costs including and excluding productivity costs. All searches 
were undertaken independently by two reviewers (M. Krol and J. Papenburg).
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Analysis
After the identification of relevant publications, the articles were scanned for 
the inclusion of productivity costs. We examined whether studies followed 
their national health economic guidelines (according to the study’s country 
of origin) regarding the inclusion of such costs. This was done to investigate 
whether guidelines can potentially explain their inclusion or exclusion. Next, 
of the articles that included productivity costs, the percentage of total cost re-
flected by these costs was calculated. The results are reported separately for the 
HCA and FCA. The incremental costs excluding productivity costs were then 
calculated and compared with those presented in the original article, in order 
to analyze the impact of productivity costs on incremental costs.
Finally, meta-regression analyses were used to investigate whether the 
level of (monthly) productivity costs could be explained by type of depres-
sive disorder, treatment and study characteristics (e.g. time horizon applied, 
methodology used to value productivity losses). For this purpose, a database 
was created of 27 of the 30 economic evaluations including productivity costs 
in the numerator. Three studies (131-133) were not included in the database due 
to a lack of information on the absolute amount of productivity costs. The 27 
remaining studies accounted for a total of 87 treatment arms useful for the 
statistical analyses. Data were extracted for these treatment arms on the per-
patient average monthly direct costs and productivity costs, methodology 
regarding measurement of lost work time, the valuation approach (i.e. FCA or 
HCA) and the values attached to lost work time. The database also included the 
study time horizon, nature of the depression, type of intervention, mean age of 
patients under study and percentage of females. For modelling studies, data on 
mean age and percentage of females were extracted from the original clinical 
studies where possible; however, this proved impossible for 30 treatment arms. 
In these cases, missing data were imputed using the respective mean values of 
the other treatment arms included in the database.
The study characteristics examined were the applied time horizon, total 
monthly direct costs per patient, sex distribution and average age of the 
patient population. Dummy variables were created to distinguish between 
productivity cost approach used (FCA or HCA), method of measurement of lost 
work time (patient questionnaires, literature estimates, estimates by medical 
professionals and other/not specified) and values attached to lost work time 
(national average wages, values based on GDP per capita, sickness insurance 
fund payments, patients’ gross wages, other/not specified). Moreover, dum-
mies were created for the type of depression of the study population (mild, 
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major or severe depression, dysthymic disorder or a mixed population) and 
the type of treatment (combination) provided (preventive treatment, psycho-
therapy, drugs, drugs and psychotherapy, drugs administered in a hospital 
setting). Univariate correlations were first used to explore the relationship 
between study characteristics and the dependent variable ‘average monthly 
productivity costs per patient’. The dummy variables were included in the 
univariate models as single dichotomous variables.
A multivariate model was then constructed by entering all variables in the 
model and stepwise eliminating non-significant variables (P > 0.5). Standard 
econometric tests were applied to the multivariate model to test for the Nor-
mality of the residuals (skewness, kurtosis, Kolmogorov-Smirnov). Further-
more, residual plots were used to investigate the appropriateness of the model. 
The Ramsey RESET test (134) was applied to test the model specification.
The statistical analyses were performed with use of SPSS® Statistical Soft-
ware Package 17.0 (Chicago, IL, USA).
6.4 Results
Systematic review of inclusion of productivity costs
The literature search identified 732 articles (PubMed: 507, Cochrane Library: 
225). As can be seen in figure 6.1, 169 were duplicates, four were published 
before 1997 and four were not in the English language. Of the remaining 555 
articles, 164 were reviews, 178 were not exclusively concerned with depressive 
disorders, 93 were not classified as economic evaluations, 26 studied adoles-
cents or elderly people, 6 articles were not available in the Netherlands or the 
British library and 7 were (congress) abstracts. This search finally identified 
81 economic evaluations of treatments for adults with depression. Of the 81 
articles, 25 (approximately 31%) included productivity costs, of which 24 in-
cluded these costs in the numerator (i.e. as costs) and one included them in the 
denominator (i.e. using the WPA, in effects). The references of the 164 reviews 
were checked in order to detect additional economic evaluations meeting the 
inclusion criteria and additionally including productivity cost. This procedure 
resulted in the inclusion of six additional economic evaluations with productiv-
ity costs included in the numerator of the cost-effectiveness ratio. As a result, a 
total of 87 studies were included in our study, of which 30 articles were suitable 
for the analysis of the impact of productivity costs on incremental costs (i.e. all 
identified studies except the one using the WPA).
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Productivity costs and health economic guidelines
For the 87 economic evaluations, we examined whether the inclusion or ex-
clusion of productivity costs was in line with the relevant national guidelines. 
As shown in table 6.1, 64 studies (74%) complied with the relevant guidelines. 
Productivity costs were excluded (or reported separately from the base case) 
in 46 of these studies, while the remaining 18 studies included productivity 
costs. Of the 18 studies including productivity costs in line with their national 
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guidelines, five used the HCA to calculate productivity costs (despite the na-
tional guidelines recommending the FCA). A total of 21 studies deviated from 
the national guidelines: 9 did not include productivity costs, although national 
guidelines prescribed a societal perspective. However, 12 evaluations included 
productivity costs, even though the national guidelines advocated a health 
care perspective. Two studies were conducted in countries without guidelines, 
or with guidelines in development.
Table 6.1 Country guidelines on perspective and productivity costs
Country Guidelines: perspective Guidelines: productivity 
costs approach
Studies with PC Studies 
without 
PC
FCA HCA WPA
Australia Health care (for base 
case) and societal 
Not specified 2 (135,136) 
Austria Societal HCA 3 (137-139) a 
Belgium Health care HCA 1 (140) a  
Brazil Societal or health care 
payer
HCA 1 (141)
Canada Health care (for reference 
case) 
FCA 1 (142) 1 (143)
Chile Unknown - 1 (144)
Czech Guidelines in 
development 
- 1 (145)
Denmark Societal Not specified 1 (146) a
France Societal Preferable FCA (research needed 
before FCA can be applied in France)
3 (147-149) a 3 (150-152)
Germany Societal FCA 1 (153)
Italy Health care payer and 
societal perspective
HCA 1 (154)
Norway Societal and health care 
payer
FCA or HCA 1 (155) a
Spain Societal Not specified 1 (156) 1 (157)
Sweden Societal HCA 2 (158) a, (131)
The Netherlands Societal FCA 5 (159) a, 
(160-163)
1 (164) a 1 (165)
United Kingdom Health care payer Exclude PC 8 (155,166-171) a, 
(172,173)
16 (174-189)
United States of 
America
Health care payer (base 
case)
Not specified 3 (132) a, (133,190) 1 (191) 27 (192) b, 
(193-218)
Total 6 24 1 56
 a These studies performed economic evaluations from both the health care payer and the societal 
perspectives, in line with the recommendation of Brouwer et.al. (104)
 b One USA article (192) included patients of 10 countries in the study-design. Although in some of the 
corresponding country guidelines a societal perspective is prescribed, in the study a health care 
perspective was taken (in line with the USA guidelines).
FCA = Friction cost approach HCA = Human capital approach WPA = Washington panel approach PC 
= productivity costs
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Productivity costs as proportion of total costs
In total, the costs and effects of 103 treatment arms were presented within the 
30 articles suitable for studying the impact of inclusion of productivity costs 
(background information of these studies is available in Appendix 6A). In three 
of these articles, (131-133) in which ten treatment arms were presented, it was not 
possible to extract the productivity costs per treatment arm due to a limited 
level of detail for the cost items. As can be seen in table 6.2, productivity costs 
reflected an average of 60% of total costs per treatment arm. In the 20 treatment 
arms in which productivity costs were calculated with the FCA, 56% of the total 
costs per arm consisted of productivity costs; productivity costs calculated 
using the HCA reflected 61% of the total costs. These figures were somewhat 
influenced by one study, (142) in which the HCA was used and productivity costs 
represented just 3% of total costs. How units of lost work time were valued 
in that study was not specified. Excluding this outlier increased the average 
percentage of productivity costs in total costs in the HCA group to 65%, and 
the percentage of the total group to 64%. The range of percentages in the HCA 
group then changed from 3–92% to 24–92%.
Diversity in productivity costs measurement
The level of productivity costs in individual studies depended not only on the 
valuation approach used (HCM or FCA), but also on how lost work time was 
measured and which values were attached per unit of time (e.g. average national 
income or patients’ gross income). The level of detail presented on productivity 
cost measurement and valuation differed across studies. To summarize: almost 
all studies (28 of 30 studies) only collected data on absenteeism related to paid 
work. One study also included productivity losses related to presenteeism, (132) 
while another study included absenteeism, presenteeism and unpaid labor. (162) 
Clearly, the focus in productivity cost valuation is still on absence from paid 
work. Ten studies (133,142,156,161-163,167-169,172) used questionnaires to collect data on 
absenteeism, ten (131,132,137,140,149,155,158,159,166,167) used literature estimates, three (146-
148) used estimates provided by medical professionals, one (161) used cost diaries, 
Table 6.2 Productivity costs as percentage of total costs
Productivity costs 
approach
Number of 
articles
Number of arms Average percentage 
PC of TC 
Range
Friction costs approach 6 20 56% 19 – 78 %
Human capital approach 24 a 73 61% 3 – 92 %
Total 30 93 60% 3 – 92 %
a In 3 articles (131-133) only incremental costs are presented, which makes it impossible to recalculate 
percentage PC of TC
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one (173) used data on doctors’ certificates for absenteeism and five (138,139,164,170,171) 
did not specify the methods used to collect data on lost work time. Regarding 
the valuation of time lost from work, 13 studies (138,139,158,160-162,164,168-170,173,190) ap-
plied average (age/sex dependent) wage and employment rates, five (147-149,159,166) 
used values based on GDP per capita, one (156) based the values on national 
minimum wages and four (137,142,146,167) used sick fund/insurance payments made 
to patients. Only two studies (133,172) specifically mentioned basing the values on 
patients’ wages and five (131,132,140,155,163) did not specify the source of the values 
used. 
The impact of productivity costs on incremental costs
The 30 economic evaluations that included productivity costs used more than 
ten different effectiveness outcomes (e.g. QALYs based on EQ-5D-scores, the 
Quality of Life in Depression Scale (QLDS), (219) incidence rates of depressive 
disorders, time without depression and the Beck depression inventory). (220) 
However, the majority used the increase in proportion of successfully treated 
patients as the main outcome measure. The indication of the severity of de-
pression and successful treatment can be based on instruments such as the 
Montgomery Asberg Depression Rating Scale (MADRS), (221) the Hamilton Rat-
ing Scale for Depression (HAM-D) (222) or the Hopkins Symptom Checklist 90 
(SCL-90). (223) In these three measures, lower scores indicate better functioning. 
Obviously, the use of different outcome measures hampers direct comparisons 
of studies as well as more general observations on the influence of productivity 
costs on incremental cost-effectiveness ratios (ICERs). Hence, we focus here on 
the influence on incremental costs.
The 30 economic evaluations (103 treatment arms) presented a total of 61 
incremental cost comparisons of treatment arms. In some studies, more than 
two therapeutic options were compared and, in seven of the studies, ICERs 
were calculated with multiple effects measures. ICERs were calculated for 74 
cases. In five cost-effectiveness comparisons, the incremental effectiveness 
was zero, implying that an ICER could not be calculated.
The differences in incremental costs including or excluding productivity 
costs are illustrated in figure 6.2. All costs were converted to euros, year 2007 
values. Incremental costs excluding productivity costs are expressed on the 
vertical axis and those including productivity costs are on the horizontal axis. 
The five comparisons of the study of Valenstein et al. (132) were excluded from 
this figure due to insufficient details presented on incremental costs to allow 
recalculations as required here. As can be seen by the points in the north-west 
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Table 6.3 Regression analyses
Monthly productivity costs per patient (N=87) Monthly productivity costs (n= 78), extreme 
values excluded
Univariate Multivariate Univariate Multivariate
Beta P-value Adjusted R² Beta P-value Beta P-value Adjusted R² Beta P-value
Age -0.094 0.388 -0.003 -0.154 0.018 -0.076 0.510 -0.007 -0.273 0.002
Direct costs p/m 0.728 0.000 0.525 0.501 0.000 0.670 0.000 0.441 0.344 0.000
Time horizon -0.176 0.103 0.020 -0.252 0.000 -0.107 0.352 -0.002
FCA (vs. HCA) -0.261 0.015 0.057 -0.290 0.010 0.072
Percentage 
females
-0.312 0.003 0.087 -0.036 0.755 -0.012
Major 
depression a
-0.157 0.146 0.013 -0.222 0.000 -0.026 0.820 -0.012 -0.238 0.002
Severe 
depression a
-0.106 0.327 0.000 -0.244 0.000 -0.118 0.304 0.001 -0.496 0.000
Dysthymic 
disorder a
-0.198 0.067 0.028 -0.291 0.010 0.072 -0.540 0.000
Mild depression a -0.012 0.992 -0.012 0.078 0.500 -0.007
Mixed 
population a
0.302 0.005 0.080 0.210 0.065 0.031
Prevention b -0.091 0.408 -0-004 -0.098 0.394 -0.003
Psychotherapy b -0.169 0.122 0.017 -0.146 0.201 0.009
Drug treatment b 0.193 0.073 0.026 0.084 0.467 -0.006
Drugs in 
hospital b 
-0.212 0.051 0.033 -0.294 0.009 0.075
Psych.
ther.+drugs b
0.118 0.282 0.002 0.348 0.002 0.110 0.228 0.001
Questionnaires c -0.265 0.013 0.059 -0.279 0.013 0.066 -0.322 0.001
Datacollection 
NS c
0.003 0.979 -0.012 0.162 0.012 0.217 0.056 0.035 0.293 0.000
Interview 
doctors c
0.676 0.000 0.451 0.444 0.000 Not applicable Not applicable
Literature c -0.139 0.200 0.008 0.119 0.299 0.001
Income patients d -0.148 0.171 0.010 -0.171 0.005 -0.182 0.111 0.020 -0.243 0.003
GDP d 0.253 0.018 0.053 0.105 0.050 -0.230 0.043 0.040 -0.248 0.000
Insurance 
payments d
-0.034 0.756 -0.011 -0.164 0.003 0.025 0.831 -0.013 0.306 0.000
Mean nat. 
income d
0.013 0.904 -0.012 0.376 0.001 0.130
Other values 
or NS d
-0.169 0.117 0.017 -0.162 0.157 0.013
Adjusted R² 0.822 0.784
Skewness 0.045 -0.022
Kurtosis 0.901 -0.303
Kolmogorov-
Smirnov
0.093 0.200
Ramsey RESET F = 23.005 0.000 F =2.287 0.087
 a Dummy variables for depression types, b Dummy variables for treatment modalities, c Dummy 
variables for data collection methods of lost working time, d Dummy variables for the values attached 
to lost working time
FCA = friction cost approach HCA = human capital approach NS = not specified GDP = gross 
domestic product
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quadrant, in some cases, including productivity costs caused the incremental 
costs to change from positive to negative, therefore turning the new treat-
ment into a cost-saving intervention. For other studies (those located in the 
south-east quadrant) the opposite was true; including productivity costs made 
an otherwise cost-saving intervention cost. Next to this relative impact, the 
absolute impact of productivity costs sometimes proved substantial, with oc-
casional differences between incremental costs with and without productivity 
costs of over 2000 euros (e.g. Kendrick et al. (168) and Antonuccio et al. (190)).
One might expect that ‘new interventions’ (if indeed more effective than the 
comparator) would result in reduced productivity costs (i.e. relative savings). 
However, incremental costs changed in both directions after the inclusion of 
productivity costs: decreasing in 43 cases, increasing in 16 cases and remain-
ing equal in two cases. It is possible that some new treatments, while perhaps 
being more effective than the comparator, could also be more intensive or time 
consuming (e.g. certain types of psychotherapy compared with drug therapy), 
thus causing the treatment itself to result in increased productivity costs.
The relationship between productivity costs and study 
characteristics
Univariate and multivariate linear regression models were used to tentatively 
explore the relationship between per-patient monthly productivity costs and 
study characteristics in those studies that included productivity costs. Al-
though the residuals of the multivariate model passed the tests for Normality, 
skewness and kurtosis, the QQ-plot showed that a few residuals had extreme 
values. Moreover, the multivariate model failed the Ramsey test (see table 6.3). 
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Figure 6.2 Incremental direct costs versus incremental total costs
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Given the non-Normal distribution of productivity costs and direct costs, the 
effects of several transformations (such as log-transformations and quadratic 
terms) were explored. Furthermore, we tested applying other link functions 
and the use of interaction terms. None of these measures improved the model. 
Excluding the nine observations (derived from four studies (146-148,168)) with high 
leverage and large residuals according to Cook’s distance improved the model 
specification substantially (Ramsey RESET P = 0.087). The extreme values may 
be partially explained by the use of medical professional estimates of absentee-
ism, since all eight observations from studies using such estimates were identi-
fied as extreme values. (146-148) Only one ‘outlier’ of nine could not be explained 
by having used estimates from medical professionals. Nevertheless, the exclu-
sion of extreme values should be handled with caution, especially since cost 
data are known to be positively skewed. (224) Given the explorative nature of 
the meta-regression, the results of the multivariate analyses are presented both 
including and excluding the extreme values (see table 6.3).
Monthly direct costs
Both multivariate models showed similar patterns and explained a high 
proportion of variance (adjusted R-square 0.822 and 0.784). The models 
demonstrated a significant positive association between per-patient monthly 
productivity costs and monthly direct costs (P < 0.001). In other words, the 
higher the direct costs, the higher the productivity costs. This association may 
be explained by the fact that higher direct costs may be associated with more 
severely ill patients who are consequently also less productive.
Age
Monthly productivity costs were negatively associated with the average age of 
patients in the studies. Monthly productivity costs were lower for studies with 
a higher average patient age. Since our review excluded studies that mainly 
focused on elderly patients, this association may signal that younger people in 
these samples may be more frequently involved in paid work and older indi-
viduals may more frequently be retired. It would also be possible that younger 
employees have more health-related absence days than older employees (after 
controlling for health status) or that younger employees might have more 
work-related mental health problems.
128
 
Time-horizon
Monthly productivity costs were significantly lower for studies with longer time 
horizons in the full-data model. Since patients generally recover from a depres-
sive episode within a few months, most productivity costs are likely to occur in 
a short time period. If follow-up continues after recovery, monthly productivity 
costs will, on average, decrease. However, since time horizon loses significance 
in the second model, the significant relation seemed to be especially induced 
by the few extreme values.
Valuation approach
Using the FCA instead of the HCA was significantly associated with lower 
monthly productivity costs in the univariate models; however, this significant 
association was not confirmed in the multivariate models, possibly due to cor-
relation with other methodological choices.
Type of depression
Patient populations with a dysthymic disorder seem to be related to lower 
monthly productivity costs than those with other depressive disorders. This 
negative relationship might be explained by the fact that a dysthymic disorder 
is a relatively mild but chronic condition. Unexpectedly, patient popula-
tions with major and severe depressive disorders were associated with lower 
monthly productivity costs than those with other depressive disorders. A pos-
sible explanation for this finding might be that a priori unemployment rates in 
these groups could be relatively high.
Type of treatment
The only significant variable regarding the type of treatment provided was the 
combination of drugs and psychotherapy, although only in the multivariate 
model without the extreme values. Psychotherapy combined with drugs led 
to higher monthly productivity costs, which may be related to the intensity of 
treatment.
Method of data collection
In the full-data model, lost work time based on estimates from medical doctors 
was related to higher monthly productivity costs than that based on literature 
estimates and patient questionnaires. The observations from the three studies 
using doctors’ estimates (146-148) were labeled as extreme values according to 
Cook’s distance. Medical professionals might overestimate patients’ lost work 
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time due to depressive disorders and subsequent treatments. Furthermore, 
not specifying the data collection method for lost work time was associated 
with significantly higher monthly productivity costs. Obviously, it is difficult 
to explain this. Excluding extreme values, the use of patient questionnaires 
to collect absenteeism data was associated with lower productivity costs per 
month than other methods. The effect of data collection methods on the level 
of productivity costs raises important questions regarding the accuracy of the 
individual methods.
Values attached to lost working time
Valuations of lost work time based on GDP per capita was significantly associ-
ated with the level of monthly productivity costs in both multivariate models 
compared with using mean national incomes or unspecified methods. Intrigu-
ingly, this association was positive in the full-data model but negative in the 
model that excluded extreme values. This is explained by the fact that four of 
the nine excluded extreme values (which were mostly caused by high quanti-
ties of lost work time) related to estimates in which GDP was used to attach 
values to lost work (these four extreme values were derived from two studies 
(147,148)). In the model without these extremes, using GDP per capita resulted 
in relatively low monthly productivity costs. Since the calculation of GDP per 
capita usually does not correct for employment rates, resulting in relatively low 
estimates of added value per worker (national output is divided by the total 
population: working and non-working), this result seems plausible. Values 
based on patients’ incomes were related to lower productivity costs, suggesting 
that patients’ incomes in the studies may have been relatively low compared 
with mean national income. Values based on sick fund/insurance payments 
to patients led to lower productivity costs in the full-data model and to higher 
costs in the model without the extreme values. Again, the difference between 
the models is explained by some of the excluded observations using values 
based on sick fund payments. It is not clear why this variable is positively as-
sociated in the model without the extreme values, since one might expect sick 
fund payments to result in lower estimates, since these payments might be 
lower than average national income.
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6.5 Discussion
Our study revealed that 69% of the economic evaluations of interventions 
for depressive disorder do not include productivity costs. While this may be 
seen as an important omission of real societal costs, it should be noted that 
almost three-quarters of the studies followed national guidelines regarding 
the inclusion or exclusion of productivity costs. In cases where studies did not 
follow national guidelines, it is possible that the decision to include or exclude 
indirect costs in the analysis could be endogenous, i.e. could be subject to a 
kind of perspective-selection bias. Endogenous factors around the exclusion 
of productivity costs could be the time and effort related to measurement of 
such costs. However, their inclusion or exclusion may possibly also be induced 
by the (expected) positive or negative effects of productivity cost inclusion on 
cost-effectiveness outcomes, emphasizing the need for standardization.
It is clear that differences in inclusion of productivity costs between studies 
are important, given the high average proportion of productivity costs of total 
costs and given the strong impact of productivity costs on incremental costs. 
Our results showed that productivity costs, on average, reflect more than half of 
the total costs for treatments for depressive disorders. Moreover, moving from 
excluding to including productivity costs in many cases substantially affected 
the incremental costs.
These findings indicate that the choice of perspective prescribed in reim-
bursement guidelines may influence cost-effectiveness outcomes (and con-
ceivably subsequent decision making) to a great extent in the area of depressive 
disorders. Furthermore, our findings illustrate that comparing cost-effective-
ness outcomes between studies should involve a thorough examination of the 
separate cost (and effect) items included in the analyses. Even when compar-
ing cost-effectiveness outcomes between studies that include productivity 
costs, it remains important to examine other elements of study design. Indeed, 
our results indicated that the amount of productivity costs (and consequently 
the impact of productivity costs on incremental cost-effectiveness) is associ-
ated with study characteristics such as methods used to value productivity 
losses. Several guidelines allow investigators the freedom to deviate from the 
preferred perspective if such a deviation is properly motivated. Although this 
freedom may be useful given the aim and audience of individual studies, it 
limits comparability of studies and, as such, may complicate decision making. 
Moreover, it can lead to a perspective-selection bias.
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Most of the studies that included productivity costs used the HCA to calcu-
late them. Note that we assumed that studies that did not clearly specify the 
method used, applied the HCA, which was in line with the articles’ description 
of productivity cost calculations. One study used the WPA and thus assumed 
the effects of disease and treatment on productivity to be fully valued at the 
effect side of the cost-effectiveness ratio. This study did not specify the (as-
sumed) effects of productivity changes on quality of life outcomes, making it 
impossible to indicate the impact on the ICER. For studies including the HCA 
or the FCA, it is usually expected that the HCA generates higher productivity 
costs since, in the FCA, the time in which productivity costs are assumed to 
occur is limited. However, in this review, the approach used was only signifi-
cantly associated with the amount of monthly productivity costs in a univari-
ate model. The small differences found between the HCA and the FCA in our 
findings are likely to be explained by the relatively short time horizon of the 
studied economic evaluations. Most studies used a time horizon of 6 months to 
2 years. In the first few months, the differences between the HCA and the FCA 
are expected to be negligible, considering a friction period of approximately 5 
months. Furthermore, the acute phase of most depressive disorders will last 
only a few months (maybe not exceeding the friction period). If patients return 
to work after treatment and fall ill again, a new friction period will start, and 
productivity costs between the HCA and the FCA will be quite similar. Whereas 
differences in productivity cost approaches did not seem to affect outcomes 
much, other aspects regarding the methodology of productivity costs seemed 
to matter more. Differences in data collection methods and the values attached 
to work time lost were significantly related to the level of productivity costs.
Although our study was primarily concerned with productivity cost measure-
ment, the regression analyses showed that the level of productivity costs was 
strongly associated with the level of direct costs. Although not investigated in 
this study, the diversity in direct cost measurement may be equal to the diver-
sity in productivity cost measurement. It would be worthwhile to investigate 
such differences in direct cost measurement and the effect of these differences 
on cost-effectiveness outcomes, especially given the association between 
direct costs and productivity costs found in this study.
Limitations
The productivity cost analyses in this study were based on a limited number 
of studies including productivity costs. Moreover, our study solely focused on 
depressive disorders; therefore, the results cannot be generalized. The impact 
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of productivity costs on total costs could be explored further by using larger 
and more diverse databases (covering other diseases and treatments). Ideally, 
this might facilitate a predictive model that may provide a rough indication of 
productivity costs in cases where these costs are omitted.
6.6 Conclusions
Productivity costs in economic evaluations of treatments for depressive dis-
orders reflect a large part of total costs, which implies that, in studies that do 
not include productivity costs, a large part of actual societal costs are ignored. 
This is apparently the case in the majority of economic evaluations in this area. 
In many cases, the exclusion of productivity costs is explained by not having 
taken a societal perspective, often in line with national guidelines. The influ-
ence of the inclusion or exclusion of productivity costs on incremental costs, 
and consequently on cost-effectiveness, in the area of depression underlines 
the importance of the discussion on the appropriate perspective in health 
economic evaluations.
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6A Economic evaluations including productivity costs
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Summary
In economic evaluations of very expensive intramural drugs it could be hy-
pothesized that productivity costs are not significant in terms of their impact 
on cost-effectiveness outcomes given high direct costs. If so, productivity costs 
could be excluded from the analysis. This study aimed to: (i) determine whether 
economic evaluations on expensive drugs commonly include productivity 
costs related to paid and unpaid work; (ii) investigate the effect of productiv-
ity costs on the cost-effectiveness of expensive drugs, and (iii) examine the 
relationship between in- or excluding productivity costs and countries’ health 
economic guidelines. To meet these aims, we conducted a systematic literature 
review to identify economic evaluations of 33 expensive intramural drugs. We 
then investigated the impact of productivity costs on cost-effectiveness out-
comes in studies that included productivity costs. Finally, we analysed whether 
evaluations included productivity costs and whether in- or exclusion could be 
explained by the study populations’ age, health and the relevant national health 
economic guidelines. Of the 249 identified economic evaluations of expensive 
drugs 22 (9%) included productivity costs related to paid work. Only one study 
included unpaid productivity. Productivity cost inclusion sometimes had a 
strong impact on incremental cost-effectiveness. Productivity costs were more 
often included if the economic evaluation originated from countries whose 
guidelines prescribed a societal perspective. The results of this study indicate 
that productivity costs in economic evaluations of expensive intramural drugs 
are ignored in the majority of studies. Given their potential impact, caution 
is warranted when interpreting the cost-effectiveness of expensive intramural 
drugs based on evaluations that a priori exclude productivity costs.
143
A noticeable difference?
Ch
ap
te
r 7
7.1 Introduction
The development of new and expensive health care technologies has increased 
the pressure on national health care budgets as well as hospital budgets, 
leading to difficult questions of affordability of new medicines at the national 
and hospital level. The Netherlands is no exception in this context. Tradition-
ally, Dutch hospitals received a fixed budget from which they should finance 
intramurally dispensed pharmaceuticals. With the increase in new, expensive 
intramural drugs, this leads to difficulties, since the budgets did not increase at 
the same pace as the expenses did. While these fixed budgets controlled costs 
at the national level, they appeared to lead to differences in patients’ access 
to expensive intramural drugs, as some hospital specialists were reluctant to 
prescribe very expensive drugs. (225) 
In 2006 the Netherlands therefore introduced a new policy for reimburse-
ment and financing of expensive intramural drugs, (226) which aimed to avoid 
unequal access and prevent delays in treatment. The policy implies that hospi-
tals, normally subject to a yearly fixed budget, receive additional financing for 
drugs placed on the ‘expensive drug list’. (226) A drug is eligible for placement on 
the list and thus additional financing if it is administered within the hospital 
and its total expenses exceed a certain threshold. Placement on the list is held 
for four years, within which the drug is subject to a mandatory real-life cost-
effectiveness study. The outcome of the study partially determines the drug’s 
eligibility for re-enlistment in the next period. 
Given the methodological challenges involving real-life studies, the Dutch 
Health Insurance Board (CVZ) prescribes a pragmatic approach in conduct-
ing the studies, implying that data collection should be focused on the most 
relevant and influential costs and effects in terms of their impact on final 
cost-effectiveness outcomes. (227) Such an approach in some ways resembles 
‘the rule of reason’ recommended in the influential health economics textbook 
of Gold et al. (2) which states that if costs “…are trivially small or do not differ 
across regimens, their inclusion will have little effect on the final results of an 
analysis, and they may therefore be omitted at the analyst’s discretion.”
Inter alia, costs that may be expected to be less relevant in cost-effectiveness 
studies of expensive intramural drugs are productivity costs. Productivity costs 
can be defined as “costs associated with production loss and replacement costs 
due to illness, disability and death of productive persons, both paid and unpaid.” 
(8) Productivity costs (at least related to paid work) may not be expected to 
be very influential in expensive intramural drugs studies, given the typically 
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older age of patients and the absolute height of direct costs. Furthermore, most 
drugs placed on the Dutch expensive drugs list (226) are prescribed to patients in 
very poor health, such as those suffering from severe rheumatoid arthritis or 
metastatic cancer, who are unlikely to return to paid work even with treatment. 
If productivity costs only marginally affect cost-effectiveness outcomes in 
studies of expensive intramural drugs, the collection of productivity data is in 
itself not a cost-effective exercise and is unnecessarily burdensome to patients. 
Currently, little is known regarding productivity costs in studies of intramural 
expensive drugs and how they affect cost-effectiveness outcomes. It has been 
shown that productivity costs are often ignored in cost-effectiveness studies 
(10,43,44), but it is unclear why and what the impact of ignoring these costs on final 
outcomes has had. However, ignoring costs following the ‘rule of reason’ must 
be based on the assertion that their impact on final outcomes is negligible. 
Obviously, another plausible reason for exclusion of productivity costs is that a 
country’s health economic reimbursement submission guidelines disallow or 
do not prescribe their inclusion, since a health care perspective is prescribed. 
Whether this is the dominant reason for current exclusion is unknown, how-
ever. 
Our research therefore aims to determine whether cost-effectiveness studies 
of expensive intramural drugs normally include productivity costs related to 
paid and unpaid work and whether inclusion of these costs in expensive drugs 
studies is relevant, in other words, whether they have a substantial impact on 
cost-effectiveness outcomes. A secondary objective is to determine whether 
including productivity costs is related to factors that may indicate the applica-
tion of the rule of reason (patients’ age and health status) as well as countries’ 
health economic reimbursement submission guidelines.
To meet the study objectives, we conducted an extensive systematic review 
of economic evaluations of 33 drugs on the Dutch ‘expensive drug list’. (226) 
The effect of including productivity costs on the cost-effectiveness outcomes 
was assessed by investigating the studies that included productivity costs and 
evaluating their impact on final results.
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7.2 Background
Productivity costs can be influential. For instance, in economic evaluations of 
treatments for depression such costs, on average, reflect more than half of total 
costs, often strongly influencing incremental costs and, in turn, cost-effective-
ness (44). The inclusion of productivity costs thus can influence the allocation of 
scarce health care resources across diseases and patients when determined – at 
least to some extent – by incremental cost-effectiveness. 
Although productivity costs and savings can be substantial, previous studies 
suggest that, depending on the types of interventions and economic evalua-
tions studied, not more than 8 to 31 per cent of economic evaluations include 
productivity costs related to paid work. (10,43,44) To our knowledge the extent to 
which economic evaluations include production loss related to unpaid labour 
has only been investigated once, (43) suggesting that unpaid labour is seldom 
included in economic evaluations.
If productivity costs (related to both paid and unpaid labour) are indeed of-
ten ignored, it is important to understand why. Several factors may contribute 
to neglecting productivity costs in economic evaluations, such as the prin-
ciples on which the economic evaluation is based or pragmatic considerations 
throughout the execution of the economic evaluation. Economic evaluations 
adopting a societal perspective aim to include all relevant effects and costs, 
regardless of who bears the costs and who receives the benefits. Influential 
health economics text books such as the book of Drummond et al. (7) and Gold 
et al. (2) promote a societal perspective consistent with the theoretical welfare 
foundations of economic evaluations. (104) Only by including all relevant costs 
and effects is it possible to make optimal (welfare improving) decisions. More-
over, if the underlying objective of economic evaluations is to inform decision 
makers about costs and consequences of alternative actions, taking a broad 
perspective seems reasonable. (41) Although adopting a societal perspective is 
often advocated, (2,7,34,35,40) it is certainly not an undisputed choice. When eco-
nomic evaluations are seen as a tool to aid decision makers in spending a fixed 
health care budget in line with a goal (such as maximising or optimising health), 
some have argued for evaluations with a narrower health care perspective that 
includes costs falling on the health care budget only (e.g. (33)). Productivity costs 
should be excluded in such cases since their effects are external to the health 
care budget and thus irrelevant to the allocation problem addressed.
The lack of consensus regarding the appropriate perspective seems also to 
be reflected in national health economic guidelines, which stipulate how to 
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conduct economic evaluations for reimbursement of health interventions. 
National guidelines are likely (and intended) to influence how economic evalu-
ations are conducted in practice. Approximately half of the national guidelines 
on the ISPOR ‘pharmacoeconomic guidelines around the world’ website (124) 
prescribe taking a health care perspective (at least for the base case scenario) 
and the other half a societal perspective or a health care and societal perspec-
tive. 
Prescribing a health care perspective and excluding productivity costs may 
also be related to important equity concerns (12,13) because their inclusion 
may lead to favouring reimbursement of health interventions targeted at the 
working population. If such interventions produce substantial societal savings 
by improving productivity levels, including productivity costs may result in 
more favourable cost-effectiveness outcomes than when similar interventions 
are used in less productive populations (e.g. very young or elderly). Equity 
concerns potentially favouring the employed are explicitly mentioned in some 
guidelines (e.g., Australia (228) and New Zealand (229)) as an argument for adopt-
ing a health care rather than societal perspective.
We could question whether ignoring the existence of costs and savings 
outside the health care sector is the proper solution to such ethical concerns. 
The approach denies decision makers the opportunity to make well-informed 
decisions and balance potential savings with the equity implications of their 
decisions, which might be why most countries (except the United Kingdom (72) 
and New Zealand (229)) prescribing a health care perspective allow presenting 
additional costs-effectiveness scenarios that include broader societal costs. 
Pragmatic factors that contribute to ignoring productivity costs in economic 
evaluations could be a lack of time, data, or research experience. (230) It could 
also be related to the lack of scientific consensus regarding appropriate meth-
ods to measure and value such costs. Numerous instruments, for example, can 
measure productivity costs (mainly related to paid work) but which instru-
ment provides the most valid estimate is currently unknown. Estimates that 
vary substantially (82,83) by using different instruments can result in a lack of 
confidence in the trustworthiness of productivity cost estimates. 
Next to measurement difficulties, the valuation of productivity costs (related 
to paid work) has been fiercely debated. (22,23,47,58,59,231) The suitability of three 
valuation approaches has dominated the debates: the human capital approach, 
(88) the friction cost approach, (47) and the Washington panel approach. (2) With 
the human capital approach a monetary value is placed on ‘all working hours 
lost due to health problems and related treatments’ (88) regardless of the period 
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of absence. The friction cost approach limits productivity cost calculations to 
the duration of time it takes to hire and train a replacement. The idea behind it 
is that a sick worker being replaced by, for example, a previously unemployed 
worker restores societal production levels. The duration of the friction period 
depends on countries’ unemployment rates and vacancy durations. In contrast 
to the first two, the Washington Panel approach values productivity costs in 
terms of quality of life effects related to income changes. Strong criticism of the 
Washington panel approach (8,22,22,31) initiated a number of empirical studies to 
establish whether quality of life instruments could capture the effects of health 
changes on income. (61-67,232) Outcomes indicated that quality of life instruments 
are rather insensitive to such effects, invalidating the approach. The Washing-
ton panel approach thus receives little theoretical and practical support, but 
lack of consensus on whether to apply the friction cost or the human capital 
approach translates to the use of both in practice. (43,44,233) How to measure and 
value productivity costs related to unpaid work has received little attention in 
the scientific literature. 
Following ‘the rule of reason’ (2), productivity costs need only be included in 
economic evaluations when deemed relevant. If productivity is not affected 
by some treatment, including productivity related costs would be superfluous, 
such as with some treatments aimed at very mild conditions or treatments 
aimed at very severe conditions in which patients are fully impaired without 
expectation of returning to paid or unpaid work. In most cases, however, 
whether health interventions will affect patients’ productivity is difficult to 
predict.
According to the rule of reason, productivity cost inclusion would also be 
irrelevant if productivity is unchanged relative to the comparator (i.e. if pro-
ductivity changes are similar in both the intervention and comparator groups), 
since productivity costs will not change incremental cost-effectiveness ratios. 
For most interventions determining up front whether productivity costs in 
both study arms are equal is difficult and excluding productivity costs is thus 
debatable.
In practice, productivity costs may also be regularly omitted based on pa-
tients’ age. For instance, if most of the patients receiving an intervention are 
above retirement age productivity losses related to paid work may be negli-
gible. Note, however, that this is not the case for losses related to unpaid work. 
Treatments targeted at the very young patients could affect future productivity, 
rendering productivity costs an important factor. Whether such effects are con-
sidered important to economic evaluations depends on the valuation method 
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chosen: related costs or savings should be included if using the human capital 
approach (88) but not the friction cost approach (47). 
A final rationale for ignoring productivity costs in line with the rule of rea-
son might be the expectation that these costs are not very influential if direct 
costs are relatively high. This might be the case in economic evaluations of 
(very) expensive drugs, especially when these drugs are administered in a 
(costly) inpatient setting. If, as a rule, productivity costs have little effect on 
cost-effectiveness outcomes in economic evaluations of expensive intramural 
drugs, they might be excluded a priori, limiting burden to patients and saving 
time and other resources. If the costs are influential (as they are in some areas 
(9,42,44)), ignoring productivity costs upfront could lead to sub-optimal decision 
making.
7.3 Methods
Review of economic evaluations of intramural expensive drugs.
We performed an extensive systematic review of all 33 drugs on the Dutch ‘ex-
pensive drug list’ in June 2009 (table 7.1) to identify any economic evaluations. 
We used the Cochrane Library and PubMed databases with a publication date 
limit of January 1998 to June 2009. 
Queries used for the database search were the drugs’ names and “cost” or 
“costs.” Inclusion criteria were (i) unique scientific articles in peer-reviewed 
journals in English and (ii) titles with terms or phrases such as cost(s), budget, 
economic, financial, price, money, dollar, economy, expenditure, pay, expense, 
fund, resource, reimbursement, consumption, or expensive. After excluding 
any reviews, we read abstracts of the remaining articles to determine if they 
were indeed economic evaluations. Finally, the full texts of the remaining 
articles were examined (with the exception of those unavailable in the Neth-
erlands or British Library). Title and abstract searches were independently 
undertaken by two researchers. Full text examinations were carried out by two 
people in close collaboration.
Table 7.1 Pharmaceuticals included in the review (Dutch expensive intramural drug list June 2009) (226) 
Docetaxel, Irinotecan, Gemcitabine, Oxaliplatin, Paclitaxel, Rituximab, Infliximab, Immunoglobulin, Trastuzumab, 
Botulin toxin, Verteporfin, Doxorubicin liposomal, Vinorelbine, Bevacizumab, Pemetrexed, Bortezomib, 
Omalizumab, Ibritumomab, Pegaptanib, Alemtuzumab, Palifermin, Drotrecogin-alfa, Natalizumab, Cetuximab, 
Ranibizumab, Abatacept, Voriconazole, methyl aminolevulinate, Panitumumab, Anidulafungin, Caspofungin, 
Temsirolimus, Temoporfin
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Inclusion of productivity costs and the impact on costs and cost-
effectiveness. 
After identifying economic evaluations of expensive drugs, we investigated 
whether they included productivity costs related to paid or unpaid work. Next, 
(where possible) we extracted the average or median age and the severity of 
illness of the patients in the study populations. To explore whether age may 
explain the inclusion of productivity costs related to paid work, we assumed 
that at least a considerable part of a study population would be in working 
age if the average age of the study population was between 18 and 70. Sub-
sequently, it was investigated whether inclusion or exclusion of productivity 
costs could be explained by the (estimated) health related ability to work, or the 
likelihood that at least a part of the patient populations in individual studies 
would lose or regain ability to work (in comparison to the control group). These 
estimations were based on a medical doctor’s expert opinion regarding the 
severity of disease of the patient populations (e.g., in case of metastatic cancer 
it was assumed that (most) patients would not be able to perform paid work 
regardless of treatment).We also examined whether studies aligned with their 
national health economic guidelines regarding productivity costs. National 
and regional health economic guidelines were retrieved through the ISPOR 
‘pharmacoeconomic guidelines around the world’ website. (124) Where possible 
the original guideline documents were studied. If the guidelines were not avail-
able in English we followed the ISPOR ‘Key Features’ pages. If guidelines were 
non-existent or not listed, they were labelled ‘unknown’ and productivity cost 
exclusion could not be related to a recommended perspective. 
For the studies that included productivity costs, the percentage of total cost 
accounted for by productivity costs was calculated and reported. We then 
excluded productivity costs from the study’s incremental cost-effectiveness 
ratio(s) to analyse the impact of productivity costs on cost-effectiveness 
outcomes. We described whether inclusion of productivity costs led to change 
in incremental cost-effectiveness and the magnitude of the change. For cost-
minimization studies (where incremental effects are insignificant) we exam-
ined only changes in incremental costs. All prices were adjusted to 2009 euros 
using the European Union Harmonized Indices of Consumer Prices published 
by Eurostat (234).
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7.4 Results
Review
The database search resulted in 2,157 articles in Pubmed and 422 in the Co-
chrane Library, 834 of which were doubles (figure 7.1). The number of doubles 
was quite high because many economic evaluations included more than one 
expensive drug and, as a consequence, appeared in several of the database 
searches of the individual drugs. Ten articles were not in English; 1,120 did not 
include an economic term or phrase in the title; 15 were not available in the 
Netherlands or British library; 52 were not scientific research articles; 89 were 
congress abstracts; three did not evaluate one of the 33 drugs; and 95 could not 
be qualified as economic evaluations. This resulted in 249 studies that quali-
fied as economic evaluations of drugs from the Dutch expensive intramural 
drug list. (226) Of these, 22 (about 9%) included productivity costs related to paid 
work and only one included productivity costs related to unpaid work. (235) (See 
appendix 7A for details of the studies.) Of the 22 economic evaluations includ-
ing productivity costs, three were identified as cost minimization analyses 
(CMA); (236-238) the remaining 19 were cost-utility analyses (CUA), where effects 
are expressed in quality adjusted life years (QALYs).
Productivity costs methodology
Three (239-241) of the 22 studies including productivity costs provided no details on 
how productivity costs were measured and valued. Ten (235-238,242-247) used average 
(age- and gender-dependent) wage and employment rates to value lost working 
time. One study (248) assumed that productivity costs would be either one or three 
times the direct costs and another (249) used employers’ annual labour costs. The 
remaining ten studies (239-241,250-256) did not specify the values used. 
Two economic evaluations (236,250) explicitly assumed that productivity would 
be relatively unaffected in all study arms; i.e., productivity costs were assumed 
not to vary. Only seven studies (238,244-246,250-252,254) described actual data collection 
on productivity among the patient population, but none of them specified the 
productivity costs measurement instrument used. Three studies that applied 
the friction cost approach (235,236,255) also applied the human capital approach. 
Only four of the remaining studies (245,246,253,256) explicitly mentioned applying 
the human capital approach. Most other studies appeared to have used the hu-
man capital approach (in some form) without explication. The one study that 
included productivity costs related to unpaid work based the cost estimates on 
changes in household work and volunteer work. (235) The time spent on unpaid 
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work was valued at the same rate as informal care (correcting for the costs 
already included for household help and informal care).
Productivity costs inclusion: the proportion of total costs
We could not determine the proportion of total costs accounted for by pro-
ductivity costs for 11 of the 22 articles due to a limited level of detail in the 
presented cost items. Four of these 11 (240-242,244) did not provide specifications 
 
Studies more closely examined (n =615) 
 
Studies included in title scan (n =1735) 
Economic evaluations of relevant drugs (n = 249) 
 
Studies excluded 
 Not available in Dutch/British library (n = 15) 
 No scientific research article (n = 52) 
 Congress abstracts (n = 89) 
 Reviews (n =111) 
 No relevant drugs included (n = 3) 
 No economic evaluation (n = 95) 
 
Studies excluded 
 No economic words in title (n = 1120) 
Studies excluded 
 Double articles (n = 834) 
 Not in English (n = 10) 
 
Potentially relevant studies (n = 2579) 
Figure 7.1 Flow diagram of the systematic literature review
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regarding the amount of productivity costs and seven only provided informa-
tion on incremental productivity costs. (245,246,249-253) 
The remaining 11 articles provided information on the absolute amount of 
productivity costs and accounted for 37 study arms; i.e., 37 estimates of produc-
tivity costs as a proportion of total costs related to an intervention or comparator 
were available. Twenty-four of these estimates valued productivity costs accord-
ing to the human capital approach; 13 applied both the human capital and the 
friction costs approach. As expected, studies applying the human capital ap-
proach generated higher productivity costs, since in the friction cost approach 
the duration of inclusion of productivity loss is shorter. For studies applying the 
human capital approach, productivity costs on average comprised 45% (range: 
-106% to 83%) of total costs per treatment arm (table 7.2). Note that we assumed 
that studies not clearly specifying method applied the human capital approach, 
which was indeed in line with their descriptions of productivity cost calcula-
tions. Productivity costs for the 13 study arms for which both the methods were 
applied were on average 24% (range: 4% to 38%) of the total with the friction cost 
approach and 44% (range: -106% to 80%) with the human capital approach. For 
the study on unpaid labour, (235) costs were on average 0.7% of the total, ranging 
from -25% (i.e., led to savings) to 15%, depending on treatment arm.
The impact of productivity costs on cost-effectiveness outcomes
To study the impact of productivity costs on cost-effectiveness outcomes the 
incremental cost-effectiveness ratios (ICERs) including productivity costs were 
recalculated after excluding these costs in the analyses. Because only one study 
considered unpaid labour, we limited our calculations to paid labour only. Recal-
culation of cost-effectiveness outcomes was only possible for the 15 CUAs and 
three CMAs (representing a total of 36 ICERs and eight incremental cost calcula-
tions) specifying the amount of productivity costs, or the effect of productivity 
costs on the ICER. The change in incremental cost-effectiveness after excluding 
productivity costs is shown in figure 7.2. For all ICERs two bars are included. The 
first reflects the incremental cost-effectiveness in 2009 euros per QALY excluding 
Table 7.2 Productivity costs inclusion
Economic evaluations % PC of TC (range)
Including PC (paid) 22 of which 19 HCA and 3 FCA + HCA 45 (-106 - 83) HCA
24 (4 - 38) FCA
Including PC (unpaid) 1 0.7 (-18 - 15)
Excluding PC 227
Total 249
PC = productivity costs, FCA = friction cost approach, HCA = human capital approach
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productivity costs; the second reflects the incremental cost-effectiveness includ-
ing productivity costs. The incremental costs of the three CMAs are presented on 
the right-hand side of the vertical line in figure 7.2. 
We drew two fictive ICER thresholds in the figure for illustrative purposes: 
one at approximately €40,000 per incremental QALY in the region of the upper 
limit of the NICE threshold (257) and one at €80,000, a suggested threshold for 
diseases with a very high burden of disease by the Dutch Council for Public 
Health and Health Care. (258) These threshold lines illustrate how productivity 
cost inclusion (exclusion) potentially affects decision making for treatments 
where the ICER with productivity cost falls below (above) the threshold and the 
ICER without productivity costs above (below) the threshold. Note that we did 
not include uncertainty around the ICERS and the thresholds.
A comparison of ICERs with the in- and exclusion of productivity costs shows 
that ICERs increase due to inclusion of productivity costs in six out of 36 cases. In 
four of these cases the new treatment changed from cost-saving to cost-spending. 
Including productivity costs led to a decrease of the IC(ER) in 30 cases. In six of 
these 30 cases the decrease caused the incremental costs to change from positive 
to negative, therefore turning the new treatment into a cost-saving intervention.
Taking into account the fictive threshold of €40,000 per QALY, eight ICERs 
exceed the threshold when excluding productivity costs, while none exceed the 
threshold when including productivity costs. The other way around, three IC-
ERs lie below the €40,000 threshold without productivity costs and exceed this 
threshold after including productivity costs. In other words, in 11 of the 36 ICERs 
(31%) including or excluding productivity costs would alter decision making (if 
exclusively based on an ICER decision rule), based on a fixed €40,000 threshold. 
If we raise the threshold to €80,000, three ICERs exceed the threshold excluding 
productivity costs and none exceed the threshold including productivity costs. 
Table 7.3 Patients’ age and health related work-ability 
Studies including PC (n = 22) Studies excluding PC (n = 227)
Productive age (18-65)
Yes (mean age 18-70) 19 (86 %) 163 (72 %)
No (mean age > 70) - 21 (9 %)
Unknown 3 (14 %) 42 (19 %)
Work ability based on severity of illness a
Likely to be able to work 21 (95 %) 146 (64 %)
Doubtful 1 (5 %) 8 (4 %)
Unlikely to be able to work - 73 (32 %)
a These estimations were based on a medical doctor’s expert opinion regarding the severity of 
disease of the patient populations. 
PC = productivity costs
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With the €80,000 threshold, none of the ICERs is above the threshold including 
productivity costs and below the threshold after excluding these costs. With an 
€80,000 euro threshold decision making could alter in three of 36 cases (8%).
Inclusion of productivity costs inclusion and health economic 
guidelines
Inclusion (or exclusion) of productivity costs of all 249 economic evalua-
tions was compared with the study-populations median or average age, the 
estimated work ability and the health economic guidelines of the respective 
countries. As can be seen in table 7.3, most study-populations had an average 
age below 70 in both the studies including and excluding productivity costs. 
Based on doctor’s opinion, the study populations of approximately one-third 
of the studies excluding productivity costs were expected not to be able to 
perform paid work regardless of treatment.
Based on national health economic guidelines, for 56 of the 249 economic 
evaluations productivity cost inclusion was not allowed but four of the 56 included 
productivity costs anyway. In all four studies the ICERs decreased due to including 
productivity costs. Fourteen economic evaluations originated from countries for 
which no guidelines were available, only one of which included productivity costs. 
(238) In 74 economic evaluations inclusion of productivity costs was mandatory 
according to the relevant health economic guidelines but only 11 studies followed 
the rule. Despite this low level of inclusion, table 7.4 shows that productivity costs 
were (as expected) more often included in evaluations originating from countries 
with guidelines prescribing inclusion. Only six of the 106 studies from countries in 
which productivity cost inclusion is allowed but not required included the costs.
Table 7.4 Productivity cost inclusion and national health economic guidelines
Perspectives in HE guidelines Economic 
evaluations
Studies including 
PC
% inclusion
Health care for base case: PC not allowed in any 
scenario
56 4 7
Health care for base case: PC allowed in additional 
scenarios 
74 4 5
Societal 41 7 17
Societal and health care 33 4 12
Societal or health care 32 2 6
Unknown 13 1 8
Total 249 22 9
HE = health economic, PC = productivity costs
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7. 5 Discussion
The first aim of this study was to determine whether economic evaluations of 
expensive intramural drugs usually included productivity costs related to paid 
and unpaid work, and whether such costs had a substantial impact on cost-
effectiveness outcomes. Only one of the 249 identified economic evaluations 
of expensive intramural drugs included productivity costs related to both paid 
and unpaid work and 21 (8%) included productivity costs related to paid work. 
Such results indicate that productivity costs related to unpaid work rarely seem 
to play a role in cost-effectiveness calculations of expensive intramural drugs 
and productivity costs related to paid work are ignored in the vast majority of 
studies. That is not to say differences in outcomes are unimportant; including 
productivity costs can clearly affect cost(-effectiveness) outcomes. Despite 
the high direct costs related to expensive drug treatment, productivity costs 
reflect a relatively high proportion of total costs and can strongly affect incre-
mental cost-effectiveness ratios. With a fixed €40,000 threshold, for example, 
decisions regarding reimbursement of expensive drugs could alter in almost 
one-third of the cases by including or excluding productivity costs in the cost-
effectiveness analyses. Given these potential strong effects on final outcomes, 
productivity costs cannot be simply excluded in economic evaluations of 
expensive intramural drugs based on ‘the rule of reason’ introduced by Gold 
et al. (2) Consequently, for the recommended pragmatic approach of real-life 
cost-effectiveness studies of expensive intramural drugs in the Netherlands the 
results imply that productivity costs should be included when possible and are 
ethically acceptable. If direct measurement of productivity costs is not possible 
because of severity of illness it might be possible to predict productivity losses 
based on quality of life data. (55)
A secondary objective of our study was to determine the extent to which 
productivity costs in- or exclusion is related to patients’ age, severity of illness 
and countries’ health economic reimbursement submission guidelines. If 
assuming that with an average study-population age below 70 a considerable 
part of the patients is in working age, age does not seem to explain the exclu-
sion of productivity costs in economic evaluations of expensive intramural 
drugs. Health status may be of influence, however. In approximately one-third 
of the studies, the severity of illness of the patients could have been a reason 
to exclude productivity costs (related to paid work) upfront. Moreover, our 
results indicate that health economic guidelines influence productivity cost 
inclusion or exclusion, but most guidelines leave room for judging when to 
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include productivity costs and how to do so. Moreover, in most of the studies 
we examined, clear information on how productivity costs were derived was 
lacking. It has been suggested that the decision to include productivity costs 
may be driven by strategic considerations regarding the expected influence 
on final outcomes, resulting in a selection-perspective bias. (44) Although too 
few studies in our review included productivity costs to be able to confirm this 
suggestion, the ICERs of every economic evaluation that included productiv-
ity costs against the relevant health economic guidelines decreased. The 
existence of a selection-perspective bias emphasizes the importance of stan-
dardizing economic evaluations. Given the large impact of productivity costs, 
transparency in measurement and valuation methods is paramount. Studies’ 
comparability, completeness and transferability would be served by consistent 
and preferably uniform inclusion of productivity costs, perhaps presented as 
a separate item. Inclusion also raises decision makers’ awareness of societal 
costs (or savings). If these costs are for any reason not included it is important 
to justify their exclusion.
A limitation of our review is that by necessity we assessed the impact of 
productivity costs on cost-effectiveness outcomes based on the studies that 
actually included them. The amount of productivity costs in these studies may 
poorly reflect productivity costs in studies excluding these costs, especially if 
based on strategic considerations. Moreover, we were unable to determine how 
inclusion or exclusion of productivity costs related to unpaid work affects cost-
effectiveness outcomes, since only one economic evaluation in our review 
considered unpaid work. 
7.6 Conclusions
Productivity costs lead to noticeable differences in cost-effectiveness out-
comes of economic evaluations of treatments with expensive intramural drugs. 
Despite the high direct costs related to the drugs, productivity costs reflect a 
non-negligible part of total costs when included and, therefore, a priori ex-
clusion of productivity costs is not easy to defend when adopting a societal 
perspective. Ignoring productivity costs in economic evaluations of expensive 
intramural drugs without clear motive could imply ignoring important societal 
costs. That notwithstanding, productivity costs related to paid work are omit-
ted in the majority of cases and productivity costs related to unpaid work are 
seldom included. The neglect of productivity costs is to some extent explained 
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by the relevant national health economic guidelines prescribing a health 
care perspective, but the rationale for the majority of studies is unclear. We 
would argue that if productivity costs are ignored, motivation should be clear. 
Moreover, excluding productivity costs simply to comply with national guide-
lines does not render them less relevant to society or welfare improvement. 
An intermediate solution for economic evaluations in countries prescribing 
a health care perspective could be to measure and value productivity costs 
whenever relevant and report them separately (as was done by some studies in 
this review). A two-perspective approach, in which ICERs are presented from 
both a societal and health care perspective, may be advisable. (41)
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Appendix
7 A Studies including productivity costs (all costs in 2009 euros)
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8. 
Productivity cost calculations in health 
economic evaluations: 
Correcting for compensation mechanisms and 
multiplier effects
Based on: Krol M, Brouwer WB, Severens JL, Kaper J, Evers SM. 
Productivity cost calculations in health economic evaluations: Correcting for 
compensation mechanisms and multiplier effects. 
Social Science & Medicine. 2012 Dec;75(11):1981-1988.
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Summary
Productivity costs related to paid work are commonly calculated in economic 
evaluations of health technologies by multiplying the relevant number of work 
days lost with a wage rate estimate. It has been argued that actual productivity 
costs may either be lower or higher than current estimates due to compensa-
tion mechanisms and/or multiplier effects (related to team dependency and 
problems with finding good substitutes in cases of absenteeism). Empirical 
evidence on such mechanisms and their impact on productivity costs is scarce, 
however. This study aims to increase knowledge on how diminished productiv-
ity is compensated within firms. Moreover, it aims to explore how compen-
sation and multiplier effects potentially affect productivity cost estimates. 
Absenteeism and compensation mechanisms were measured in a randomized 
trial among Dutch citizens examining the cost-effectiveness of reimbursement 
for smoking cessation treatment. Multiplier effects were extracted from pub-
lished literature. Productivity costs were calculated applying the friction cost 
approach. Regular estimates were subsequently adjusted for (i) compensation 
during regular working hours, (ii) job dependent multipliers and (iii) both 
compensation and multiplier effects. A total of 187 respondents included in the 
trial were useful for inclusion in this study, based on being in paid employment, 
having experienced absenteeism in the preceding six months and completing 
the questionnaire on absenteeism and compensation mechanisms. Over half 
of these respondents stated that their absenteeism was compensated during 
normal working hours by themselves or colleagues. Only counting productiv-
ity costs not compensated in regular working hours reduced the traditional 
estimate by 57%. Correcting for multiplier effects increased regular estimates 
by a quarter. Combining both impacts decreased traditional estimates by 29%. 
To conclude, large amounts of lost production are compensated in normal 
hours. Productivity costs estimates are strongly influenced by adjustment for 
compensation mechanisms and multiplier effects. The validity of such adjust-
ments needs further examination, however.
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8.1 Introduction
Economic evaluations are increasingly used to inform decision-makers on 
cost-effectiveness of health interventions. Such economic evaluations can be 
performed from different perspectives. Most national health economic guide-
lines prescribe either a health care perspective or a societal perspective (233). 
In economic evaluations performed from a health care perspective only costs 
falling on the health care budget are included. In analyses from the societal 
perspective all relevant costs and effects are included regardless of who bears 
the costs and who receives the benefits (7). Although no consensus seems to 
exist on which perspective to use for decisions regarding reimbursement of 
health interventions, there are strong arguments to perform economic evalu-
ations from a societal perspective (2,7,34,40,41). The most compelling argument is 
that costs falling outside the health care budget are equally real as costs that 
fall inside this budget and thus affect overall welfare of a society. Subsequently, 
ignoring these costs could lead to suboptimal decisions for the society as a 
whole, especially if these costs strongly affect cost-effectiveness outcomes, 
which is often the case for productivity costs (9,44). Productivity costs can be 
seen as “Costs associated with production loss and replacement costs due to 
illness, disability and death of productive persons, both paid and unpaid” (8). In 
this chapter we focus on productivity costs in relation to paid work. 
It is important to note that the inclusion of productivity costs in economic 
evaluations is not without dispute. This relates to two broad issues: (i) which 
perspective to adopt in economic evaluations and (ii) the equity implications 
of including productivity costs. Regarding the first issue, it is clear that not 
all (national) guidelines for economic evaluations recommend adopting a 
societal perspective. Many prescribe a narrower perspective, i.e. a health care 
perspective. Then, only costs falling on the health care budget, and thus are 
the responsibility of the health care policy maker economic evaluations seek to 
advice, are deemed relevant (33,41). Second, inclusion of productivity costs (like 
many other cost categories, including medical costs) can have equity implica-
tions. Their inclusion may sometimes lead to favoring interventions targeted 
at the working age population (12,13), although it may also work in the opposite 
direction (44). The equity implications may be particularly pronounced when 
only costs of paid labor are included while costs of unpaid labor are ignored. 
To provide policy makers with information on the distributional consequences 
of including productivity costs, it has been recommended that final cost-
effectiveness ratios may be best presented both with and without productivity 
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costs (41,43). This chapter will not further address the issue of whether to include 
productivity costs. It rather focuses on the question how to do so. This is by no 
means a trivial question. 
Productivity costs related to paid work can reflect over half of total costs 
(11,44) and because of their substantial potential impact on cost-effectiveness 
outcomes estimates should be accurate. Most commonly, productivity costs 
related to paid work are estimated through measuring absenteeism and/or 
diminished productivity while at work. Productivity loss is estimated by cal-
culating the number of days individuals are absent from work due to illness 
and treatment and/or the amount of diminished productivity at work. These 
estimates are then multiplied with a relevant value of production per time unit 
(e.g. hour), commonly some wage rate estimate. Such estimations implicitly 
assume a direct linear relation between diminished input (through absentee-
ism and diminished productivity while being at work) and diminished output 
(lost production). However, a linear translation from diminished productive 
input to diminished economic output may not be accurate.
It has been suggested that diminished productivity may partly be compen-
sated during normal working hours by the ill worker itself or its colleagues. 
Koopmanschap & Rutten (76) describe that sometimes absenteeism may not 
change production levels and lead to extra costs. “This situation may occur if 
work can be made up for by the sick employee on his return to work or if an 
internal labor reserve exists, allowing work to be taken over by colleagues with-
out extra costs.” However, they note that “the existence of permanent internal 
labor reserves raises labor costs, which may have medium term macroeconomic 
implications”. The existence of such compensation mechanisms was explored 
further by Severens et al. (17) and Jacob-Tacken et al. (18). It seemed that missed 
work was indeed partly compensated during normal working hours. Moreover, 
compensation mechanisms seemed related to occupational and job charac-
teristics. Severens et al. (17) and Jacob-Tacken et al. (18) argued that, given these 
compensation mechanisms, traditional productivity cost calculations might 
overestimate true productivity losses. 
Others (14), on the contrary, suggested that common productivity estimates 
are, in fact, underestimations of ‘true’ productivity costs. They concluded that 
“when there is a team production and substantial team-specific human capital, 
the value of lost output to the firm from an absence will exceed the wage per day 
of the absent worker.” In other words, a person’s absenteeism or diminished 
productivity at work can negatively affect the output of coworkers in cases of 
team dependencies. Moreover, substitution of ill workers can be difficult and 
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imperfect. To incorporate effects of substitution difficulties and effects on team 
output it is suggested to multiply the individual’s wage with a job-dependent 
multiplier (15,16). The multiplier is determined by considering the level of team 
dependency in realizing the teams’ output, the time sensitivity of the output 
and the ease of substitution of the ill employee.
Traditional productivity cost estimates can be adjusted for such ‘multiplier 
effects’ and ‘compensation during normal working hours’, if this is deemed 
desirable. To date, however, only a limited amount of empirical research is 
available regarding the existence of multiplier effects or compensation mecha-
nisms (15-18), and there is no empirical study investigating both concepts inte-
grally. Recently, a new productivity cost questionnaire was developed which is 
the first to simultaneously include questions on compensation mechanisms 
and the effects on coworkers (85). The validity of this questionnaire needs to be 
further investigated, however.
In this chapter we present an empirical study on compensation mechanisms 
of reduced productivity among a large group of smokers in a smoking-cessa-
tion program. Moreover, based on this information and estimated effects of 
ill-health on coworkers, we calculated productivity costs for several scenarios. 
To our knowledge, this is the first study to simultaneously explore multiplier ef-
fects and compensation effects. The aim of this study is twofold. First, it aims to 
increase knowledge on how diminished productivity is actually compensated 
within firms and to further investigate the association between compensation 
mechanisms and occupational and job characteristics. Second, the study aims 
to explore how compensation and multiplier effects potentially affect produc-
tivity costs. In doing so, this study seeks to contribute to the discussion on how 
to increase accuracy of productivity cost estimates. This chapter starts with 
presenting the methods of our empirical study on compensation mechanisms 
and describing the productivity costs scenarios. Subsequently, the results are 
presented and then discussed. Finally, some suggestions are made regarding 
future research and the estimation of productivity costs.
168
 
8.2 Methods
Study population
In order to meet our first aim to increase knowledge on compensation of dimin-
ished productivity within firms, absenteeism and compensation mechanisms 
were measured in 2002 in a large randomized trial conducted among smokers 
living in the North of the Netherlands examining the cost-effectiveness of 
including smoking cessation treatments in the basic benefit package. Par-
ticipants in the smoking cessation study had to be daily smokers, aged over 18 
years. A detailed description of the randomized trial was reported elsewhere 
(260). For this study, we only used the data of respondents who had experienced 
absenteeism. 
Questionnaire 
Information on absenteeism and compensation mechanisms was collected 
cross-sectional among the participants in paid employment at six months 
follow up through a mail-based questionnaire. Besides the smoking cessation 
questions, questions were included regarding age, gender, educational level 
and labor participation. Next, respondents’ occupational and job character-
istics were evaluated as an indicator for the work situation. Respondents were 
requested to provide information on job characteristics. These questions were 
based on the Karasek Job Demand-Control model (261) and involved questions 
on the autonomy to plan own work, the possibility to postpone work, the re-
quirement of special knowledge/skills, the frequency of complex problems and 
the number of colleagues in similar professions. Subsequently, respondents 
were asked to state their occupational sector (e.g. industry, health care, educa-
tion etc.). Next, respondents were asked to state their contracted number of 
working hours, the number of hours actively worked and over how many days 
per week these hours were divided. Respondents were also asked whether they 
were working in shifts or irregular hours and whether they were working in 
an executive function. Subsequently, respondents were questioned on absen-
teeism and compensation mechanisms. These questions were obtained from 
the PROductivity and DISease Questionnaire (PRODISQ) (262). Respondents 
were asked whether they had experienced absenteeism from work during the 
past six months. If so, they were asked about the cause of absenteeism, the 
incidence of periods of absenteeism and the duration of absenteeism. Next, 
the respondents were asked whether their missed work time was compensated 
and in what manner. Choice options to this question were: colleagues took 
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over work in normal hours, colleagues took over in extra time, hired workers 
took over, the respondent took over work later in normal hours, the respondent 
took over in extra hours, the work was not compensated, and compensation is 
unknown. Subjects not responding to the mailed questionnaire were contacted 
by phone. Subsequently, a limited telephone interview was undertaken includ-
ing questions on absenteeism, compensation mechanisms and baseline char-
acteristics. The questions regarding occupational and job characteristics were 
not included in the telephone interview. The randomized smoking cessation 
trial was approved by the Medical Ethics Committee of the Trimbos Institute in 
Utrecht, the Netherlands.
Analysis of compensation mechanisms, occupational and job 
characteristics
The association between compensating mechanisms and job characteristics, 
occupational characteristics and personal characteristics was examined 
through chi-square tests and binary logistic regression analysis. For the logistic 
regression, the measure of association was reported by the odds ratio and the 
95% confidence interval. 
In line with previous research on compensation mechanisms, to serve as 
dependent variable in the logistic regression compensation mechanisms were 
dichotomized in (1) compensation mechanisms leading to productivity costs 
and (0) compensation mechanisms suggested not to result in productivity 
costs. The first category included absenteeism compensated in extra time and 
uncompensated absenteeism (assumed to lead to productivity costs through 
extra investments needed to maintain productive output or by a decrease in 
output). The second category included absenteeism compensated in normal 
working hours by the ill worker or his or her colleagues. Unknown compensa-
tion was not included in the logistic regression. Independent demographic 
variables included in the model were income level, educational level, age and 
gender. Occupational variables included were the possibility to postpone work, 
being in an executive function, dealing with complex problems, needing special 
skills, weekly working hours, having over three colleagues in the same profes-
sion, autonomy in planning work and having a mental or physical demand-
ing profession. First, the correlation between the independent variables was 
examined to prevent problems with multicollinearity. Next, back and forward 
stepwise procedures were used to construct the optimal model fit. Variables 
with a P-value of ≤ 0.05 were retained in the model. Categorical variables with 
more than two levels were included as a block if one of the levels had a P-value 
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of ≤ 0.05 as compared to the excluded level. We additionally tested the effects 
of including all variables with a P-value of ≤ 0.10. Subsequently, the Hosmer & 
Lemeshow test was performed to test the goodness of fit of the model. 
Multiplier estimates
While information on absenteeism, compensation mechanisms, age, sex and oc-
cupation was extracted from the smoking cessation trial (260), multiplier estimates 
were obtained from the paper by Nicholson et al. (15). Nicholson et al. define the 
multiplier ‘as the cost of an absence as a proportion (often greater than one) of the 
absent worker’s daily wage’. The multipliers vary between jobs based on ease of 
substitution, the extent to which productive output is team dependent and the 
time sensitivity of a team’s output. The paper of Nicholson et al. provides a list 
with multiplier estimates for a number of distinct professions. The respondents’ 
reported professions in the smoking cessation study were compared with the list 
of professions in the paper of Nicholson and colleagues. If the professions were 
a (near) match the published profession specific estimate was applied and, if 
not, the median multiplier of 1.28 was applied. The applied multipliers ranged 
from 1.00 (waiter) to 2.26 (medical assistant). The two week multiplier estimates 
reported in the paper were used in cases were absenteeism exceeded one week 
and in other cases the 3-day multiplier estimates were used.
The potential impact of compensation mechanisms and multiplier 
effects
In order to meet our second research aim to explore the potential impact 
of compensation mechanisms and multiplier effects on productivity cost 
estimates, productivity costs were calculated both including and excluding 
compensation and multiplier effects. Productivity costs were calculated ap-
plying the friction cost approach following the Dutch pharmacoeconomic 
guidelines (263) and the corresponding Dutch Costing Manual (264). The friction 
cost approach assumes that productivity losses only occur during the ‘fric-
tion period’; this period reflects the time needed to replace (and train) a new 
worker (47,56,90). If a person returns to work after a period of absenteeism shorter 
than the friction period and then falls ill again (and subsequently this illness 
leads to absenteeism), a new friction period starts. The friction period for the 
Netherlands was estimated to be 160 days (5.3 months) in 2008. If a person is 
absent for a longer period of time, productivity is assumed to be restored and, 
therefore, productivity costs are no longer assumed to occur. Productivity cost 
estimates were based on Dutch age and sex dependent national hourly wage 
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rates in 2009 multiplied with 0.8 to adjust for the elasticity between working 
time and productivity, as prescribed by the costing manual (264).
In the regular scenario, scenario 1, productivity costs were calculated as is 
commonly done; i.e. these calculations do not take into account multiplier 
effects or compensation mechanisms. Productivity costs were calculated by 
multiplying the total lost work time of the individuals in the smoking cessation 
study during the last six months by the age and sex dependent average wages 
and an elasticity factor of 0.8. This calculation is illustrated by equation 8.1.
Equation 8.1
PC =
N T
wi ⋅ 0.8 ⋅ (1 – pit)Σ Σ
i = 1 t = 1
In equation 8.1, T represents the 6 months’ time horizon given the way data 
were gathered in this specific trial. And wi the average age and sex dependent 
Dutch gross wage over 6 months based on the individuals’ contracted hours, 
age and sex (age was assumed to be constant over the total six months). T could 
also represent smaller time periods, such as days. In that case wi would reflect 
daily wages. The individuals’ productivity is expressed by p. If an individual 
was absent from work (and the friction period would be irrelevant) the total 6 
month p equals zero and if a respondent had not experienced any absenteeism 
p equals one. 
In the compensation mechanisms scenario, scenario 2, productivity costs 
were only calculated in cases were lost work was not compensated, or compen-
sated through extra working hours by the respondent, by colleagues or by extra 
hired employees. I.e., in cases were lost work was compensated during normal 
hours it was assumed that absenteeism did not lead to extra costs and/or lost 
productive output. Productivity cost calculation in scenario 2 is expressed by 
equation 8.2 where c is the fraction of diminished productivity that is compen-
sated during normal working hours and 0 ≤ c ≤ 1.
Equation 8.2
PC =
N T
wi ⋅ 0.8 ⋅ (1 – cit) (1 – pit)Σ Σ
i = 1 t = 1
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In the multiplier scenario, scenario 3, regular productivity costs estimates were 
adjusted by adding costs to the regular scenario related to effects of absenteeism 
on coworkers’ and team productivity. These additional costs were calculated 
as a proportion of the absent worker’s daily wage by multiplying absenteeism 
(1- p) with the corresponding wage rate (wi) and the job dependent effects 
of absenteeism on coworkers’ and team productivity (1- mi). Consequently, 
productivity costs were estimated as illustrated by equation 8.3 where mi is 
the job-dependent multiplier and mi ≥ 1. We assumed that the multipliers used 
already capture the elasticity of 0.8 normally used in the friction cost approach. 
We therefore did not correct for that elasticity in calculating multiplier costs. 
Equation 8.3 
PC =
N T
wi ⋅ 0.8 ⋅ (1 – pit) + wi ⋅ (1 – pit) (mi – 1)Σ Σ
i = 1 t = 1
In scenario 4, compensation mechanisms and multiplier effects were simul-
taneously accounted for. This is illustrated by equation 8.4 including both c 
and m. In this scenario productivity costs were calculated if absenteeism was 
compensated in extra time, or not compensated. Subsequently, costs were ad-
justed by adding the costs related to team effects based on professions specific 
multipliers.
Equation 8.4
PC =
N T
wi ⋅ 0.8 ⋅ (1 – cit) (1 – pit) + wi ⋅ (1 – pit) (mi – 1)Σ Σ
i = 1 t = 1
In the final scenario (5), which may be viewed as a sensitivity analysis, again com-
pensation mechanisms were simultaneously accounted for. Moreover, the 0.8 
elasticity factor was removed under the assumption that including this elasticity 
together with correcting for compensation mechanisms would result in ‘double 
correction’, since the elasticity factor may already represent internal labor slack 
and compensation of lost work during normal working hours. Besides, it was 
assumed that compensation in normal working hours is not costless, but, per 
hour, involves half of the costs of compensation in extra hours. The productivity 
costs calculation in scenario 5 is expressed by equation 8.5.
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Equation 8.5
PC =
N T
wi ⋅ (1 – 0.5 ⋅ cit) (1 – pit) + wi ⋅ (1 – pit) (mi – 1)Σ Σ
i = 1 t = 1
The statistical analyses were performed with use of SPSS Statistical Software 
Package 17.0 (Chicago, Illinois).
8.3 Results
In total, 1,266 persons were included in the smoking cessation trial (see (260)). 
The response on the absenteeism and compensation questionnaire was 66% 
(n = 836) of the initial response. In total, 501 respondents were in paid employ-
ment. Of these, 187 respondents had experienced absenteeism in the past 6 
months and, as a result, completed the questions on compensation mecha-
nisms. Baseline characteristics of these 187 respondents are shown in table 8.1.
Compensation mechanisms
As can be seen in table 8.2, as much as 64% of the respondents stated that lost 
work was compensated during normal working hours by either colleagues or 
the employee themselves and 23% stated that their lost work was compensated 
in extra hours. For absenteeism of more than two week, fewer respondents 
stated missed work was compensated in normal hours. However, the differ-
ences in compensation mechanisms between the periods of absence were not 
significant (Chi-square, P = 0.214). Even for absenteeism longer than two weeks 
in 52% of the cases missed work was compensated in normal hours. 
Differences in income and educational level of respondents in our sample 
did not lead to significant differences in compensation mechanisms (Chi-
square, P = 0.290 and 0.109). Some significant differences in compensation 
mechanisms were associated with work related factors. Respondents in jobs 
involving both physical and mental tasks more often reported that diminished 
productivity was compensated in extra hours compared with respondents in 
jobs with either physical or mental tasks. Absenteeism occurring in occupa-
tions that require ‘special skills’ led to a larger percentage of missed work being 
compensated in extra hours compared with absenteeism in occupations that 
did not require such skills (Chi-square, P = 0.008). To note, only 22 of the 187 
respondents stated not to need special skills in their occupation. A higher 
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Table 8.1 Personal and job characteristics of respondents with absenteeism (n = 187)
Baseline characteristics
Age (SD) 37.8 (9.5)
Females (%) 96 (51.3)
Income level a
Low (&) 47 (25.1)
Intermediate (%) 120 (64.2)
High (%) 10 (5.3)
Missing (%) 10 (5.3)
Educational level b
Low (%) 38 (20.3)
Intermediate (%) 96 (51.3)
High (%) 53 (28.3)
Occupational and job characteristics
Mental (%) 73 (39)
Physical (%) 64 (34.2)
Mixed (%) 50 (26.7)
Autonomy in work (%) 91 (48.7)
Possibility to postpone (%) 9 (4.8)
Special skills needed (%) 165 (88.2)
Complex problems (%) 86 (46.0)
Shift work/irregular work (%) 101 (54.0)
Executive function (%) 95 (50.8)
Colleagues in similar professions > 3 (%) 97 (51.9)
Numbers of hours worked (SD) 34.0 (12.2)
Hours worked >36 (%) 81 (43.3)
a Monthly net individual income: low = < 1000, intermediate = >1000, <2000, high = > 2000
b Educational level: low = primary and lower-level vocational school, intermediate = lower-level 
secondary and intermediate-level vocational school, high = higher-level secondary and higher-level 
vocational school and university.
Table 8.2 Compensating mechanisms
Compensated in 
normal hours a (%)
Compensated in 
extra hours b (%)
Not compensated (%) Compensation 
unknown (%)
Absence n = 187 119 (64) 42 (23) 17 (9) 9 (5)
Period of absence n=184
One day n=44 27 (61) 7 (16) 6 (14) 4 (9)
2 - 7 days n=71 48 (68) 16 (23) 5 (7) 2 (3)
7-13 days n=25 19 (76) 3 (12) 3 (12) 0
> 2 weeks n = 44 23 (52) 15 (34) 3 (7) 3 (7)
Chi-Square test P = 0.214
Income level n=186
Low n=47 26 (55) 13 (28) 5 (11) 3 (6)
Intermediate n=120 83 (69) 23 (19) 9 (8) 5 (4)
High n=10 4 (40) 5 (50) 1 (10) 0
Missing n=9 5 (56) 1 (11) 2 (22) 1 (11)
Chi-Square test P = 0.290
Educational level 
Low n=38 23 (61) 9 (24) 4 (11) 2 (5)
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Table 8.2 continued
Compensated in 
normal hours a (%)
Compensated in 
extra hours b (%)
Not compensated (%) Compensation 
unknown (%)
Intermediate n=96 64 (67) 21 (22) 4 (4) 7 (7)
High n=53 32 (60) 12 (23) 9 (17) 0
Chi-Square test P = 0.109
Occupational characteristics
Physically demanding n=64 40 (63) 14 (22) 5 (8) 5 (8)
Mentally demanding n =73 56 (77) 11 (15) 5 (7) 1 (1)
Mixed n=50 23 (46) 17 (34) 7 (14) 3 (6)
Chi-Square test P = 0.028
Autonomy to plan tasks n=91 57 (63) 20 (22) 12 (13) 2 (2)
No autonomy to plan tasks n 96 62 (65) 22 (23) 5 (5) 7 (7)
Chi-Square test 0.120
Ability to postpone n=9 7 (78) 1 (11) 1 (11) 0
No ability to postpone n =178 112 (63) 41 (23) 16 (9) 9 (5)
Chi-Square test 0.720
Special skills needed n=165 119 (63) 40 (24) 16 (10) 5 (3)
No special skills needed n =22 15 (68) 2 (9) 1 (5) 4 (18)
Chi-Square test P = 0.008
Complex work n=86 51 (59) 25 (29) 9 (11) 1 (1)
No complex work n=101 68 (67) 17 (17) 8 (8) 8 (8)
Chi-Square test P = 0.040
Irregular/shift work n=101 56 (55) 26 (26) 13 (13) 6 (6)
No irregular/shift work n=83 61 (74) 5 (18) 4 (5) 3 (4)
Chi-Square test P = 0.065
Executive function n=95 62 (65) 15 (16) 11 (12) 7 (7)
No executive function n=90 56 (62) 27 (30) 6 (7) 1 (1)
Chi-Square test P = 0.023
<3 Colleagues n=90 61 (68) 19 (21) 7 (8) 3 (3)
>2 Colleagues n=97 58 (60) 23 (24) 10 (10) 6 (6)
Chi-Square test P = 0.631
Full-time employment n=81 52 (64) 18 (22) 6 (7) 5 (6)
< Full-time employment n=106 67 (63) 24 (23) 11 (10) 4 (4)
Chi-Square test P = 0.800
Sector of occupation
Industry n=42 27 (64) 6 (14) 5 (12) 4 (10)
Health/wellbeing n=42 19 (45) 18 (43) 4 (10) 1 (2)
Public n=5 5 0 0 0
Education n=14 7 (50) 4 (29) 2 (14) 1 (7)
Commercial n=45 34 (18) 8 (76) 2 (4) 1 (2)
Others n=37 25 (67) 6 (16) 4 (11) 2 (5)
Chi-Square test P = 0.107
a Includes colleagues taking over in work in normal hours or the employee itself compensates missed 
work after returning to work, b Includes colleagues taking over work in extra hours or the employee 
compensates missed work in extra hours or extra workers are hired
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proportion of respondents regularly or often facing complex problems in their 
occupation reported that their missed work was compensated in extra hours 
compared with respondents seldom facing such problems (Chi-square, P = 
0.040). Respondents in executive functions more often reported that missed 
work was not compensated or that they did not know how the work was com-
pensated. Moreover, a lower proportion of respondents in executive functions 
reported that missed work was compensated in extra hours (Chi-square, P = 
0.023).
Table 8.3 reports the outcomes of the binary logistic multivariable regres-
sion model investigating the association between compensation mechanisms, 
demographic characteristics and work related factors. It did not make a dif-
ference whether we only included variables in the model with a P-value of ≤ 
0.05 (or categorical variables with at least one level with a P-value of ≤ 0.05) or 
variables with P-value ≤ 0.10. As can be seen, work involving complex problems 
was associated with an increased likelihood of absenteeism being compen-
sated in extra hours (odds ratio 2.346). Similarly, diminished productivity was 
more often compensated in extra hours in jobs involving both physical and 
mental work compared with jobs with mainly mental tasks (odds ratio 4.073). 
The other way around, being in an executive function was associated with a 
lower likelihood of absenteeism being compensated in extra hours. 
Table 8.3 Logistic regression of compensation of lost work time and work-related factors (n = 178).
Odds ratio (95% CI) P-value
Constant 1.269 0.786
Executive function 0.393 (0.176 - 0.878) 0.23
Complex work 2.346 (1.018 – 5.405 0.045
Physical/ mental occupation
Mental Reference category
Physical 2.361 (0.830 – 6.718) 0.107
Mix 4.073 (1.429 – 11.604) 0.009
Income
High Reference category
Low 0.343 (0.067 – 1.753) 0.199
Intermediate 0.137 (0.031 – 0.617) 0.010
Unknown 0.142 (0.11 – 1.799) 0.132
Absence
> 7 days Reference category
One day 0.142 (0.011 – 1.799) 0.132
Two days 0.930 (0.337 – 2.564) 0.888
3-7 days 0.238 (0.074 – 0.765) 0.016
Hosmer & Lemeshow P = 0.463
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Different from the results of the Chi-square tests, the multivariable analysis 
did not expose a significant association between compensation in normal 
or extra hours and ‘needing special skills’. In the multivariable analysis, this 
relation may have been captured by the ‘complex work’ variable. Although, the 
correlation between ‘complex work’ and ‘needing special skills’ was low (Spear-
man’s rho 0.246) the correlation was significant (P = 0.001). Another difference 
was that both income and period of absenteeism now did turn out to be signifi-
cantly associated with compensation mechanisms. A higher income was asso-
ciated with higher levels of compensation in extra hours. Similarly, a period of 
absenteeism of more than one week was more likely to lead to compensation in 
extra hours, compared with shorter absenteeism. The multivariable model did 
not fail the Hosmer&Lemeshow test (P = 0.463), suggesting a good model fit.
The potential impact of compensation mechanisms and multiplier 
effects on productivity cost estimates
We investigated how adjusting for compensation mechanisms and the effects 
of absenteeism on team productivity potentially affect productivity costs 
estimates (separately and simultaneously). Again, respondents indicating not 
to know how their absenteeism was compensated were not included in the 
analyses. As shown in table 8.4, adjusting regular productivity cost estimates 
for either compensation mechanisms or multiplier effects leads to a substantial 
alteration of the total amount of calculated productivity costs. If productivity 
costs were only calculated for absenteeism compensated during extra hours or 
not compensated absenteeism, only 43 percent of the initial calculated produc-
tivity costs remained. Productivity cost estimates per patient were 1,100 euros 
lower in the compensation mechanisms scenario than in the regular scenario. 
Productivity cost estimates including multiplier effects were 28 percent higher 
than the regular estimates. I.e., the decreasing effect of including compensa-
tion mechanisms was approximately twice as strong as the increasing effect of 
Table 8.4 Six month Productivity costs based on 4 scenarios in 2009 euros (n=178)
Scenarios Six months friction costs 
Sum Mean SD a Difference (%)
1 Regular approach € 349,748 € 1,965 € 3,040
2 Compensation mechanisms € 152,116 € 855 € 2,507 -€ 1,110 (-57%)
3 Multiplier € 447,487 € 2,514 € 3,802 € 549 (+28%)
4 Multiplier and compensation 
mechanisms
€ 249,855 € 1,404 € 3,166 -€ 561 (-29%)
5 Multiplier and partial 
compensation mechanisms
€ 370,491 € 2,081 € 3,540 € 116 (+6%)
a SD = Standard deviation
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including multiplier effects. Accounting for both compensation mechanisms 
and multiplier effects resulted in productivity cost estimates 29 percent lower 
than common estimates. Again accounting for compensation mechanisms 
and multiplier effects, but assuming that, per hour, compensation in normal 
working hours involves half of the costs of compensation in extra hours and 
removing the 0.8 elasticity, resulted in a productivity costs estimate of 2081 
euros per patient. This approximates the baseline estimate of 1965 euros.
8.4 Discussion
The first aim of our study was to increase knowledge on how diminished 
productivity is compensated within firms. Over half of the respondents in the 
smoking cessation trial indicated that their absenteeism was compensated in 
normal working hours by either themselves or their colleagues. These findings 
are in line with the results from previous research by Severens et al. (17) and 
Jacob-Tacken et al. (18). The way lost work was compensated was associated with 
work type characteristics, such as being in an executive function, having a job 
that is both physically and mentally demanding, facing complex problems at 
work and needing special skills. The need of special skills and facing complex 
problems may increase the difficulty to postpone work and may decrease the 
possibility to work taken in over in normal hours by colleagues. A significant 
association between being in an executive function and compensation mecha-
nisms was previously seen in the research by Jacob-Tacken et al. (18). In (some) 
executive functions it might be possible to postpone work and additionally, it 
may be difficult to find substitutes.
If a large amount of absenteeism is indeed, as it seems, compensated dur-
ing normal working hours this raises the question of how such compensation 
would affect productivity cost estimates. Compensation during normal hours 
may be taken to suggest that normal productivity levels may be maintained or 
restored without resulting in productivity costs. If lost work time compensated 
in normal hours is kept out of productivity cost calculations it is indeed im-
plicitly assumed that such compensation is, in fact, ‘for free’. However, it seems 
unlikely that this assumption is correct. To clarify, if compensation in normal 
hours is possible due to the existence of an amount of internal labor slack, 
this implies that (some) firms may (deliberately) have more labor present to 
compensate reduced productivity in ill workers. This is obviously not costless. 
If internal labor slack is not present, compensating absenteeism in normal 
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hours probably involves putting extra strain on employees to maintain normal 
productive output. Such extra strain may also not be costless in an economic 
sense, as it may cause stress, may involve fewer breaks and may induce (work-
related) health problems potentially leading to new absenteeism or impaired 
functioning at work. In our fifth productivity cost scenario we arbitrarily as-
sumed these costs to approximate about half of the costs of compensation in 
extra ours, but at present, it seems unclear what the exact costs are of com-
pensation of lost work in normal hours. Hence, to use a zero cost estimate (i.e. 
keeping lost work time compensated in normal hours outside productivity cost 
calculations) seems a strong assumption. Clearly, the translation of compensa-
tion mechanisms into productivity cost estimates deserves more attention as 
it is not straightforward. 
Next to increasing knowledge on compensation mechanisms, the second 
aim of our study was to provide some insight on the (combined) potential 
impact of compensation mechanisms and so-called ‘multiplier effects’ (related 
to team dependency and problems with finding good substitutes in cases of 
absenteeism) on productivity cost estimates. The results indicated that con-
ventional friction cost estimates differ substantially from estimates adjusted 
for compensation mechanisms.
Compared with conventional estimates, 43% of productivity costs remained 
if assumed that compensation in normal working hours was costless. In the 
research of Jacob-Tacken et al. (18) this percentage ranged from 23 to 32%. These 
lower percentages are likely to be explained by differences in calculations. Our 
43% included compensation in extra hours and uncompensated absenteeism, 
whereas the percentages of Jacob-Tacken et al. (18) only included compensation 
in extra hours. Conventional estimates, moreover, differ substantially from 
estimates accounting for multiplier effects, or compensation and multiplier 
effects simultaneously. The diminishing effect of adjusting for compensation 
mechanisms (naively assuming compensation in normal hours is for free) 
on regular estimates seems stronger than the amplifying effect of applying 
multipliers. However, it is important to note that, although we simultaneously 
adjusted productivity costs estimates for compensation in normal hours and 
the effects of absenteeism on team output, the applied adjustment factors were 
originally not simultaneously assessed. In reality, compensation mechanisms 
and team dependencies are likely to interact with each other. In some profes-
sions team work may increase the opportunity that work is compensated by 
colleagues in normal hours, however, at the same time such compensation may 
jeopardize the team’s future health and productive output. To study potential 
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interaction between compensation mechanisms and team dependencies it 
would be worthwhile to investigate these effects on productive output within 
one study sample, ideally in a context with objectively measurable costs and 
output of teams and individuals. This could demonstrate the influence of both 
team effects and compensation mechanisms, also in the context of different 
job types etc., more clearly. Potentially, (context specific) average multiplier ef-
fects and compensation effects could be estimated for use in future economic 
evaluations. 
It is important to acknowledge the impact of some (implicit) assumptions 
on our results. For instance, within the friction cost approach it is common 
to apply an elasticity factor of 0.8 between working time and productivity, as 
was done here in the first four scenarios. The 0.8 elasticity was first applied by 
Koopmanschap et al. (56), as a general correction factor for the notion that a 
reduction of labor time causes a less than proportional decrease in productiv-
ity. However, it remains unclear what this 0.8 elasticity exactly represents, i.e. 
which mechanisms underlie it. To some extent this elasticity may for instance 
already embody internal labor slack and compensation of lost work during 
normal working hours. If this is the case, then correcting for compensation 
mechanisms on top of the general correction factor of 0.8 used in the friction 
cost approach may be considered a ‘double correction’ and, subsequently, 
will lead to too low productivity cost estimates. If considering adjusting 
productivity cost estimates for compensation mechanisms within the fric-
tion cost approach it may seem reasonable to not additionally apply the 0.8 
elasticity factor. As shown in scenario 5, if the elasticity factor is not applied, 
and it is assumed that compensation in normal hours is not without costs, 
but amounts to half of the costs of compensation in extra hours, productivity 
cost estimates including multipliers approximate the baseline estimate of sce-
nario 1. Although more research is needed to further investigate compensation 
mechanisms, multiplier effects and the costs of compensation, the standard 
productivity costs estimates (scenario 1, using a general 0.8 correction factor) 
may therefore be considered a reasonable base case, in which multiplier effects 
as well as compensation mechanisms are included. 
While our study was mainly intended to increase the knowledge on compen-
sation mechanisms and to demonstrate the potential impact of compensation 
mechanisms and multiplier effects on productivity cost estimates, it suffered 
from some important limitations. First, our sample size was relatively small. 
Although 1266 people were included in the smoking cessation trial, only 187 
were in paid profession and had experienced absenteeism during the previ-
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ous six months. Second, we used a convenient sample existing of smokers 
willing to quit instead of a general public sample. The results may, therefore, 
not be fully generalizable. Third, compensation mechanisms were based on 
self-reporting data among employees who had experienced the absenteeism 
themselves. In some cases, employers or colleagues may have better insight in 
how work was compensated during the employees’ absenteeism. Fourth, the 
multiplier effects applied were extracted from previous research (15). In half of 
the cases we needed to apply the median multiplier of 1.28 presented in the 
paper by Nicholson et al. (15) because the professions of our respondents did 
not match the professions presented in their empirical work. Moreover, the 
original multipliers were collected in the United States and therefore may not 
be directly transferable to the Dutch occupational situation (for an extensive 
discussion on transferability issues, see (265)). Since Dutch estimates of multipli-
ers are lacking, we took the US figures as the best available estimates. Fifth, 
we only focused on absenteeism. Compensation mechanisms and multiplier 
effects are, however, potentially equally important in diminished functioning 
at work due to health problems (i.e. presenteeism).
Despite these limitations, our research indicates that both multiplier ef-
fects and compensation mechanisms are important to consider in the area of 
productivity cost research. This study was the first to simultaneously explore 
these effects. How to exactly consider compensation mechanisms and multi-
plier effects concurrently in future research remains uncertain. Nevertheless, 
adjusting productivity cost estimates for compensation mechanisms while 
ignoring the effects of ill health on team output, or the other way around, may 
potentially lead to incorrectly low or high productivity cost estimates and may 
therefore not be advisable. Although our research (and the previous research 
by Severens et al. (17) and Jacob-Tacken et al. (18)) implies that over half of the lost 
work is compensated in normal working hours, the actual effects on produc-
tive output and related productivity costs are unknown. Moreover, the pres-
ence of team dependencies and the subsequent tangible productivity costs are 
equally underexplored. Therefore, further research to increase insight in these 
processes is critical before considering adopting adjustments for compensa-
tion mechanisms and multiplier effects as common standard. 

9. 
Predicting productivity costs based on 
EQ-5D: 
An explorative study
Based on: Krol M, Stolk E, Brouwer W. 
Productivity costs predictions based on EQ-5D: an explorative study. 
Submitted paper.
184
 
Summary
Background: Productivity costs are often ignored in economic evaluations. In 
order to facilitate productivity costs inclusion it has been suggested to estimate 
productivity costs indirectly using quality of life data. Objective: This study 
aimed to derive and validate an algorithm for predicting productivity on the 
basis of quality of life data using the EQ-5D-3L. Methods: A large representative 
sample of the Dutch general public (n = 1,100) was asked in a web-based ques-
tionnaire to state their expected level of productivity in terms of absenteeism 
and presenteeism for multiple EQ-5D health states. Based on these data, two 
generalized estimating equations (GEE) prediction models were constructed: i) a 
model predicting levels of absenteeism and ii) a model predicting presenteeism. 
The models were validated by comparing model predictions with convention-
ally measured productivity within a group of low back pain patients. Results: 
Predicted absenteeism levels based on EQ-5D health state closely resembled 
conventionally measured absenteeism levels. Productivity losses related to pre-
senteeism seemed somewhat overestimated by our prediction model. Measured 
and predicted productivity were moderately but highly significantly correlated. 
Conclusions: Overall, it appears possible to make reasonable productivity pre-
dictions based on EQ-5D data. Further exploration and validation of prediction 
algorithms remains necessary, however, especially for presenteeism. 
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9.1 Introduction
Economic evaluations are increasingly used to assist national decision mak-
ers in selecting which new and established medical technologies should be 
included in national health care benefit packages. In an economic evaluation 
an intervention is compared to one or more alternatives in terms of costs and 
(health) effects. Which costs (and effects) are to be included in the evaluation 
depends on the perspective from which economic evaluations are performed.
Both in terms of theory and practice, there is dissensus regarding the ap-
propriate perspective from which to perform economic evaluations. These 
opposing viewpoints appear to be related to different assumptions regarding 
the decision making context in which the results of economic evaluations need 
to be used (e.g. (33)). Broadly speaking, two dominant perspectives can be dis-
tinguished: (i) a health care perspective, which reflects the notion that health 
economic evaluations aim to inform health care decision makers (allocating 
some –fixed – health care budget), and (ii) a societal perspective, reflecting the 
notion that the underlying aim of the decision maker informed by economic 
evaluations is to improve social welfare. Here, we will not revisit this discus-
sion, but merely take the viewpoint that from a conventional welfare-economic 
view the societal perspective can be considered and commonly is considered 
(e.g. (2)) an appropriate viewpoint since only by including all relevant societal 
costs and effects optimal (that is welfare improving) societal decision-making 
is possible (34). If one adopts this viewpoint, this implies that all relevant effects 
and costs, also those falling outside the health care sector (and thus may be 
deemed irrelevant when taking a health care perspective) should be included 
in the evaluation, in principle. This obviously expands the scope of economic 
evaluations. In practice, it regularly proves difficult to adopt such a societal 
perspective and adequately include all relevant costs in an evaluation. 
One cost category that is sometimes difficult to include is that of productivity 
costs, which can be defined as “costs associated with production loss and replace-
ment costs due to illness, disability and death of productive persons, both paid and 
unpaid.” (8) Despite the societal importance of unpaid production loss, in this 
chapter, we focus on productivity costs related to paid profession. Productivity 
costs are frequently neglected in economic evaluations, also by those claiming 
to take a societal perspective (10,44). If included, however, productivity costs often 
reflect a large part of total costs in the evaluation and can have a strong impact 
on cost-effectiveness outcomes (9,42,44). This makes the neglect of productivity 
costs in a majority of economic evaluations particularly worrisome.
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The neglect of productivity costs in economic evaluations may partly be 
related to concerns regarding the equity implications of including productivity 
costs. Indeed, inclusion of such costs may have distributional consequences. 
For instance, it can lead to more favorable cost-effectiveness results in persons 
with a paid job than in those without paid work. It is questionable whether 
distributing health care accordingly will be in line with societal preferences. (13) 
However, while such concerns must be addressed, it must be noted that inclu-
sion of productivity costs can also result in more favorable results in patients 
without paid work (e.g. if the treatment itself causes absenteeism) (44) and that 
fully ignoring these real societal costs as a response to potential conflicts be-
tween efficiency and equity seems hard to defend as well.
Another reason why productivity costs may be neglected in economic 
evaluations claiming to adopt a societal perspective may be the time and effort 
needed to collect the data required to calculate productivity costs. Collect-
ing the appropriate data involves asking patients a broad range of questions 
regarding their employment status. Additionally it is necessary to repeatedly 
ask patients about their attendance at work and their level of functioning while 
being at work. Besides, it may not always be possible to collect necessary data 
regarding patients’ productivity. For instance, when working with retrospective 
data, or when data collection is bounded to information available in medical 
files productivity data is commonly unavailable. Moreover, at this moment, 
there is no scientific consensus on how to identify, measure and value produc-
tivity losses and gains, which may make researchers reluctant to collect data 
(11,51,233).
In order to facilitate the inclusion of productivity costs and thus reducing the 
neglect of these important costs in economic evaluations that wish to adopt a 
societal perspective, also in cases where primary data collection is difficult, it 
has been suggested to create prediction models capable of predicting produc-
tivity costs based on patient characteristics such as age, sex and quality of life 
data (20). Previous research indeed has shown that productivity is significantly 
correlated with levels of quality of life (19), but prediction models have not yet 
been created, to our knowledge. These models would facilitate inclusion of pro-
ductivity costs on the basis of typically easily available information. Although 
using such models may be perceived to be a second best option compared to 
the collection of actual data on productivity, including a reasonable estimate 
of productivity costs seems preferable to neglecting these costs and, therefore, 
implicitly estimating them to be zero, as has also been argued in the context 
of other societal costs (266). This point seems especially valid for productivity 
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costs, since these can have such a profound effect on the results of economic 
evaluations (and therefore decision making). Obviously, the desirability of us-
ing predicted productivity costs rather than excluding these costs also depends 
on the accuracy of such predictions. 
Creating a prediction model requires establishing a link between productivity 
(involving absenteeism and reduced productivity at work, commonly labeled 
‘presenteeism’) and quality of life. Establishing such a link is not straightfor-
ward. It has been previously attempted by combining existing patient data on 
quality of life and productivity (19). However, it turned out to be difficult to create 
a prediction model with the available data due to limited sample size; difficulty 
in linking observed productivity to disease stage and a lack of variety in health 
states in terms of quality of life. A possible way of establishing the link between 
productivity and quality of life more directly is to ask individuals to state to 
what extent they expect to be productive in different health states, described 
with some generic quality of life measure. This has as advantage that it allows 
including a wider range of health states in terms of quality of life and therefore 
a better analysis of the statistical link between health state and productivity 
than commonly would be the case with data including information on actual 
absenteeism, presenteeism and quality of life. Notably, such an approach does 
require a more elaborate validation of the prediction model, since there may 
be discrepancies between expected and actual absenteeism and presenteeism. 
This chapter presents the results of a study exploring the possibility to predict 
patients’ productivity based on the three level version of the EuroQol’s EQ-5D 
(24). The EQ-5D is a descriptive system with five dimensions and three levels per 
dimension, summing up to a total of 243 unique health states. Health states are 
expressed in five-digit codes. For example, 22311 describes the following state: 
Some problems with walking about, some problems with washing and dress-
ing, unable to perform usual activities, no pain or discomfort and no anxiety 
or depression. In order to facilitate creating a productivity prediction model, 
a large sample of the general public was asked to state their expected level of 
productivity (in terms of both absenteeism and diminished functioning while 
attending work) for multiple EQ-5D health states. Based on these data, two 
models were constructed: i) a model predicting levels of absenteeism and ii) a 
model predicting presenteeism. Subsequently, these two models were validated 
by comparing model predictions with conventionally measured productivity 
within a group of low back pain patients, demonstrating the predictions to be 
reasonably close to actual losses.
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9.2 Methods
Data collection
Respondents
To establish a link between productivity and EQ-5D health states we collected 
data on expected productivity through an online survey among a large sample 
of the Dutch general public. Invitations were sent out to potential respondents 
to obtain a representative sample of 1,000 members of the Dutch general pub-
lic in paid profession aged between 18 and 65.
Questionnaire
The questionnaire was designed for self-completion. Respondents were first 
asked some general back ground characteristics such as age, sex, education 
and their self-assessed health today by means of the EQ-5D (3 level version). 
Subsequently, respondents were presented with 16 distinct EQ-5D health 
states. For each of these states respondents were asked to indicate whether 
they expected to be present at work (absenteeism), and if so, how they would 
expect to function while attending work in terms of productivity (presentee-
ism). Productivity loss at work was assessed using the quantity scale of the QQ-
method. The QQ-method is an instrument developed to quantify productivity 
loss related to presenteeism (48). Respondents in our study were asked to state 
the quantity of production on a ten-point scale, where ‘0’ represented not 
able to do any work and ‘10’ represented being able to do the same amount of 
work as usual. Respondents not showing any variation in the responses in the 
absenteeism and presenteeism questions were excluded from further analyses.
In total, 96 EQ-5D health states out of the 243 possible states were included 
in our study. Health states were selected based on orthogonal design. An or-
thogonal array of strength 3 provided 54 different combinations of domains 
and levels (267). We used two generators to create two additional orthogonal sets 
of 54 health states. Subsequently, we removed implausible states (26), and we 
removed doubles. The 96 remaining EQ-5D states were divided into 6 subsets 
(See appendix 9A) of 16 EQ-5D states by means of block design in order to have 
an optimal variety of health states within these subsets. Respondents to the 
questionnaire were randomly assigned one of these six subsets. Health states 
within these subsets were presented to the respondent in a random order. With 
a sample of 1000 respondents, this would result in approximately 160 observa-
tions per each of the 96 health states.
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Data analysis
Model construction
Based on the respondents’ expected productivity in the EQ-5D states, two 
prediction models were constructed (one for absenteeism and one for presen-
teeism). For this purpose generalized equation estimations (GEE) were used. 
GEE are appropriate for analyzing correlated response data (which in this case 
refers to the 16 productivity estimates made by each individual respondent). 
Respondents were numbered to be included as subject variable to account for 
within-subject correlation. Since the 16 EQ-5D states were presented to the 
respondents randomly, an exchangeable working correlation matrix structure 
was specified. This structure assumes homogenous within-subject correlation 
between the 16 productivity estimates. 
GEE models 
Given the binomial outcome of the absenteeism question, a GEE binary logis-
tic regression was applied to create the absenteeism model. The dependent 
variable in the absenteeism model was the dichotomous variable ‘expected to 
present work in presented EQ-5D state’. Independent variables included were 
respondents’ age and dummy variables for sex (males labeled ‘1’ and females 
‘0’) and the domain levels of the EQ-5D states. Other (work-related) covariates 
were not included, since this study aimed to explore the possibilities to estimate 
productivity effects in absence on data on absenteeism and presenteeism. We 
assumed that in cases where data on absenteeism and presenteeism is lacking, 
other work related information will also be unavailable.
The absenteeism model is expressed in equation 1 where y is the logit of the 
probability of attending work. Mob2 represents a level 2 score on the EQ-5D 
mobility domain and mob3 a level 3 score on mobility. Likewise, sc2 and sc3 
represent self-care domains, levels 2 and 3, respectively and da2 and da3 daily 
activities level 2 and 3 and so on. By means of equation 2 the probability P of 
attending work in a specific EQ-5D health state is calculated. Xβ denotes the 
linear combination of regression coefficients and covariates for each EQ-5D 
health state.
Equation 9.1 Absenteeism model
Y = β0 + β1 * mob2 + β2 * mob3 + β3 * sc2 + β4 * sc3 + β5 * da2 + β6 * da3 + β7 * pain2 + β8 
* pain3 + β9 * mood2 + β10 * mood3 + β11 * age + β12* male
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Equation 9.2 Probability of attending work
P =
exβ
exβ + 1
Equation 3 represents the presenteeism prediction model. A negative binomial 
distribution with a log link demonstrated to be the best fit model, based on 
the Quasi Likelihood under Independence Model Criterion and the Cor-
rected Quasi Likelihood under Independence Model Criterion. The dependent 
variable in the presenteeism model was the expected level of functioning Elf 
(ranging from zero and ten) in the given health states, when at work. Similar 
to the absenteeism model the following independent variables were included: 
respondents’ age, sex and dummy variables for the domain levels of the EQ-5D 
states.
Equation 9.3 Presenteeism model
Elf = ln
-1[β0 + β1 * mob2 + β2 * mob3 + β3 * sc2 + β4 * sc3 + β5 * da2 + β6 * da3 + β7 * pain2 
+ β8 * pain3 + β9 * mood2 + β10 * mood3 + β11 * age + β12* male]
Equation 4 combines the absenteeism and presenteeism prediction model 
into one predicted productivity measure (expected productivity in a EQ-5D 
state: Epr) by multiplying the probability of attending work (P) by the expected 
level of functioning while attending work Elf. Outcomes are divided by 10 to 
arrive at a 0 to 1 scale, where ‘0’ illustrates zero productivity and ‘1’ normal 
productivity (i.e. no absenteeism and no presenteeism).
Equation 9.4 Expected productivity level
Epr = 
P ⋅ Eif
10
Data analysis was conducted in SPSS 18.0, Chicago, Illinois.
Validation
Internal validity
Internal validity of the absenteeism and presenteeism models was tested in 
several ways. First, it was examined whether the EQ-5D model parameters 
pointed in the right direction; i.e. a level two or three on the EQ-5D domains 
was expected to have a diminishing effect on the probability to attend work 
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and on the level of functioning if attending work. Moreover, a level three score 
was expected to have a stronger negative effect than a level two score.
Subsequently, productivity levels were estimated for an average aged worker 
for all possible EQ-5D states based on the models’ parameters. For illustrative 
purposes we chose this to be a 40 year old male, since in the Netherlands, 
males fulfill a larger fraction of paid productivity than females. The absentee-
ism model outcomes were presumed to cover the full range of probabilities, 
e.g. health state 11111 was hypothesized to have a probability of (almost) one 
of attending work and for health state 33333 this probability was hypothesized 
to be (almost) zero. The presenteeism model outcomes range was expected to 
start at 1 (normal functioning in 11111). However, it was not expected to range 
to zero, since in case of almost zero productivity, it is unlikely that people are 
still at work (and as long as they can get to work, their productivity is unlikely 
to be zero). 
To test how well the constructed models predict within sample, we used the 
models to predict the sample populations estimated absenteeism, presentee-
ism and productivity levels in the given EQ-5D states. We subsequently calcu-
lated the Mean Absolute Error.
External validity
External validity was assessed on the predictive validity of the two models. It 
was evaluated through how well the models were able to predict productivity 
levels measured with a commonly used instrument in economic evaluations. 
In order to do so, conventionally measured absenteeism by means of the in the 
Netherlands quite often applied Health and Labor Questionnaire (HLQ) (84) was 
compared with predicted absenteeism based on EQ-5D health state. Similarly, 
measured presenteeism by means of the quantity scale of the QQ method, 
where ‘0’ represented not able to do any work and ‘10’ represented being able 
to do the same amount of work as usual (48) was compared with predicted 
presenteeism Moreover, the association between conventionally measured 
and predicted productivity was assessed by means of correlation coefficients. 
Given the skewed nature of productivity outcome measures (e.g. many indi-
viduals experience little to no absenteeism and few have very high levels of 
absenteeism), correlation was examined non-parametrically by determining 
Spearman’s rank correlation coefficients and their 95% Bootstrap confidence 
intervals.
The external validity data set consisted of data of 500 patients’ with low back 
pain included in a clustered randomized controlled trial to test the effects of an 
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active implementation strategy for the Dutch physiotherapy guideline for low 
back pain. Details of this study and the piggy-back economic evaluation can 
be found elsewhere (268,269). Patients were included in the study before receiving 
physiotherapy for their low back pain. Patients’ were requested to complete 
a questionnaire at baseline, and at 6, 12, 26 and 52 weeks follow-up. Among 
other things, the questionnaire included questions on the patients’ quality of 
life (measured through the EQ-5D) and on productivity. Absenteeism was mea-
sured using the Health and Labor Questionnaire (84) and included questions on 
attendance at work during the last 14 days. Presenteeism was measured by 
means of the Quality and Quantity method (48). Patients were asked to state how 
much work they were able to perform on their last day of work, as compared 
with their normal functioning, and how they rated the quality of their work on 
that day. For our study we only included data of the quantity question.
A disadvantage of the validation dataset was that patients’ stated EQ-5D 
reflected their quality of life on the day they completed the questionnaire, 
while the productivity questions related to their productivity during the last 
two weeks. Although the patients’ EQ-5D on the day of the questionnaire does 
not necessarily reflect their quality of life during the last two weeks, we had 
to assume it was the same during the previous two weeks in order to test our 
prediction models. For this reason, baseline data seemed most appropriate; 
patients had not received treatment yet and the vast majority (91%) stated to 
suffer from low back pain for longer than one week. In the baseline data pa-
tients’ EQ-5D would have been more likely to be constant during the preceding 
period than in the data collected during and after treatment.
Low back pain patients in the external validation data set were included if 
they were in paid profession and data was available on their age, sex, EQ-5D at 
baseline and their productivity during the past two weeks. Patients’ productiv-
ity levels were constructed from the data in the following manner. Data was 
available on the number of days a week normally worked and the days absent 
during the last two weeks. Based on these numbers the percentage work at-
tendance during the past two weeks compared to normal was calculated. This 
calculated percentage served as a proxy for the probability of attending work 
in the patients’ EQ-5D states. Presenteeism was based on patients’ stated 
quantitative level of functioning (compared with patients’ normal functioning) 
during the last working day.
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9.3 Results
Respondents
In total, 1,100 respondents completed the online questionnaire. 87 of these 
respondents were excluded from further analysis since they seemed insensi-
tive to variation in the presented health states; 33 respondents stated to attend 
work in any given health state and 54 respondents stated always to call in sick. 
Excluded respondents did not differ from the not excluded respondents in 
terms of age, sex, education and income.
As seen in Table 9.1, the respondents were in good health on average. Most 
of them were married or living together, had a medium level of education and 
were in paid employment. A small minority was self-employed.
Prediction models
The absenteeism analysis was based on 16,208 estimations of respondents 
on whether they would expect to be able to attend work in the presented EQ-
5D health states; i.e. this resulted in over 160 estimations for each of the 96 
included EQ-5D health states. In 5,803 of these cases respondents expected 
to attend work and were subsequently asked how they expected to function 
while attending work as compared to their normal functioning. Table 9.2 shows 
the output of both GEE models expressed in equation 1 and the presenteeism 
prediction model expressed in equation 3. Sex proved insignificant in the ab-
senteeism analysis and was therefore not included in this model. Likewise, age 
Table 9.1 characteristics of respondents to the online questionnaire
Respondents’ characteristics n =1013
Age (SD) 41.6 (12.40)
Females (%) 502 (49.6)
EQ-5D score (SD) 0.92 (0.14)
Education 
 Lower (%) 117 (11.5)
 Medium (%) 575 (56.8)
 Higher (%) 321 (31.7)
Marital status
 Single (%) 158 (15.6)
 Married/living together (%) 728 (71.8)
 Divorced (%) 89 (8.8)
 Widow/widower (%) 11 (1.1)
 Other (%) 27 (2.7)
Work
 In paid employment (%) 931 (91.9)
 Self-employed (%) 82 (8.1)
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was not significantly associated with productivity in the presenteeism analysis 
and excluded accordingly. 
Validity
Internal validity
Internal validity of both the absenteeism and the presenteeism model appeared 
satisfactory. All EQ-5D parameters were highly significant in the GEE models 
and all pointed in the expected (negative) direction. Moreover, all level 3 scores 
had a stronger negative effect on outcomes than level 2 scores. A level 3 score 
in the domain mobility was the most influential parameter in both models. The 
probability of attending work in a given health state was negatively affected by 
age. This indicates, all other things equal, older persons would be more likely to 
call in sick in a specific health state. However, when at work, age did not seem 
to affect (expected) functioning. Females expected to be less productive than 
males did when being at work while ill. 
To further explore internal validity we compared the models’ estimated 
productivity levels for all EQ-5D states for a 40 year old male with our prior 
expectations (the full list of estimates can be found in appendix 9B). Different 
from our expectations, the productivity in health state 11111 (full health) did 
not equal 1. The probability to attend work in ‘full health’ was 0.89 and level of 
functioning while attending work was estimated to be 7.9. The ‘level of func-
tioning scale’ ranged from 7.9 to 3.7. As hypothesized, the scale did not end at 
‘0’, since it would be unlikely that fully unproductive persons would be present 
Table 9.2 GEE Models
Absenteeism n = 16,208 Presenteeism n = 5,803
Variable Coefficient
95% confidence 
interval
SE P-value Coefficient
95% confidence 
interval
SE P-value
Lower 
limit
Upper 
Limit
Lower 
limit
Upper 
Limit
Intercept 2.414 2.087 2,741 .167 <.001 2.029 2.005 2.053 .012 <.001
Mobility 2 -.264 -.341 -,188 .039 <.001 -.045 -.057 -.033 .006 <.001
Mobility 3 -2.054 -2.217 -1,891 .083 <.001 -.179 -.215 -.144 .018 <.001
Self-care 2 -.316 -.405 -,227 .045 <.001 -.034 -.050 -.019 .008 <.001
Self-care 3 -1.193 -1.314 -1,072 .062 <.001 -.096 -.118 -.074 .011 <.001
Daily activities 2 -.395 -.495 -,296 .051 <.001 -.063 -.078 -.048 .008 <.001
Daily activities 3 -1.761 -1.889 -1,633 .066 <.001 -.173 -.194 -.151 .011 <.001
Pain 2 -.360 -.452 -,267 .047 <.001 -.065 -.081 -.050 .008 <.001
Pain 3 -1.740 -1.875 -1,604 .069 <.001 -.178 -.202 -.154 .012 <.001
Mood 2 -.229 -.322 -,136 .048 <.001 -.068 -.083 -.053 .008 <.001
Mood 3 -.942 -1.047 -,836 .054 <.001 -.135 -.153 -.117 .009 <.001
Age -.009 -.016 -,003 .003 .006
Male .037 .010 .064 .0137 .006
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at work. The highest point of the scale did not equal ‘10’. The probability of 
attending work in state 33333 was, as one would expect, 0.00. 
We found no straightforward relationship between utility score and produc-
tivity. To illustrate, state 31311 has a Dutch national tariff value of 0.477 and 
an estimated productivity level of 0.08, whereas state 22123 has a tariff value 
of 0.166 yet an estimated productivity level of 0.32. Different levels of the EQ-
5D domains impact quality of life differently than they impact productivity. 
Impaired mobility and not being able to perform daily activities have a rela-
tively strong impact on expected productivity, whereas the impact of anxiety or 
depression on expected productivity is much smaller.
The mean absolute error comparing the respondents expected absenteeism, 
presenteeism and subsequent total productivity with the models predictions 
was low, (respectively 0.05, 0.32 and 0.03) indicating a good within sample 
prediction.
External validity
In order to examine external validity we investigated how well our prediction 
models predicted productivity levels in an external data set concerning a group 
of patients suffering from low back pain (269). Data on productivity was available 
of 341 patients and included information on absenteeism, productivity on the 
last day at work and quality of life as measured using the EQ-5D. Characteris-
tics of these patients are presented in table 9.3. Average age was approximately 
40 years, their average Dutch national tariff EQ-5D score was 0.71 and most 
respondents suffered from low back pain for more than 1 month.
Based on the patients reported EQ-5D scores for each dimensions and their 
age and sex, we predicted the population’s probability of attending work and 
their level of functioning if attending work with our two models. We tested 
whether our models’ predictions were significantly associated with the con-
ventionally measured productivity levels in the low back pain patients. As can 
be seen in table 9.4, the correlation coefficient between measured productivity 
by means of the HLQ and predicted productivity was significantly different 
from zero (all P-values < 0.001). Attending work and total productivity were 
moderately correlated (between 0.3 and 0.5) and the ‘functioning when attend-
ing work’ correlation was low (< 0.3). 
We subsequently compared the model predictions with the patients reported 
absenteeism during the last two weeks and their reported level of function-
ing on their last working day. Additionally, we compared the conventionally 
measured productivity levels with the predicted levels (calculated by means 
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of equation 4). In figures 9.1, 9.2 and 9.3 the measured and predicted levels of 
attending work in a particular EQ-5D state were plotted against each other. 
Within these figures distinction is made between EQ-5D states with 10 or more 
observations, EQ-5D states with 3 to 10 observations and EQ-5D states with 
only one or two observations. The diagonal illustrates the ‘perfect fit line’ 
between observed and predicted productivity. As figure 9.1 illustrates, when 
there are more observations per state, on average, predicted absenteeism 
seems reasonably comparable to measured absenteeism. However, when there 
are only a few observations, predicted and measured absenteeism differ more.
Notably, the measured percentage of attending work of the low back pain 
patients’ stating to be in health state 11111 (i.e. full health) was 0.87 (similarly 
as the predicted percentage of attendance in full health) and not one. The aver-
age measured percentage of attending work of the low back pain patients was 
0.74 (95% confidence interval 0.70-0.78). The mean predicted probability of 
attending work was 0.71 (95% confidence interval 0.69-0.73). Our model only 
slightly overestimated absenteeism levels for the low back pain patients.
Table 9.3 Characteristics low back pain patients
Characteristic n = 341
Age (SD) 39.9 (10.6)
Females (%) 154 (45)
Education 
 Lower (%) 11 (3)
 Medium (%) 201 (59)
 Higher (%) 128 (38)
 EQ-5D score (SD) 0.71 (0.2)
Duration of complaints
 < 7 days (%) 30 (9)
 1 to 4 weeks (%) 87 (26)
 1 to 6 months (%) 139 (41)
 > 6 months (%) 81 (24)
 Cannot recall (%) 4 (1)
Working hours a week (SD) 32.0 (11.0)
Absenteeism (%) 149 (44)
Level of functioning last working day (SD) 7.5 (2.7)
Table 9.4 Correlation between measured and predicted productivity 
R Bootstrapped 95% confidence interval P-value
Lower limit Upper limit
Attending work 0.351 0.252 0.444 < 0.001
Functioning at work 0.257 0.154 0.363 < 0.001
Total productivity 0.375 0.276 0.469 < 0.001
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The average measured level of functioning when attending work was 0.75 
(95% confidence interval 0.72-0.78) and the average predicted level of func-
tioning was 0.66 (95% confidence interval (0.66-0.67). As can also be seen in 
figure 9.2, our presenteeism prediction model overestimated production losses 
due to presenteeism. 
The combined average measured productivity level was 0.59 (95% confidence 
interval 0.56-0.63) and the average predicted productivity level for the low back 
pain patients was 0.48 (95% confidence interval 0.46-0.49). I.e., total productiv-
ity estimates based on our absenteeism and presenteeism model seemed to 
overestimate productivity loss with about 11% for this particular patient group. 
As can be seen in the figures 9.1, 9.2 and 9.3, the prediction models are not able 
to adequately predict productivity on an individual level.
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Figure 9.1 Measured versus predicted absenteeism in low back pain patients
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Figure 9.3 Measured versus predicted productivity in low back pain patients
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9.4 Discussion
This study explored whether (impaired) productivity, and subsequently pro-
ductivity costs, can be reasonably predicted based on patients’ EQ-5D health 
states. The results of this large web-based study among the Dutch general 
public seem promising. Measured and predicted productivity were moderately 
(but highly significantly) correlated. Predicted absenteeism levels based on 
EQ-5D health state on average closely resembled conventionally measured ab-
senteeism levels for a group of low back pain patients. Note that absenteeism 
normally induces the major part of total productivity costs and, in that sense, 
this finding is encouraging. Productivity losses related to presenteeism, and 
consequently total productivity losses, seemed to be somewhat overestimated 
by our prediction model. 
A surprising finding was that respondents to the online survey as well the low 
back pain patients indicated that in full health (11111) they (would) function 
less than normal. This may be explained by several reasons: i) respondents are 
known to suffer from end-aversion bias (109), ii) respondents may have inter-
preted a ‘10’ as optimal rather than as normal functioning, iii) the low back 
pain patients in health state 11111 may have had other (non-health) reasons 
for functioning less than normal and iv) state 11111 may leave room for mild 
problems not necessitating moving to level 2 on any domain, yet somewhat 
limiting functioning.
Limitations
Some limitations of our study need noting. A first obvious limitation of our 
study was that we based the prediction models on hypothetical estimates in-
stead of actual absenteeism and presenteeism. Respondents to our survey were 
asked whether they expected to attend work in a given EQ-5D state and, if so, 
how they expected to function. Such a task might be experienced as quite dif-
ficult, especially given the rather abstract nature of EQ-5D state descriptions. 
Second, our prediction model for presenteeism seemed less accurate than the 
absenteeism model. Predicted productivity loss related to presenteeism was 
approximately 9% higher than measured productivity loss. Respondents of 
the general public may overestimate the effects of ill-health on productivity, 
perhaps due to underestimation of coping strategies and adaptation. In that 
sense, there is an analogy with the common observation that the general public 
values health state lower, on average, than patients do (270). A related explana-
tion might be the nature of the QQ-scale we used to measure presenteeism. 
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Respondents in our survey as well as in the study of low back pain were asked 
to compare their (expected) level of functioning with their normal functioning. 
If people with low back pain have a lower reference point for ‘normal function-
ing’, this may lead to relatively high levels of indicated productivity, whereas 
the scores would be relatively low for healthier individuals. 
How the model’s overestimation of productivity losses related to presentee-
ism would affect subsequent cost-effectiveness outcomes is unclear. In that 
way, two aspects are important to consider. First, the overestimation of the 
model was determined by comparing predicted outcomes with measured 
outcomes by means of self-assessment. Obviously, such measured outcomes 
will be surrounded with uncertainty. 
Second, within an economic evaluation the overestimation of productivity 
losses using the prediction model would affect both the estimated productivity 
changes in the intervention and the control group. As a result, predicted incre-
mental changes are a combination of the production losses in both arms with 
less predictable outcomes. This may mitigate the effect of the overestimation 
in certain cases, where the losses in both arms are overestimated.
An additional limitation of our study was that we only compared our models’ 
productivity estimates with productivity measured with the HLQ (84) and the 
QQ-method (48). Productivity cost calculations based on different measurement 
instruments sometimes differ substantial (83). It is unclear how our model esti-
mates relate to productivity measured with other instruments. 
Implications
The findings of our study indicate that the absenteeism prediction model 
produces reasonable estimates based on comparing predicted absenteeism 
with measured absenteeism by means of the HLQ. If this finding proves gener-
alizable, using these estimates may be preferred over the common alternative 
of using zero estimates when direct measurement of productivity is, for some 
reason, not possible. Since our presenteeism model seems to lead to an over-
estimation of productivity losses additional research is needed to investigate 
whether a different study design, preferably using actual data on presenteeism 
and EQ-5D health states, would lead to more accurate estimates.
It is important to note that our models are neither intended nor appropri-
ate for individual productivity predictions. Productivity and quality of life are 
(evidently) not perfectly correlated. Productivity losses for instance also partly 
depend on job characteristics and personality. Our models are based on gen-
eral public estimations with respondents in a large variety of professions and 
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consequently, these models maybe less appropriate for productivity predic-
tions for more homogeneous groups (e.g. groups in similar professions when 
evaluating some firm-based intervention). 
Although the productivity prediction models we constructed could be used 
to provide rough estimates of absenteeism and presenteeism in cases where 
EQ-5D data is available, but direct productivity measurement is impossible, 
translating productivity estimates into productivity cost estimates may not 
be easy, also given the valuation approach applied. When applying the hu-
man capital approach (88) it is sufficient to have information on age, sex and 
total productivity levels during the time period of interest. Subsequently, 
productivity estimates can be translated into costs based on national statistics 
regarding average age and sex dependent employment rates and average in-
come. However, calculating productivity costs when applying the friction cost 
approach would be more difficult, since this requires information on duration 
and frequency of individual absence periods (9,90). In the friction cost method 
productivity costs are calculated for every period of absenteeism, up to a cer-
tain limit (i.e. the friction period). Accordingly, additional assumptions need to 
be made if productivity costs are based on predicted absenteeism, especially 
regarding length and frequency of absenteeism. Such assumptions could be 
based on disease characteristics (and potentially disease models). 
It is important to investigate how productivity predictions can be best trans-
lated into productivity costs and subsequently to test the accuracy of such cost 
estimates. Moreover, given the promising results of this explorative study it 
would be worthwhile to conduct research aiming at constructing productivity 
prediction models based on actual rather than hypothetical productivity and 
to further test the validity of such models.
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9.5 Conclusions
Based on our findings, productivity estimates based on quality of life data 
seems of additional value as a second best solution if the first best solution 
of direct measurement is impossible. Although the constructed productivity 
prediction models presented in this chapter are not adequate nor intended for 
predictions on an individual level, they seem to provide relatively reasonable 
estimates on group level. If nothing else, this makes future research in this area 
appear worthwhile. These findings moreover imply that productivity estimates 
based on EQ-5D data may be an improvement over ignoring productivity costs, 
implicitly assuming these costs are zero. Reasonable estimates seem better 
than unreasonable neglect. 
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Appendices
9 A EQ-5D states stratified by group 
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
11133 11123 11113 11111 11221 12121
11233 11212 11231 11122 11311 12211
12123 12321 11312 11313 12312 12232
12323 12332 12112 11331 12333 12233
13232 13223 12313 11332 13213 13231
13311 21112 13312 13222 13322 21212
13313 21123 21332 13323 21121 21312
21233 21232 22111 21133 21211 22132
21311 21331 22122 22123 21323 22133
22223 23221 22232 22231 22222 22313
22311 23233 23213 23311 23231 22322
31121 23313 23321 31322 23332 22331
31231 31311 31232 32222 31223 23312
32231 32312 32321 33212 32121 31313
33211 33221 32331 33233 32213 32233
33312 33321 33333 33311 33232 32311
9 B Predicted productivity based on EQ-5D state for 40 year old males
EQ-5D state Dutch national tariff (115) Probability attending work Level of functioning attending work Total productivity
11111 1 0.89 7,9 0,7
11211 0.897 0.84 7,4 0,62
21111 0.893 0.86 7,6 0,65
21211 0.861 0.8 7,1 0,57
12111 0.847 0.85 7,6 0,65
11121 0.843 0.84 7,4 0,62
12211 0.815 0.79 7,2 0,57
22111 0.811 0.81 7,3 0,59
11221 0.811 0.79 6,9 0,55
21121 0.807 0.81 7,1 0,57
11112 0.805 0.86 7,4 0,64
22211 0.779 0.75 6,9 0,51
21221 0.775 0.74 6,6 0,49
11212 0.773 0.81 6,9 0,56
21112 0.769 0.83 7,1 0,58
12121 0.761 0.8 7,2 0,57
21212 0.737 0.76 6,6 0,5
12221 0.729 0.73 6,7 0,49
22121 0.725 0.75 6,8 0,51
12112 0.723 0.82 7,1 0,58
11122 0.719 0.81 6,9 0,56
22221 0.693 0.67 6,4 0,43
12212 0.691 0.75 6,7 0,5
22112 0.687 0.78 6,8 0,53
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EQ-5D state Dutch national tariff (115) Probability attending work Level of functioning attending work Total productivity
11222 0.687 0.74 6,5 0,48
21122 0.683 0.77 6,6 0,51
22212 0.655 0.7 6,4 0,45
21222 0.651 0.69 6,2 0,43
11311 0.638 0.57 6,6 0,38
12122 0.637 0.76 6,7 0,51
12222 0.605 0.68 6,3 0,43
21311 0.602 0.51 6,4 0,32
22122 0.601 0.71 6,4 0,45
22222 0.569 0.62 6,0 0,37
12311 0.556 0.49 6,4 0,32
11321 0.552 0.48 6,2 0,3
13111 0.543 0.7 7,2 0,5
31111 0.534 0.5 6,6 0,33
22311 0.52 0.43 6,1 0,26
21321 0.516 0.42 6,0 0,25
11312 0.514 0.52 6,2 0,32
13211 0.511 0.61 6,7 0,41
23111 0.507 0.64 6,9 0,44
31211 0.502 0.4 6,2 0,25
13311 0.486 0.29 6,0 0,17
21312 0.478 0.45 5,9 0,27
31311 0.477 0.15 5,6 0,08
23211 0.475 0.55 6,4 0,35
12321 0.47 0.41 6,0 0,24
13121 0.457 0.62 6,7 0,42
32111 0.452 0.42 6,4 0,27
23311 0.45 0.24 5,8 0,14
31121 0.448 0.41 6,2 0,25
22321 0.434 0.34 5,8 0,2
12312 0.432 0.44 6,0 0,26
11322 0.428 0.43 5,8 0,25
13221 0.425 0.53 6,3 0,33
23121 0.421 0.56 6,4 0,36
32211 0.42 0.33 6,0 0,2
13112 0.419 0.65 6,7 0,44
31221 0.416 0.32 5,8 0,19
31112 0.41 0.44 6,2 0,27
13321 0.4 0.22 5,7 0,12
22312 0.396 0.37 5,7 0,21
32311 0.395 0.11 5,4 0,06
21322 0.392 0.36 5,6 0,2
31321 0.391 0.11 5,2 0,06
23221 0.389 0.46 6,0 0,28
13212 0.387 0.56 6,3 0,35
23112 0.383 0.59 6,4 0,38
33111 0.382 0.23 6,0 0,14
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EQ-5D state Dutch national tariff (115) Probability attending work Level of functioning attending work Total productivity
31212 0.378 0.35 5,8 0,2
11113 0.37 0.75 6,9 0,52
11131 0.366 0.58 6,6 0,38
32121 0.366 0.34 6,0 0,2
23321 0.364 0.18 5,4 0,1
13312 0.362 0.24 5,6 0,14
31312 0.353 0.12 5,2 0,06
23212 0.351 0.49 6,0 0,3
33211 0.35 0.17 5,6 0,1
12322 0.346 0.35 5,6 0,2
11213 0.338 0.67 6,5 0,44
21113 0.334 0.7 6,6 0,46
11231 0.334 0.48 6,2 0,3
32221 0.334 0.26 5,6 0,14
13122 0.333 0.57 6,3 0,36
21131 0.33 0.51 6,3 0,32
32112 0.328 0.37 6,0 0,22
23312 0.326 0.2 5,4 0,11
33311 0.325 0.05 5,0 0,02
31122 0.324 0.36 5,8 0,21
11313 0.313 0.34 5,8 0,2
22322 0.31 0.29 5,4 0,16
32321 0.309 0.08 5,0 0,04
11331 0.309 0.19 5,6 0,11
21213 0.302 0.61 6,2 0,38
13222 0.301 0.47 5,9 0,28
21231 0.298 0.41 5,9 0,25
23122 0.297 0.5 6,0 0,3
33121 0.296 0.17 5,6 0,1
32212 0.296 0.28 5,6 0,16
31222 0.292 0.27 5,4 0,15
12113 0.288 0.69 6,7 0,46
11123 0.284 0.68 6,5 0,44
12131 0.284 0.5 6,4 0,32
21313 0.277 0.29 5,6 0,16
13322 0.276 0.18 5,3 0,1
21331 0.273 0.15 5,3 0,08
32312 0.271 0.09 5,0 0,05
31322 0.267 0.09 4,9 0,04
23222 0.265 0.4 5,6 0,23
33221 0.264 0.12 5,3 0,07
33112 0.258 0.19 5,6 0,11
12213 0.256 0.6 6,3 0,37
22113 0.252 0.63 6,4 0,4
11223 0.252 0.59 6,1 0,36
12231 0.252 0.4 6,0 0,24
21123 0.248 0.62 6,2 0,38
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EQ-5D state Dutch national tariff (115) Probability attending work Level of functioning attending work Total productivity
22131 0.248 0.43 6,1 0,26
11132 0.242 0.52 6,2 0,32
32122 0.242 0.29 5,6 0,16
23322 0.24 0.15 5,1 0,07
33321 0.239 0.04 4,7 0,02
12313 0.231 0.28 5,6 0,15
11323 0.227 0.27 5,4 0,15
12331 0.227 0.15 5,4 0,08
33212 0.226 0.14 5,3 0,07
22213 0.22 0.53 6,0 0,32
13113 0.218 0.48 6,3 0,3
21223 0.216 0.52 5,8 0,3
22231 0.216 0.34 5,7 0,2
13131 0.214 0.29 6,0 0,18
11232 0.21 0.42 5,8 0,25
32222 0.21 0.21 5,2 0,11
31113 0.209 0.28 5,8 0,16
21132 0.206 0.46 5,9 0,27
31131 0.205 0.15 5,5 0,08
12123 0.202 0.61 6,3 0,38
33312 0.201 0.04 4,7 0,02
22313 0.195 0.23 5,4 0,12
21323 0.191 0.22 5,2 0,11
22331 0.191 0.12 5,1 0,06
13213 0.186 0.38 5,9 0,23
32322 0.185 0.07 4,7 0,03
11332 0.185 0.16 5,2 0,08
23113 0.182 0.41 6,0 0,25
13231 0.182 0.22 5,6 0,12
23131 0.178 0.24 5,7 0,14
31213 0.177 0.21 5,4 0,11
21232 0.174 0.36 5,5 0,2
31231 0.173 0.11 5,2 0,05
33122 0.172 0.14 5,3 0,08
12223 0.17 0.51 5,9 0,3
22123 0.166 0.54 6,0 0,32
13313 0.161 0.14 5,3 0,07
12132 0.16 0.44 6,0 0,26
13331 0.157 0.07 5,1 0,03
31313 0.152 0.06 4,9 0,03
23213 0.15 0.32 5,6 0,18
21332 0.149 0.13 5,0 0,06
31331 0.148 0.03 4,7 0,01
23231 0.146 0.18 5,4 0,1
12323 0.145 0.21 5,3 0,11
33222 0.14 0.1 4,9 0,05
22223 0.134 0.44 5,6 0,25
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EQ-5D state Dutch national tariff (115) Probability attending work Level of functioning attending work Total productivity
13123 0.132 0.39 5,9 0,23
12232 0.128 0.35 5,6 0,2
32113 0.127 0.22 5,6 0,12
23313 0.125 0.11 5,0 0,05
22132 0.124 0.38 5,7 0,22
31123 0.123 0.21 5,4 0,12
32131 0.123 0.11 5,3 0,06
23331 0.121 0.05 4,8 0,03
33322 0.115 0.03 4,4 0,01
22323 0.109 0.17 5,0 0,09
12332 0.103 0.12 5,0 0,06
13223 0.1 0.3 5,5 0,17
23123 0.096 0.33 5,6 0,19
32213 0.095 0.16 5,2 0,08
22232 0.092 0.29 5,4 0,16
31223 0.091 0.15 5,1 0,08
32231 0.091 0.08 5,0 0,04
13132 0.09 0.25 5,6 0,14
31132 0.081 0.12 5,2 0,06
13323 0.075 0.1 4,9 0,05
32313 0.07 0.05 4,7 0,02
22332 0.067 0.09 4,8 0,05
31323 0.066 0.04 4,5 0,02
32331 0.066 0.02 4,5 0,01
23223 0.064 0.25 5,3 0,13
13232 0.058 0.18 5,3 0,1
33113 0.057 0.11 5,2 0,06
23132 0.054 0.2 5,4 0,11
33131 0.053 0.05 5,0 0,03
31232 0.049 0.09 4,9 0,04
11133 0.041 0.35 5,8 0,2
32123 0.041 0.17 5,2 0,09
23323 0.039 0.08 4,7 0,04
13332 0.033 0.05 4,7 0,03
33213 0.025 0.07 4,9 0,04
31332 0.024 0.02 4,3 0,01
23232 0.022 0.15 5,0 0,07
33231 0.021 0.03 4,7 0,02
11233 0.009 0.26 5,4 0,14
32223 0.009 0.12 4,9 0,06
21133 0.005 0.29 5,5 0,16
33313 -0.000 0.02 4,4 0,01
32132 -0.001 0.09 5,0 0,05
23332 -0.003 0.04 4,5 0,02
33331 -0.004 0.01 4,2 0
32323 -0.016 0.03 4,4 0,01
11333 -0.016 0.08 4,9 0,04
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EQ-5D state Dutch national tariff (115) Probability attending work Level of functioning attending work Total productivity
21233 -0.027 0.22 5,2 0,11
33123 -0.029 0.08 4,9 0,04
32232 -0.033 0.06 4,7 0,03
12133 -0.041 0.28 5,6 0,16
21333 -0.052 0.07 4,6 0,03
32332 -0.058 0.02 4,2 0,01
33223 -0.061 0.05 4,6 0,02
33132 -0.071 0.04 4,7 0,02
12233 -0.073 0.21 5,2 0,11
22133 -0.077 0.23 5,3 0,12
33323 -0.086 0.01 4,1 0,01
12333 -0.098 0.06 4,7 0,03
33232 -0.103 0.03 4,4 0,01
22233 -0.109 0.17 5,0 0,08
13133 -0.111 0.14 5,2 0,07
31133 -0.12 0.06 4,8 0,03
33332 -0.128 0.01 3,9 0
22333 -0.134 0.05 4,5 0,02
13233 -0.143 0.1 4,9 0,05
23133 -0.147 0.11 5,0 0,06
31233 -0.152 0.04 4,5 0,02
13333 -0.168 0.03 4,4 0,01
31333 -0.177 0.01 4,1 0
23233 -0.179 0.08 4,7 0,04
32133 -0.202 0.05 4,7 0,02
23333 -0.204 0.02 4,2 0,01
32233 -0.234 0.03 4,4 0,01
32333 -0.259 0.01 3,9 0
33133 -0.272 0.02 4,4 0,01
33233 -0.304 0.01 4,1 0,01
33333 -0.329 0.00 3,7 0
10.
Discussion
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10.1 Introduction
Economic evaluations are increasingly used to inform decision makers about 
the relative efficiency of new health interventions. Moreover, the role of eco-
nomic evaluations in reimbursement decisions is increasingly formalized. An 
important cost category in economic evaluations is that of productivity costs. 
Productivity costs can strongly affect cost-effectiveness outcomes; however, 
the proper place of productivity costs in economic evaluations is still disputed. 
The inclusion of these costs is sometimes seen as unethical, since it may lead to 
favoring treatments targeted at illnesses affecting the working population over 
other treatments (13). As described in chapter 2, the debate on in- or excluding 
productivity costs in an economic evaluation is closely related to the issue of 
the appropriate perspective to take in economic evaluations and (therefore) 
the relevant decision context and decision rule. Theoretically, there are 
compelling arguments to take a societal perspective in economic evaluations 
(and consequently to include productivity costs). Reimbursement decisions 
based on other perspectives may lead to inefficient use of resources and hence 
welfare decreasing decisions, since these decisions are based on incomplete 
information on societal costs and effects (35). However, in practice health care 
decision-makers may favor economic evaluations performed from a health 
care perspective (in which case only costs falling on the health care budget are 
included) over evaluations performed from a societal perspective. Moreover, 
decisions based on economic evaluations adopting a societal perspective must 
be sensitive to the responsibility and budgetary constraints of health care 
decision makers. For instance, if the costs of some intervention fall inside the 
health care sector, but savings fall outside the health care sector, the interven-
tion may be cost-effective from a societal perspective, but hard to implement 
for the health care decision maker. In theory, such savings outside the health 
care sector could then be (partially) transferred into the health care budget in 
order to prevent budgetary problems. Such transfers, however, may be difficult 
to realize in practice. (33) Moreover, the opportunity costs within the health care 
sector may be disproportionally high when high costs fall on the budget. The 
lack of consensus regarding the appropriate perspective and the inclusion of 
productivity costs in economic evaluations is reflected in variations in the 
recommendations in national health economic guidelines regarding these 
matters.
Next to debates on whether to include productivity costs, debates have fo-
cused on how productivity costs should actually be included (2,15-18,21,39,47,48,56,90). 
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As described in chapter 2, many issues on how to include productivity costs in 
economic evaluations have not yet been resolved. Moreover, new important 
questions have emerged from these earlier debates, of which five have been 
addressed in this thesis. 
10.2 Questions addressed in this thesis
1.  Do respondents to health state valuations include the effects of ill-health 
on income and if so, how does such inclusion affect valuations?
The recommendation of the United States Panel on Cost Effectiveness in Health 
and Medicine (2) to abandon valuing productivity costs in monetary terms was 
based on the hypothesis that these costs would already be captured in QALYs. 
Their recommendation received much criticism (8,22,31). Indeed, it seems unlikely 
that respondents to health state valuations would be able to include all societal 
effects of productivity changes. If respondents would consider the effects of 
ill-health on income, they would probably focus on the effects on their net 
income. Moreover, the link between productivity and income on an individual 
level may be weak because of private and social security systems. (22,31) In spite 
of the theoretical criticisms of the US Panel approach, the suggestion of double 
counting resulting from some (partial) valuation of productivity costs in terms 
of QALYs when also applying the human capital or friction cost approach to 
value productivity losses could not be easily rejected, since it was unknown 
whether respondents in health state valuations include the effects of ill-health 
on income during the valuation process and, if so, how such considerations 
would affect health state valuations.
Chapters 3, 4 and 5 of this thesis showed that, in our studies, around half 
of the respondents to health state valuations spontaneously considered the 
potential effects of ill-health on income during health state valuation exercises. 
These outcomes indicate that if productivity costs are included, as commonly 
done, on the cost side of the cost-effectiveness ratio, this may indeed lead to 
double counting. However, it turned out that spontaneous inclusion or exclu-
sion of income effects had only a limited effect on subsequent health state 
values. In other words, the QALY measure does not seem to be sensitive enough 
to capture the effects of ill-health and treatment on productivity and the ‘pol-
lution’ created by double counting is small (if not non-existent). Therefore, it 
seems advisable to measure productivity costs in monetary terms on the cost 
side of the cost-effectiveness ratio where these costs do have a noticeable ef-
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fect, rather than to try and capture (a part of ) these costs on the effect side. 
Given the evidence regarding at best very small effects of taking the effects of 
ill-health on income into consideration, it does not seem to be necessary to 
explicitly instruct respondents to health state valuation to ignore potential 
income-effects and double counting does not appear to pose a threat in prac-
tice.
2. How common is productivity cost inclusion in economic evaluations?
Though the inclusion of productivity costs has been extensively debated in the 
literature over the last two decades, only little information was available on 
how often productivity costs are actually included in economic evaluations. 
Moreover, not much was known about the effects of inclusion or exclusion of 
productivity costs on cost-effectiveness outcomes. Such information is, how-
ever, critical in providing insight in the potential effects of the choice to include 
or exclude productivity costs. The research described in chapters 6 and 7 of 
this thesis indicated that in most published economic evaluations productivity 
costs are, in fact, ignored. Inclusion of productivity costs was more common in 
economic evaluations of therapies for depressive disorders targeted at patients 
in the working age groups, than in economic evaluations of treatments with 
expensive drugs administered in a hospital setting. In the former, just under 
one-third of economic evaluations included productivity costs and in the latter 
these cost were included in less than ten percent of the economic evaluations. 
The fact that inclusion of productivity costs was more common in the field 
of depressive disorders than in expensive drug treatments probably is partly 
explained by differences in the age and the severity of illness of the patient 
populations. Nevertheless, productivity costs in both fields were less frequently 
included than expected, indicating that productivity costs may regularly be 
‘unjustly’ excluded, reasoning from the premise that decision makers should 
be informed about all relevant societal costs and benefits of an intervention. 
It is also worth to note that sometimes productivity costs were included 
in economic evaluations when this was not expected, given the fact that the 
relevant national health economic guidelines prescribed adopting a health 
care perspective. Such unexpected inclusion in the studies reviewed in chapter 
7 in all cases led to more favorable cost-effectiveness outcomes for the new 
drug. While this thesis cannot draw any firm conclusions regarding this issue, 
this finding may indicate the existence of some kind of ‘perspective bias’; i.e. 
productivity costs may sometimes be included based on the (desired) expected 
214
 
effects on incremental cost-effectiveness outcomes. It is worth to investigate 
this in future studies. 
3. How does productivity cost inclusion or exclusion affect cost-
effectiveness outcomes?
As shown in chapters 6 and 7, the inclusion or exclusion of productivity costs 
can influence both incremental costs and incremental cost-effectiveness 
relatively strongly. Mostly, inclusion of productivity costs was to the advantage 
of the ‘new’ intervention rather than the alternative intervention in terms of 
incremental cost-effectiveness. Notably, the precise impact of productivity 
cost inclusion differed strongly between studies, both expressed as a fraction 
of total costs and as the effect on incremental cost (-effectiveness) outcomes. 
It was not possible to gain full insight in the nature of these differences, since 
in most studies the level of detail of underlying methods and figures was insuf-
ficient to allow further investigation. Besides, the limited information that was 
presented in the studies suggested that there was much variation in applied 
methods regarding the identification, measurement and valuation of produc-
tivity costs.
The strong potential impact of productivity costs on cost-effectiveness 
outcomes emphasizes that in countries where a health care perspective is pre-
scribed (i.e. where productivity costs are structurally ignored) reimbursement 
decisions based on cost-effectiveness studies adhering to this perspective may 
lead to inefficient use of societal resources.
4. How do compensation mechanisms and multiplier effects potentially 
affect productivity cost estimates?
The infrequent inclusion of productivity costs in economic evaluations may 
be influenced by uncertainty regarding the accuracy of productivity cost 
estimates. Indeed, it has been questioned whether such estimates accurately 
reflect ‘true’ productivity costs. On the one hand, it has been suggested that 
common productivity costs estimates are, in fact, overestimations (17,18). If ab-
senteeism and presenteeism are compensated either by the ill employee herself 
or her colleagues during normal working hours or in extra working time, this 
may lower production losses. While these compensation mechanisms need not 
be costless, they may result in lower costs than when production would have 
been lost. 
On the other hand, it has been advocated that common estimates of produc-
tivity costs are, in fact, underestimations (15,16). In many professions team de-
215
Discussion
Ch
ap
te
r 1
0
pendencies exist. If one of the team members falls ill, or is not able to function 
properly, the productive output of the whole team may be negatively affected. 
Thus production losses would be higher than expected by considering only the 
directly affected individual. 
In chapter 8 of this thesis, results were presented of a randomized trial on 
smoking cessation treatments. Patients in this trial were questioned on how 
their work was compensated in cases of absenteeism due to ill-health. Based 
on their responses and previously published profession dependent effects 
of ill-health on coworkers (referred to as multipliers) productivity costs were 
calculated using multiple scenarios to explore the potential impact of compen-
sation mechanisms and multiplier effects. 
The results indicate that when simultaneously accounting for multiplier ef-
fects and compensation mechanisms, the amplifying effect on regular produc-
tivity cost estimates of applying multipliers is outweighed by the diminishing 
effect of adjusting for compensation mechanisms, assuming – naively – that 
compensation in normal hours is costless. However, in reality it is unlikely 
that compensation in normal hours is, in an economic sense, costless. Com-
pensation in normal working hours implies that companies may have some 
type of internal labor reserve, and hence that they are not functioning at full 
capacity, which would result in economic costs. If such labor reserve is not 
present, compensation during normal working hours would result in putting 
extra non-costless strain on employees, potentially even leading to additional 
(work-related) ill-health.
5. Can productivity losses be predicted based on quality of life estimates?
Next to the controversies and debates regarding productivity costs inclusion 
and the lack of standardization, the neglect of productivity cost inclusion in 
economic evaluations may to some extent be explained by practical limita-
tions. Researchers do not always have the opportunity to collect data on the 
effects of ill-health and treatment on patients’ productivity. Sometimes only 
retrospective data is available and in other cases resources maybe insufficient 
to collect additional data. To date, if such problems regarding data collection 
emerge, productivity costs are likely to be simply ignored. However, previous 
research has indicated a relationship between quality of life and productivity 
(19), leading to the question whether it would be possible to estimate productiv-
ity changes based on quality of life data.
In Chapter 9 the results are presented of a study exploring the possibility to 
predict productivity levels in terms of absenteeism and diminished productiv-
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ity while being at work based on quality of life information described with the 
EuroQol descriptive system (EQ-5D, 3-level version (24)). In order to do so, an 
online survey was conducted in which respondents were questioned on their 
expected productivity in numerous EQ-5D health states. Subsequently, based 
on the responses a prediction model was constructed for absenteeism and 
presenteeism. The validity of the models was tested among a group of low back 
pain patients. The results of the validation study were promising, although the 
model predicting presenteeism seemed to overestimate productivity losses 
somewhat. Nevertheless, applying prediction models to estimate productiv-
ity losses in cases where no actual data on productivity is available may be 
considered preferable over the alternative of ignoring the effect of ill-health on 
productivity altogether. 
10.3 Limitations
Although this thesis has addressed some important issues regarding productiv-
ity cost inclusion in economic evaluations, other equally important issues have 
been neglected. Moreover, the theoretical and practical choices made during 
the process of constructing this thesis may be criticized. 
For instance, all questionnaires used in the research on income consider-
ations in health state valuation exercises presented in chapters 3, 4 and 5 were 
designed for self-completion and most questions were close-ended. Although 
this approach was beneficial in terms of sample size, it provided little infor-
mation on the actual thought process of respondents during the health state 
valuation exercises. For this purpose, it would have been useful if the research 
had included a more qualitative part including semi-structured face-to-face 
interviews (e.g. such as done before with the Visual Analogue Scale (271)).
The research presented in chapter 6 and 7 focused on productivity cost 
inclusion in economic evaluations in specific disease areas (i.e., depressive 
disorders and disorders requiring expensive intramurally administrated 
drugs). The (lack of) productivity cost inclusion and the strong impact when 
included on cost-effectiveness outcomes may differ in other areas. In addition, 
the impact of productivity cost inclusion could only be determined based on 
outcomes of the few studies that had included productivity costs. Especially if 
in- and exclusion (to some extent) is the result of a perspective-selection-bias, 
the impact of productivity costs on cost-effectiveness described in this thesis 
may be a poor representation of its ‘true’ impact.
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A limitation of the research presented in chapter 8 is that it has focused 
merely on compensation of diminished productivity in case of absenteeism. It 
would be worthwhile to further investigate how diminished productivity while 
being at work is compensated. Furthermore, the multipliers applied in this 
research were based on previous published estimates based on a study con-
ducted in the United States. These multipliers may not adequately resemble 
potential effects of ill-health on coworkers in the Netherlands. Research in 
the line of Nicholson and Pauly and colleagues (15,16) on the effects of ill-health 
on coworkers’ productivity among Dutch workers may provide more insight 
in this matter. Moreover, it is important to further explore how diminished 
productivity is compensated and especially the costs of such compensation 
mechanisms need further investigation. 
In chapter 9 the constructed prediction models were based on respondents’ 
hypothetical productivity in distinct EQ-5D health states, rather than actual 
productivity. To an extent this limitation may explain why the model predicting 
presenteeism seemed to overestimate productivity losses. Respondents who 
are inexperienced in the presented ill health states may have the tendency to 
overestimate the effects of ill-health on their productivity. Individuals actually 
experiencing the health problems may adjust to their limitations. Moreover, 
individuals in ill health may have to choose professions in which their health 
problems have a limited effect on their working abilities, particularly if these 
health problems are related to chronic conditions.
Next to the limitations of the research presented in this thesis, another limi-
tation is that some important aspects regarding the inclusion of productivity 
costs in economic evaluations have not received the attention these aspects 
would deserve. For instance, most of the research presented in this thesis has 
limited its focus on productivity costs related to the effects of ill-health and 
treatment on paid work. In doing so, productivity costs related to unpaid pro-
fessions remain as underexplored as before. Important questions to address 
in future research in the area of productivity costs related to unpaid work are: 
how can unpaid productivity best be identified and measured to be included in 
economic evaluations and which valuation approaches are most appropriate? 
Furthermore, in this thesis relatively little attention has been paid to the 
question whether productivity costs should be included in economic evalua-
tions. Although in this thesis it is advocated that the societal perspective is the 
most appropriate perspective to take in economic evaluations and this view is 
widespread (2,7,34,35,40,41), in practice many national health economic guidelines 
prescribe a health care perspective (at least for the reference case) (124,233,272). 
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In that context, an underlying underexplored issue is the question of how to 
deal with productivity costs in health care decision making. The role and place 
of productivity costs in actual health care decision making could be explored 
further. It could be investigated how, when and to what extent decision makers 
(wish to) include productivity costs in their decisions. It may well be that such 
costs receive different weight in health care decisions, than, for instance, health 
care costs. Exploring the practical possibilities for redirecting savings outside 
the health care system, occurring due to health care interventions financed 
from the health care budget, back into the health care budget is also interest-
ing. Note that this does not imply that health care policy makers should only 
take these costs into account when this is possible. Such research may contrib-
ute to the awareness of the importance of productivity costs, stimulate their 
inclusion in economic evaluations and decision making, and, consequently, 
may help to improve overall welfare.
10.4 Implications for policy and future research
This thesis aims to contribute to the ongoing (predominantly methodological) 
debates in the area of productivity costs measurement and valuation. More-
over, the outcomes of the research in this thesis may have some implications 
for health policy and future research.
To start, the results of the empirical work presented in this thesis indicate 
that the QALY does not seem capable to fully capture the impact of ill-health 
and treatment on productivity and income. This finding invalidates the rec-
ommendation of the United States Panel to include productivity costs on the 
effect side of the cost-effectiveness ratio. Nevertheless, since approximately 
half of the respondents in health state valuation exercises do seem to consider 
the effects of ill-health on income, one may wonder which other non-health 
related effects respondents are including in their valuation process. It seems 
clear that respondents include more than anticipated, considering the QALY 
measure is normally expected to capture health related quality of life rather 
than broader notions of quality of life.
Another important finding is that the decision to include or exclude 
productivity costs in economic evaluations can have a very large effect on 
outcomes. Decision makers should be aware of the strong potential impact on 
incremental cost-effectiveness. If a societal perspective is prescribed, decision 
makers may have to put more emphasis on the actual and systematic inclusion 
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of productivity costs. Although in particular circumstances it may prove to be 
impossible or irrelevant to include productivity measurement in economic 
evaluations, exclusion of productivity costs should always be explicitly justi-
fied. Otherwise, inclusion or exclusion because of strategic reasons rather than 
because of theoretical considerations may be the consequence. Moreover, in 
situations where inclusion is difficult for practical reasons, estimates based 
on productivity predictions may be more appropriate than simply ignoring 
the effects of ill-health and treatment on productivity. Currently, productivity 
costs seem to be often excluded without sufficient argumentation. For decision 
makers it is important to understand that reimbursement decisions based on 
economic evaluations ignoring actual costs (or savings) risk an inefficient use 
of societal resources. 
Comparing results of economic evaluations including different aspects on 
the cost side of the cost-effectiveness ratio comes dangerously close to com-
paring apples to oranges. Where (for the sake of comparability) most national 
health economic guidelines are uniformly prescribing the QALY as preferred 
outcome measure10, the same guidelines are less consistent and explicit in 
their guidance on cost-inclusion. This is probably strongly related to issues dis-
cussed in this thesis, such as the lack of consensus on appropriate perspective, 
on methods to measure and value productivity costs, the role and influence of 
compensation mechanisms and multiplier effects, and so on. More research 
and debate, working towards a further standardization of productivity costs 
identification, measurement and valuation, remains crucial therefore. 
10.5 Concluding remarks
Despite the scientific research conducted in the area of productivity costs in 
economic evaluations over the years, consensus has not been reached on the 
issues of whether and how to include productivity costs in economic evalu-
ations. This lack of consensus is reflected in the diversity in national health 
economic guidelines and has likely contributed to productivity costs being 
often ignored in economic evaluations. This thesis has provided more insight 
in the potential impact of productivity costs on cost-effectiveness outcomes. 
It seems clear that wrongful exclusion of productivity costs could lead to wel-
10  To note, the use of use the QALY measure in economic evaluations is not free of dispute. Several 
problems with the QALY have been discussed in the literature (see for instance Lipscomb et al. 
and Nord et al. (275,276)).
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fare damaging decisions, since decisions regarding reimbursement of health 
interventions may then be based on inaccurate information on incremental 
cost-effectiveness ratios.
Considering the adoption of the societal perspective as most appropriate, it 
is pivotal to increase productivity cost inclusion in economic evaluations. In 
that context, it is important that decision makers are more aware of the strong 
potential impact of productivity costs on cost-effectiveness outcomes and that 
they put more emphasis on adhering to the prescribed perspective. Moreover, 
the lack of standardization of productivity cost methodology is a serious con-
cern. In this thesis it is shown that in daily health economic practice a variety 
of methods is used to identify, measure and value productivity costs. Since the 
different methods can lead to a large difference in productivity cost estimates, 
the trustworthiness of outcomes inevitably may become a matter of debate. 
Moreover, the diversity in methodology seriously hampers the possibilities 
to compare outcomes between studies. This thesis has emphasized that, 
standardization is crucial for productivity cost inclusion to become standard 
practice instead of an exception.
This thesis has further increased to the theoretical and practical knowledge 
regarding productivity cost inclusion in economic evaluations. Although, given 
the findings of this thesis, achieving full consensus regarding the appropriate-
ness of inclusion of productivity costs and best methods for identifying as well 
as measuring and valuing productivity costs may be challenging, it remains an 
ultimate goal. Difficulties in reaching consensus may partly be due to differ-
ences in basic assumptions regarding the context and goal of health care deci-
sion making. Especially such differences may prove to be difficult to bridge.
Moreover, in jurisdictions wishing to take a societal perspective and hence 
include productivity costs, consensus on how to include these costs may not 
be easily reached. Again there, normative judgments and schools of thought 
may lead to fundamental differences in opinion on how to measure and value 
productivity costs (and other costs and effects for that matter) (273). The debates 
regarding the friction cost method versus the human capital method, and the 
underlying differences in schools of thought, may illustrate this. An intermedi-
ate solution in this matter would be calculating productivity costs with both 
approaches, which, as shown in chapters 6 and 7, is commonly done in studies 
applying the friction cost approach. Additionally, it is critical to standardize 
how both approaches are applied best, as variation within methods may be 
large as well. 
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Some form of consensus on main productivity cost issues (and at least on 
standards for transparency regarding applied methods and presentation of 
outcomes) could contribute to an increase in productivity costs inclusion in 
economic evaluations and to a higher level of quality and comparability of 
productivity cost estimates. Such a consensus, for instance laid down in the 
form of a consensus document, is already available for other (maybe less 
controversial) topics in the field of health technology assessment (274). For con-
sensus regarding productivity cost calculation to be successful in increasing 
comparability in productivity cost outcomes, recommendations need to be 
made on a relatively detailed level. Some of the issues that need to be stan-
dardized are: which productivity costs to include (e.g. paid and unpaid labor, 
absenteeism and presenteeism, effects on coworkers’ productivity, costs and 
savings due to compensation mechanisms, etc.), which of the available instru-
ments are appropriate to measure lost productivity, which values to attach to 
lost production units (e.g. a fraction of GDP, patients’ income, workers’ added 
value, or average incomes). It seems worthwhile attempting to take first steps 
on the road to standardization of productivity cost methodology. 
The above remarks may illustrate that while productivity costs are obviously 
important, both societally and in the context of economic evaluation, their 
sound consideration in health care decision making remains an important 
objective. Hopefully this thesis ultimately contributes to that goal. 

Summary
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Economic evaluations are increasingly used to inform decision makers about 
the relative efficiency of new health interventions. While the influence of 
this information on subsequent decisions may still be limited (3-5), more and 
more countries appear to wish to include this information in the process of 
reimbursement decisions (6). The increased use of economic evaluations in 
health care also emphasizes the need to ensure a sound methodology of these 
evaluations. Obviously, when the influence of outcomes of economic evalua-
tions on subsequent decision making becomes stronger, the need for sound 
methodology becomes weightier as well. In that context it must be stressed 
that numerous methodological debates regarding how to best perform 
economic evaluations are ongoing. One of the areas of debate concerns (the 
inclusion of) productivity costs, which can be defined as “Costs associated with 
production loss and replacement costs due to illness, disability and death of 
productive persons, both paid and unpaid.” (8). Productivity costs can strongly 
affect cost-effectiveness outcomes; however, the proper place of productivity 
costs in economic evaluations is still disputed. 
This thesis aimed to answer five questions which emerged from previous re-
search and debates concerning productivity costs. These five questions relate 
to the inclusion of productivity costs and the methodology to estimate these 
costs in economic evaluations of health care interventions: 
1. Do respondents to health state valuations include the effects of ill-health 
on income and if so, how does such inclusion affect valuations?
2. How common is productivity cost inclusion in economic evaluations?
3. How does productivity cost inclusion or exclusion affect cost-effectiveness 
outcomes?
4. How is reduced productivity related to ill-health compensated and how 
do compensation mechanisms and multiplier effects potentially affect 
productivity cost estimates?
5. Can productivity losses be predicted based on quality of life estimates?
In chapter 2 of this thesis an overview was presented of the most important 
past and present debates and developments regarding productivity cost inclu-
sion, identification, measurement and valuation. Reviewing the published 
literature, demonstrated that despite the progress and the substantial amount 
of scientific research conducted, consensus has not been reached on either 
the inclusion of productivity costs in economic evaluations or the methods 
used to produce productivity cost estimates. Such a lack of consensus has 
likely contributed to ignoring productivity costs in economic evaluations and 
is reflected in variations in national health economic guidelines. Given the cur-
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rent variety in applied productivity cost methodology, accurately reporting the 
methods used to estimate productivity costs in economic evaluations is critical 
to understand the nature of potential differences in outcomes. However, in 
published studies the level of detail provided regarding the exact methods 
used is often poor. Based on the studied literature several recommendations 
were made regarding future research topics to address, aiming to result in an 
increase in productivity cost inclusion in economic evaluations and in further 
development of productivity cost methodology.
The empirical work in chapters 3, 4 and 5 was aimed at answering research 
question 1. It was investigated whether respondents to health state valua-
tions take the effects of ill-health on income into account when participat-
ing in health state valuation exercises. Additionally, it was investigated how 
spontaneous inclusion or exclusion of income-effects influences health state 
valuations. Moreover, the effects of explicitly instructing respondents to either 
include or exclude income-effects were explored. The research in chapters 3, 4 
and 5 was initiated by the recommendation of the United States Panel on Cost 
Effectiveness in Health and Medicine in 1996 (2) to abandon valuing productiv-
ity costs, as it was commonly done, in monetary terms. This recommendation 
was based on the hypothesis that these costs would already be captured in 
quality adjusted life years (QALYs) and, therefore, measuring productivity 
costs additionally on the cost side of the cost-effectiveness ratio would lead to 
double counting. Although the panel’s recommendation received much criti-
cism (8,22,31) and it was argued that valuing productivity costs in QALYs would not 
lead to sound estimates, the suggestion of double counting could not be easily 
rejected, since it was unknown whether respondents in health state valuations 
include the effects of ill-health on income during the valuation process and, if 
so, how such considerations would affect these valuations. 
Approximately half of the respondents in the empirical studies described in 
chapters 3, 4 and 5 spontaneously included the potential effects of ill-health 
on income during health state valuation exercises. When income-effects were 
included, it had little to no effect on health state valuations. Explicitly instruct-
ing respondents to exclude or include income-effects, likewise, had a limited 
effect on outcomes. Therefore, the QALY measure does not seem to be sensitive 
enough to capture the effects of ill-health and treatment on productivity and 
the ‘pollution’ created by double counting is small (if not non-existing). There-
fore, it seems advisable to capture productivity costs in terms of monetary 
terms on the cost side. 
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In the studies described in chapters 6 and 7 of this thesis, aimed at answer-
ing research questions 2 and 3, it was investigated to what extent productivity 
costs are included in economic evaluations in order to increase insight in the 
current role of productivity costs in economic evaluations. Next, in evaluations 
where these costs were included, it was examined how these costs were identi-
fied, measured and valued and the impact of including productivity costs on 
cost-effectiveness outcomes was assessed. The findings illustrated that in most 
published economic evaluations productivity costs are not included. Inclusion 
of productivity costs was more common in economic evaluations of therapies 
for depressive disorders targeted at patients of working age, than in economic 
evaluations of treatments with expensive drugs administered in a hospital 
setting. Just under one-third of the former economic evaluations included pro-
ductivity costs, while this percentage was less than ten of the latter economic 
evaluations. The fact that inclusion of productivity costs was more common in 
the field of depressive disorders than in expensive drug treatments is, to some 
extent, explained by differences in age and severity of illness of the patient 
populations. Nevertheless, productivity costs in both fields were less frequently 
included than expected, indicating that productivity costs may regularly be 
‘unjustly’ excluded, reasoning from the premise that decision makers should 
be informed about all relevant societal costs and benefits of an intervention.
The results of the research described in chapters 6 and 7 also illustrated that 
the choice to include or exclude productivity costs can influence both incre-
mental costs and incremental cost-effectiveness relatively strongly. Mostly, 
inclusion of productivity costs was to the advantage of the ‘new’ intervention 
rather than the comparator in terms of incremental cost-effectiveness. The 
precise impact of productivity cost inclusion differed strongly between stud-
ies, both expressed as a fraction of total costs and as the effect on incremental 
cost (-effectiveness) outcomes. It was not possible to gain full insight in the 
nature of these differences, since in most studies the level of detail in reporting 
underlying methods and figures was insufficient to allow further investigation. 
Besides, the limited information that was presented in the studies suggested 
that there was much variation in applied methods regarding the identification, 
measurement and valuation of productivity costs.
In chapter 8, related to research question 4, the influence of compensation 
mechanisms and multiplier effects on productivity costs estimates was inves-
tigated. In the literature, on the one hand, it has been suggested that common 
productivity cost estimates may overestimate actual productivity costs if absen-
teeism and presenteeism are (partly) compensated either by the ill employee 
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herself or by her colleagues during normal working hours (17,18). However, on 
the other hand, it has been advocated that common estimates of productivity 
costs are, in fact, underestimations of actual productivity costs (15,16), since in 
many professions team dependencies exist. Then, if one of the team members 
falls ill, the productive output of the whole team may be negatively affected. 
The empirical study described in chapter 8 investigated how ill workers’ ab-
senteeism is compensated. Additionally, it was explored how compensation 
mechanisms and effects of ill-health on team workers potentially affect com-
mon productivity cost estimates. Over half of the respondents indicated that 
their work was compensated during normal working hours by themselves or 
their colleagues. When simultaneously accounting for effects of ill-health on 
team workers’ productivity and compensation mechanisms, the amplifying 
effect on regular estimates of accounting for team effects is outweighed by the 
diminishing effect of adjusting for compensation mechanisms. Note that this 
was done under the naive assumption that compensation in normal hours is 
costless. However, in reality it is unlikely that compensation in normal hours is, 
in an economic sense, costless. 
As chapters 6 and 7 pointed out, productivity costs are often ignored in eco-
nomic evaluations. This may have to do with practical difficulties in obtaining 
reliable estimates of productivity costs. In such cases, it has been suggested 
to estimate productivity costs indirectly using quality of life data. The study 
presented in chapter 9, answering research question 5, aimed to derive and 
validate an algorithm for predicting productivity on the basis of quality of 
life data. In order to do so, a large representative sample of the Dutch general 
public was asked in a web-based questionnaire to state their expected level 
of productivity in terms of absenteeism and presenteeism for multiple EQ-5D 
health states. Based on these data, two prediction models were constructed: i) 
a model predicting levels of absenteeism and ii) a model predicting presentee-
ism. The models were validated by comparing model predictions with con-
ventionally measured productivity within a group of low back pain patients. 
Predicted absenteeism levels using EQ-5D health states, closely resembled 
conventionally measured absenteeism levels. Productivity losses related to 
presenteeism seemed somewhat overestimated by the prediction model. 
Measured and predicted productivity were moderately but highly significantly 
correlated. Overall, it appeared possible to make reasonable productivity pre-
dictions based on EQ-5D data. Further exploration and validation of prediction 
algorithms remains necessary, however, especially for presenteeism. 
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In chapter 10 the main findings of the research presented in this thesis were 
discussed. Moreover, the implications and the limitations of this thesis were 
addressed. Based on the findings (and referring back to the five main questions 
this thesis aimed to answer), some conclusions could be drawn. First, about 
half of the respondents to health state valuations seem to include income-
effects. This seems to have little effect on subsequent valuations. Productivity 
costs therefore are preferably placed on the cost side of the cost-effectiveness 
ratio. Second, despite the scientific attention regarding productivity cost is-
sues, productivity costs are ignored in the majority of economic evaluations, 
often without clear justification. Third, when productivity costs are included 
this can have a very strong impact on cost-effectiveness outcomes. The strong 
potential impact of productivity costs on cost-effectiveness outcomes empha-
sizes that when productivity costs are not included in economic evaluations, 
reimbursement decisions based on the results, may lead to inefficient use of 
societal resources. Fourth, lost production is commonly compensated during 
normal working hours. Productivity costs estimates are strongly influenced by 
adjustment for compensation mechanisms and multiplier effects. The validity 
of such adjustments needs further examination, however. Fifth, although the 
validity of predicting productivity losses based on quality of life data needs 
further investigation, applying prediction models in cases where no actual 
data on productivity is available seems preferable over ignoring the effect of 
ill-health on productivity altogether.
This thesis ends with some final remarks regarding the inclusion of produc-
tivity costs in economic evaluations and the methodology to estimate these 
costs. Consensus has not yet been reached on whether and how to include 
productivity costs in economic evaluations. Consequently, productivity costs 
are often ignored in economic evaluations. Considering the adoption of the 
societal perspective as most appropriate, it is pivotal to increase productivity 
cost inclusion in economic evaluations, especially, given the strong potential 
impact of productivity costs on cost-effectiveness outcomes. In that context, 
it is important that decision makers are more aware of this potential impact 
and that they put more emphasis on adhering to the prescribed perspective. 
Moreover, the lack of standardization of productivity cost methodology is a 
serious concern. In this thesis it is shown that in actual economic evaluations 
a variety of methods is used to identify, measure and value productivity costs. 
Since applying different methods can lead to large variations in productivity 
cost estimates, the trustworthiness of outcomes may become a matter of de-
bate. Moreover, this diversity in methodology seriously hampers the possibili-
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ties to compare outcomes between studies. This thesis has emphasized that, 
standardization is crucial for productivity cost inclusion to become standard 
practice instead of an exception.
Concluding, this thesis has further increased the theoretical and practical 
knowledge regarding productivity cost inclusion in economic evaluations. 
Although, given the findings of this thesis, achieving full consensus regarding 
the appropriateness of inclusion of productivity costs and best methods for 
identifying as well as measuring and valuing productivity costs may be chal-
lenging, it remains an ultimate goal.
Samenvatting

233
Samenvatting
Sa
m
en
va
tt
in
g
Economische evaluaties worden steeds vaker gebruikt om besluitvormers te 
informeren over de relatieve efficiëntie van nieuwe gezondheidsinterventies. 
Hoewel de invloed van informatie over de kosteneffectiviteit op de uiteinde-
lijke beslissingen nog beperkt lijkt te zijn (3-5), zijn er steeds meer landen die dit 
soort informatie meenemen in vergoedingsbeslissingen. (6) Het is daarom be-
langrijk dat de methoden en technieken die gebruikt worden in economische 
evaluaties betrouwbaar zijn. Het belang van goed onderbouwde methodologie 
gaat vanzelfsprekend zwaarder wegen naar mate de invloed van economische 
evaluaties op besluitvorming groter wordt.
In de wetenschappelijke literatuur zijn diverse debatten gaande over hoe 
economische evaluaties het beste kunnen worden uitgevoerd. Een van de 
onderwerpen van discussie is (de inclusie van) productiviteitskosten. Produc-
tiviteitskosten zijn de kosten die samenhangen met productiviteitsverliezen en 
het vervangen van medewerkers in geval van ziekte, arbeidsongeschiktheid en 
sterfte van betaald en onbetaald productieve personen. (8)
Productiviteitskosten kunnen de kosteneffectiviteit sterk beïnvloeden, maar 
de juiste plaats van deze kosten in economische evaluaties blijft een punt van 
aandacht en debat. Dit proefschrift heeft vijf onderzoeksvragen proberen te 
beantwoorden die zijn afgeleid van eerdere onderzoeken en debatten. Deze vijf 
vragen hangen samen met de inclusie van productiviteitskosten in economi-
sche evaluaties en de methodologie om deze kosten te schatten:
1. Denken respondenten tijdens het waarderen van gezondheidstoestanden 
aan de effecten van ziekte op hun inkomen; en zo ja, hoe beïnvloedt dit die 
waarderingen?
2. Hoe gebruikelijk is de inclusie van productiviteitskosten in economische 
evaluaties?
3. Hoe beïnvloedt het wel of niet meenemen van productiviteitskosten kos-
teneffectiviteitsuitkomsten?
4. Hoe wordt ‘verminderde productiviteit door ziekte’ gecompenseerd wat is 
de mogelijke impact van het rekening houden met compensatiemechanis-
men en effecten van ziekte op teamproductie op schattingen van producti-
viteitskosten?
5. Kunnen productiviteitsverliezen geschat worden op basis van gegevens 
over kwaliteit van leven? 
In hoofdstuk 2 van dit proefschrift werd een overzicht gegeven van belang-
rijke debatten uit het verleden en het heden over productiviteitskosten. Ook 
werden de ontwikkelingen in termen van inclusie, identificatie, meting en 
waardering van productiviteitskosten samengevat. Het bestuderen van de 
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gepubliceerde literatuur heeft duidelijk gemaakt dat er, ondanks de ontwikke-
lingen en de nodige aandacht voor productiviteitskosten, nog geen consensus 
bestaat over de inclusie van deze kosten noch de methoden om deze kosten 
te schatten. Dit gebrek aan consensus heeft er waarschijnlijk aan bijgedragen 
dat productiviteitskosten vaak genegeerd worden en hun inclusie soms ook in 
nationale gezondheidseconomische richtlijnen expliciet wordt ontmoedigd.
Gezien de grote variatie in de gebruikte productiviteitskostenmethodolo-
gie, is het belangrijk dat de gebruikte methoden nauwkeurig gerapporteerd 
worden. Alleen dan is het mogelijk om verschillen in uitkomsten te begrijpen. 
Het detailniveau in rapportage van gehanteerde methoden is in gepubliceerde 
studies vaak onvoldoende. Op basis van de bestudeerde literatuur is er in 
hoofdstuk 2 een aantal aanbevelingen gedaan met betrekking tot toekomstig 
onderzoek, met als doel het bevorderen van de inclusie van productiviteitskos-
ten in economische evaluatie en het verder ontwikkelen van productiviteits-
kostenmethodologie.
Het empirische werk in hoofdstuk 3, 4 en 5 was gericht op het beantwoorden 
van onderzoeksvraag 1. Er werd onderzocht of respondenten van methoden 
om gezondheidstoestanden te waarderen de effecten van ziekte op hun in-
komen meenemen wanner ze deelnemen aan zulke waarderingsexercities. Er 
werd daarbij gekeken hoe het wel of niet denken aan inkomen de waarderingen 
beïnvloedt. Als laatste werd bestudeerd wat de effecten zijn van het expliciet 
instrueren van respondenten om inkomenseffecten wel of niet mee te nemen.
Het onderzoek in hoofdstuk 3, 4 en 5 komt voort uit de aanbeveling van ‘the 
United States Panel on Cost Effectiveness in Health and Medicine’ uit 1996 (2) om 
productiviteitskosten niet meer te waarderen in termen van geld, maar in ter-
men van hun effect op de kwaliteit van leven. Deze aanbeveling was gebaseerd 
op de hypothese dat deze kosten al in de QALY11 waarderingen zouden zitten. 
Het ook nog meenemen van productiviteitskosten aan de kostenkant van de 
kosteneffectiviteitsratio zou hierdoor tot dubbeltellingen leiden. Deze aanbe-
veling leidde tot veel kritiek (8,22,31). Er werd beargumenteerd dat het waarderen 
van productiviteitskosten in QALYs niet zou leiden tot betrouwbare resultaten. 
Desalniettemin kon de suggestie dat waarderingen in geld, naast het gebruik 
van QALYs, zouden leiden tot dubbeltellingen niet makkelijk weerlegd worden, 
omdat het niet bekend was of respondenten van gezondheidstoestandwaarde-
ringen inkomenseffecten meenemen in het waarderingsproces en hoe dit deze 
waarderingen eventueel zou beïnvloeden.
11  QALY staat voor quality adjusted life year, ofwel een voor kwaliteit gecorrigeerd levensjaar.
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In de empirische studies beschreven in hoofdstuk 3, 4 en 5 bleek ongeveer 
de helft van de respondenten spontaan aan inkomenseffecten te denken 
tijdens het waarderen van diverse gezondheidstoestanden. Deze inclusie van 
inkomenseffecten had echter weinig tot geen effect op de uiteindelijke waarde-
ringen. Het expliciet instrueren van respondenten om deze effecten wel of niet 
mee te nemen had eveneens weinig effect op waarderingen. De QALY-maat 
lijkt dus weinig gevoelig voor het wel of niet meenemen van inkomenseffecten 
en van dubbeltellingen is dus (nagenoeg) geen sprake. Het lijkt daarom aan 
te raden om productiviteitskosten mee te nemen aan de kostenkant van de 
kosteneffectiviteitsratio.
In de studies die beschreven staan in hoofdstuk 6 en 7 (gericht op het beant-
woorden van vraag 2 en 3) werd onderzocht in hoeverre productiviteitskosten 
momenteel worden meegenomen in economische evaluaties. Dit werd gedaan 
om meer zicht te krijgen op de huidige rol van productiviteitskosten in econo-
mische evaluaties. Vervolgens is, voor de evaluaties waarin productiviteitskos-
ten werden meegenomen, onderzocht hoe deze kosten werden meegenomen, 
gemeten en gewaardeerd. Daarnaast is de impact van productiviteitskosten op 
de kosteneffectiviteitsuitkomsten berekend. 
In het merendeel van de economische evaluaties bleken productiviteits-
kosten niet te zijn meegenomen. Inclusie van productiviteitskosten kwam 
vaker voor in economische evaluaties van interventies gericht op depressieve 
patiënten in de werkende leeftijd dan in economische evaluaties van dure 
geneesmiddelen toegepast in een ziekenhuissetting. In de eerste groep werden 
productiviteitskosten in minder dan een derde van de evaluaties meegenomen 
en in de laatste groep in minder dan tien procent. Dat productiviteitskosten 
vaker werden meegenomen in evaluaties van interventies gericht op depressie 
dan evaluaties van dure ziekenhuisgeneesmiddelen, werd gedeeltelijk ver-
klaard door verschillen in leeftijd en ernst van ziekte, maar in beide groepen 
was de inclusie lager dan verwacht mocht worden. Dit impliceert dat produc-
tiviteitskosten regelmatig ‘onterecht’ genegeerd worden, beredeneerd vanuit 
de gedachte dat dat besluitvormers geïnformeerd dienen te worden over alle 
relevante maatschappelijk kosten en baten van een interventie.
De beschreven resultaten in hoofdstuk 6 en 7 laten bovendien zien dat de 
keuze om productiviteitskosten wel of niet mee te nemen een groot effect kan 
hebben op zowel de incrementele kosten als de kosteneffectiviteit. In termen 
van incrementele kosteneffectiviteit was de inclusie van productiviteitskosten, 
in de meeste gevallen, in het voordeel van de ‘nieuwe interventie’ in plaats van 
de vergelijkende behandeling. De precieze impact van productiviteitskosten 
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verschilde sterk tussen studies, zowel uitgedrukt als een fractie van de totale 
kosten als het effect op de incrementele kosten(effectiviteit). Het was niet mo-
gelijk om te bepalen hoe deze verschillen precies tot stand kwamen, omdat in 
de meeste studies te weinig details werden verschaft over de onderliggende 
methoden en cijfers om dit verder te kunnen onderzoeken. De informatie 
die wel werd verschaft liet bovendien zien dat er veel variatie bestaat in de 
toegepaste methoden op het vlak van identificatie, meten en waarderen van 
productiviteitskosten. 
In hoofdstuk 8 (gerelateerd aan onderzoeksvraag 4) is de invloed van 
compensatiemechanismen en de effecten van ziekte op teamproductie op 
de productiviteitskosten onderzocht. In de literatuur is er gesuggereerd dat, 
indien afwezigheid en/of verminderde productiviteit op het werk (gedeeltelijk) 
gecompenseerd wordt in normale werkuren door de zieke werknemer of een 
collega, gebruikelijke productiviteitskostenschattingen een overschatting zijn 
van de werkelijke kosten (17,18). Er is echter ook beargumenteerd dat huidige 
schattingen juist een onderschatting van werkelijke kosten zijn (15,16), omdat 
werknemers in veel beroepen in hun werk afhankelijk zijn van hun collega’s. 
Als in dat geval één van de teamgenoten ziek wordt, kan dit een negatief ef-
fect hebben op de productiviteit van het gehele team. In de empirische studie 
beschreven in hoofdstuk 8 werd onderzocht hoe het verzuim van zieke me-
dewerkers wordt gecompenseerd. Daarbij werd onderzocht wat de mogelijke 
invloed van compensatiemechanismen en effecten op teamproductie is op 
productiviteitskostenschattingen.
Meer dan de helft van de respondenten gaf aan dat hun gemiste werk door 
verzuim gecompenseerd werd in normale werkuren door henzelf of collega’s. 
Wanneer er bij het berekenen van productiviteitskosten tegelijk rekening 
gehouden werd met het effect van verzuim op teamproductie en compensatie-
mechanismen, was het verlagende effect van compensatiemechanismen op de 
schattingen sterker dan het verhogende effect van de invloed op teamproduc-
tie. Nota bene, deze berekeningen waren gebaseerd op de naïeve assumptie 
dat compensatie in normale werkuren kosteloos is. Dit laatste is vanuit een 
economisch perspectief echter onwaarschijnlijk.
Zoals aangetoond in hoofdstuk 6 en 7 worden productiviteitskosten vaak 
niet meegenomen in economische evaluaties. Dit hangt mogelijk samen met 
praktische moeilijkheden met het verkrijgen van betrouwbare productiviteits-
kostenschattingen. Er is derhalve wel geopperd dat productiviteitskosten dan 
wellicht indirect geschat zouden kunnen worden op basis van kwaliteit van 
leven data. In hoofdstuk 9 (in antwoord op onderzoeksvraag 5) werd een studie 
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gepresenteerd die als doel had een algoritme te ontwikkelen en te valideren 
om productiviteit te schatten op basis van kwaliteit van leven data. Om dit 
te doen werd een grote representatieve groep van het algemene Nederlandse 
publiek middels een internet vragenlijst gevraagd naar hun verwachte niveau 
van productiviteit (in termen van verzuim en verminderde productiviteit op 
het werk) in diverse EQ-5D gezondheidstoestanden.
Op basis van deze gegevens werden twee predictiemodellen geconstrueerd: 
i) een predictiemodel voor verzuim en ii) een predictiemodel voor verminderd 
functioneren op het werk. Beide modellen werden gevalideerd door de mo-
delschattingen te vergelijken met conventioneel gemeten productiviteit in een 
groep patiënten met lage rugpijn. Het geschatte verzuim op basis van EQ-5D 
gezondheidstoestanden lag dicht bij het normaal gemeten verzuim van de 
lage rugpijn patiënten. Productiviteitsverliezen op het werk werden enigszins 
overschat door het predictiemodel. Gemeten en geschatte productiviteit was 
matig maar sterk significant gecorreleerd. Het bleek derhalve mogelijk om tot 
redelijke productiviteitsschattingen te komen op de basis van EQ-5D data. 
Verder onderzoek naar en verdere validatie van dergelijke predictiemodellen 
blijft echter noodzakelijk, zeker voor verminderde productiviteit op het werk.
In hoofdstuk 10 werden de belangrijkste onderzoeksbevindingen bediscussi-
eerd en werden de implicaties en beperkingen van dit proefschrift behandeld. 
Gebaseerd op de resultaten (en terugkomend op de vijf belangrijkste vragen 
die dit proefschrift probeerde te beantwoorden) konden enkele conclusies 
worden getrokken. Ten eerste, ongeveer de helft van de respondenten van 
gezondheidstoestandwaarderingen lijkt inkomenseffecten mee te nemen. Dit 
blijkt weinig effect te hebben op deze waarderingen. Productiviteitskosten 
zouden daarom bij voorkeur meegenomen moeten worden aan de kostenkant 
van de kosteneffectiviteitsratio. Ten tweede, ondanks de wetenschappelijke 
aandacht voor productiviteitskosten worden deze kosten in de meeste eco-
nomische evaluaties niet meegenomen, vaak zonder duidelijke argumentatie. 
Ten derde, wanneer productiviteitskosten worden meegenomen kan dit de 
kosteneffectiviteitsuitkomsten zeer sterk beïnvloeden. Deze sterke potenti-
ele impact op kosteneffectiviteitsuitkomsten maakt duidelijk dat wanneer 
productiviteitskosten niet worden meegenomen in economische evaluaties, 
vergoedingsbeslissingen gebaseerd op de resultaten van deze evaluaties kun-
nen leiden tot inefficiënt gebruik van maatschappelijke middelen. Ten vierde, 
verloren productiviteit wordt vaak gecompenseerd in normale werkuren. 
Productiviteitskostenschattingen worden sterk beïnvloed door eventuele 
correcties voor compensatiemechanismen en effecten op teamproductie. De 
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validiteit van zulke correcties dient echter nader onderzocht te worden. Ten 
vijfde, hoewel de validiteit van het schatten van productiviteitsverliezen geba-
seerd op kwaliteit van leven data nog verder onderzocht moet worden, lijkt het 
toepassen van predictiemodellen, wanneer data over werkelijke productiviteit 
niet beschikbaar is, te verkiezen boven het geheel negeren van het effect van 
gezondheid op productiviteit.
Dit proefschrift eindigde met enkele opmerkingen over de inclusie van 
productiviteitskosten in economische evaluaties en de methodologie om deze 
kosten te schatten. Er bestaat nog altijd geen consensus over of productiviteits-
kosten thuishoren in economische evaluaties en hoe deze kosten geschat zou-
den moeten worden. Productiviteitskosten worden dan ook vaak genegeerd in 
economische evaluaties. Vanuit een maatschappelijk perspectief is het echter 
essentieel dat de inclusie van productiviteitskosten toeneemt, vooral gezien de 
sterke potentiële impact van productiviteitskosten op kosteneffectiviteitsuit-
komsten. Het is dan ook belangrijk dat besluitvormers zich meer bewust zijn 
van deze potentiële impact en dat men meer benadrukt dat men zich dient te 
houden aan het voorgeschreven perspectief. Daarnaast is het gebrek aan stan-
daardisatie van productiviteitskostenmethodologie een belangrijk probleem. 
In dit proefschrift is aangetoond dat in economische evaluaties een diversiteit 
aan methoden wordt gebruikt om productiviteitskosten te identificeren, meten 
en waarderen. Het toepassen van verschillende methoden kan leiden tot een 
grote variatie in productiviteitskostenschattingen en komt de betrouwbaar-
heid niet ten goede. Daarbij bemoeilijkt de diversiteit in methoden de moge-
lijkheid om uitkomsten van studies met elkaar te vergelijken. Dit proefschrift 
heeft benadrukt dat standaardisatie essentieel is om te bewerkstelligen dat het 
includeren van productiviteitskosten in economische evaluaties de standaard 
wordt in plaats van een uitzondering.
Tot slot, dit proefschrift heeft bijgedragen aan de theoretische en praktische 
kennis over de inclusie van productiviteitskosten in economische evaluaties. 
Hoewel het (gegeven de bevindingen van dit proefschrift) een uitdaging zal 
zijn om volledige consensus te bereiken wat betreft de inclusie van productivi-
teitskosten in economische evaluaties en de methodologie om deze kosten te 
identificeren, te meten en te waarderen, blijft dit een belangrijk en nastrevens-
waardig doel. 
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• Q-methodology, Erasmus University Rotterdam, 2007
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• Do productivity costs matter? A study on the impact of productivity costs in cost-
effectiveness outcomes, 8th European Conference on Health Economics, poster, 2010
• Is there more to life than money? A new approach to estimating the monetary value 
of a QALY, Low Lands Health Economists’ Study Group, 2009
• Indirect costs of beta thalassemia major: results from the ITHACA study, Interna-
tional Health Economics Association 6th World Congress, poster, 2007
• A systematic review of economic analyses of pharmaceutical therapies for advanced 
colorectal cancer, International Health Economics Association 6th World Congress, 
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Stichting Post-Universitair Onderwijs Ziekenhuisfarmacie, Utrecht, 2007
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tional Society for Pharmacoeconomics and Outcomes Research 9th Annual European 
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‘Nait soez’n, moar doun’. Een vleugje Groningse mentaliteit kwam tijdens het 
schrijven van dit proefschrift zeer van pas. Dat dit echter niet voldoende is om 
een proefschrifttraject succesvol af te sluiten, weet iedereen die hier ooit aan 
is begonnen. Aan de totstandkoming van dit proefschrift hebben veel mensen 
een bijdrage geleverd, sommigen aan de inhoud van dit boekje, anderen aan 
het proces, een aantal aan beide.
Werner, jij valt duidelijk in deze laatste categorie. Zonder jou was dit proef-
schrift er niet geweest en mijn dank aan jou is groot. Na het schrijven van twee 
masterscripties onder jouw hoede was dit proefschrift een prachtig vervolg. 
Het was een plezier en een eer om hier met jou aan te werken. 
De promotiecommissie dank ik van harte voor het lezen en beoordelen van dit 
proefschrift en voor het opponeren bij de verdediging.
Ook wil ik de sponsors van het Broader Social Benefits project (AstraZeneca, 
GlaxoSmithKline, Janssen, Merck en Pfizer) bedanken voor de financiële steun 
aan het onderzoek gepresenteerd in hoofdstuk 2 van dit proefschrift en ZonMw 
voor de financiële steun aan het onderzoek waarop hoofdstuk 7 is gebaseerd.
De meeste hoofdstukken van dit proefschrift zijn ontstaan uit de samenwerk-
ing met gedreven collega-wetenschappers. Ik ben de coauteurs van de diverse 
hoofdstukken erg dankbaar. Hun enthousiasme, kennis en inzicht waren een 
grote verrijking. 
Ik ben veel dank verschuldigd aan de zeer vele (anonieme) respondenten die 
deelnamen aan de empirische studies. Hun belangeloze inspanningen waren 
essentieel voor het tot stand komen van dit proefschrift.
Mijn ouders, broer, zus en alle belangrijke mensen om hen heen zijn mij immer 
tot steun (in veel meer dingen dan enkel het voltooien van dit proefschrift). 
Jullie zijn onmisbaar. Pap, jouw aandeel in de dataverzameling in hoofdstuk 
3 en 4 was fantastisch. Ook mijn schoonouders ben ik zeer dankbaar. Jan, 
bedankt voor alle hulp bij het verbouwen van ’t Drijfhuis terwijl ik rustig aan 
dit proefschrift werkte.
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Werken bij GE-iMTA/iBMG is na zes jaar nog altijd leuk, leerzaam en uitda-
gend. Dit is te danken aan de vele inspirerende en gezellige collega’s.
Een aantal van hen wil ik in het bijzonder bedanken. Chantal, zonder jou waren 
de afgelopen jaren bij iMTA (maar ook daarbuiten...) niet hetzelfde geweest. Sa-
men een kamer delen was niet altijd even efficiënt, maar elke dag leuk. Marten, 
ontzettend bedankt voor het feit dat je er altijd bent. Je bent een grote steun 
geweest op vele vlakken. Marc, samen met jou lesgeven en het vak Health Tech-
nology Assessment coördineren is een groot plezier. Jouw bevlogenheid wat 
betreft onderzoek en onderwijs is een voorbeeld. Lucas, het is super om met 
jou te discussiëren over de vorm en inhoud van ons beider werk en over allerlei 
andere dingen. Ik had me geen fijnere ‘nieuwe’ kamergenoot kunnen wensen. 
Siok Swan, jij was er vanaf het eerste uur. Aio’s bestonden er bij iMTA nog niet in 
2006 en er was letterlijk slechts een handjevol junioren. Bedankt voor alle leuke 
momenten door de jaren heen. Job, bedankt voor je voortdurende bereidheid 
jouw ideeën te delen als ik behoefte heb aan een frisse, scherpe blik op van alles 
en nog wat. Elly, dat geldt ook voor jou. Leona, bedankt voor alle gezelligheid 
op donderdag-krokettendag (en vele andere dagen). Sander, zonder jou had 
dit proefschrift er niet hetzelfde uitgezien. Bedankt voor al je input rondom 
de vormgeving en natuurlijk voor alle leuke jaren in de activiteitencommissie. 
Karin en Maddy, bedankt voor de assistentie bij het inplannen van afspraken in 
de zeer volle agenda van Werner.
Naast familie en collega’s wil ik een aantal vriendinnen bedanken. Tjitske, ik 
ben ontzettend blij dat je er altijd voor me bent (weliswaar op enige afstand) en 
dat je mijn paranimf bent. Jocé, wat was het leuk om met jou samen te werken 
aan hoofdstuk 6 en 7 van dit proefschrift. Ik mis je ontzettend aan de andere 
kant van de oceaan. Caro, Gerda, Ingrid, Marin, Sandra en Suus, bedankt voor 
de gezellige ochtenden bij Knus, etentjes en borrelavonden.
Maarten, Myrthe-Minou en Sylvijn, jullie geven elke dag kleur! Mijn liefde voor 
jullie is niet in woorden te bevatten. Mijn leven met jullie mogen delen is een 
feest. Ik ben dankbaar voor elke dag samen.
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